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SUMMARY
The effect of sustained +Gz acceleration ("high G") upon endocrine 
function has been investigated in man using a human centrifuge.
Five male volunteers were exposed to accelerations of up to +6Gz 
for.one minute without G protection. No effect of acceleration was 
observed on the peripheral blood levels of growth hormone, prolactin, 
thyrotropin and the gonadotrophins. In contrast, cortisol levels increased 
in a "dose-related" manner following acceleration i.e. the higher the 
acceleration, the greater the response. The unusual specificity of these 
endocrine changes is discussed.
In a second experiment on the same subjects exposed to +6Gz for 
one minute, the modification of this cortisol response by two methods 
of G protection, the anti-G suit and the reclined seat, was investigated. 
Noradrenaline, adrenaline and arginine vasopressin were also measured 
and shown to increase rapidly after acceleration. These endocrine 
changes were all reduced by the anti-G suit but reductions were not 
clearly observed with seat reclination until an angle of 80° from the 
vertical was reached. The mechanisms underlying the release of these 
hormones are discussed in terms of the circulatory disturbances produced 
by acceleration.
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Finally, the endocrine effects of positive pressure breathing (PPB), 
with and without counterpressure (CP) have been compared with the use of 
an auti-G suit alone in subjects exposed to +6Gz for one minute. Arterial 
oxygen saturation (Sa02) was monitored continuously by ear oximetry.
SAO2 fell during +Gz acceleration with only anti-G suit protection but 
this was ameliorated significantly by PPB. Further benefit was obtained 
with CP. No differences in endocrine responses were observed between 
these three conditions which suggested that hypoxia was not the stimulus 
for hormonal responses to high G. This assertion was confirmed by the 
failure of hypoxia, induced by breathing a gas mixture of low oxygen 
content, to induce hormonal changes in the subjects.
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SECTION 1 : INTRODUCTION TO ACCELERATION
1,1. Acceleration
Terrestrial life exposes us all'to the acceleration of normal gravity 
for a lifetime. Man’s advance into the environment of flight and space 
has, however, exposed him to far greater accelerations which can only be 
tolerated for much shorter periods, The adverse physiological effects 
of these accelerations remain a fundamental problem in aviation medicine.
Acceleration is defined as the rate of change of velocity with time 
and occurs when there is a change in the speed or direction of motion of 
a body. Newton’s first law states that a body will remain in a state of 
rest, or uniform motion in a straight line, unless acted upon by a force.
Since gravity is a force which will produce an acceleration of 9.81 
ms-2, the magnitude (nG) of an acceleration is conveniently expressed in 
multiples (n) of the acceleration due to gravity (g), which we sense as 
weight. Thus, a military aircraft exposes its pilot to an acceleration 
of 6 times that of gravity when "pulling” 6G and his weight will con­
sequently have increased sixfold. The pilot’s physiological responses 
to this acceleration will be determined by a number of factors, the 
most important of which are its magnitude and the duration and direction 
of its action.
Duration is classified as either long or short, the time division 
between the two being set at one second. Although this separation would 
appear to be quite arbitrary, in practice it is of great functional 
significance because excessive short duration accelerations usually 
result in pathological sequelae, whereas it is a change in physiology 
that occurs with long duration acceleration. The body responds to 
inertial force, which, by Newton’s third law of motion, is equal and 
opposite to the applied accelerative force. Thus, the headwards 
acceleration of the pilot referred to above produces a footwards 
inertial force and a car driver is flung forwards in a crash by a 
rearwards acting acceleration (equivalent to a forward deceleration).
The body axis in which the inertial force acts is described, by inter­
nationally accepted terminology (Gell, 1961), as either x, y or z 
(figure 1.1).
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The accelerations to be considered in this thesis are of long 
duration, acting in the long, or z, axis of the body. Such accelera­
tions are produced by a change in the direction of motion of an air­
craft and their duration may be limited only by fuel supply. If the 
head of the pilot is directed towards the centre of rotation then the 
inertial.force is centrifugal (+Gz) so that he is forced down into his 
seat. Negative G, (-Gz) is produced when the pilot*s head is directed 
away from the centre of rotation and the inertial force therefore dis­
places body fluids toward "the head.
This thesis describes experiments to investigate the effects of 
sustained +Gz acceleration upon endocrine function, the requisite 
experimental conditions being generated by the man-carrying centrifuge 
at the Royal Air Force Institute of Aviation Medicine.
iCz.
(Footwards acceleration)
(ie ft lateral acceleration)
-AJX-
(Forwards acceleration)
Ly.y_
(Riqht lateral acceleration)(Backwards acceleration)
(Headwards acceleration)
Figure 1.1. The definition of inertial force vectors acting on the 
body. Note that the accelerative force acts in the 
opposite direction to the inertial force.
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1.2. The RAF IAM Centrifuge
The human centrifuge (figure 1.2) was commissioned in May 1955 
and has beeri in virtually continuous use since then. It consists of a 
horizontal arm 62.5 ft (19.05m) in diameter which is mounted on a 12 ton 
(12>200 Kg) flywheel coupled directly to a powerful DC motor. The arm 
carries two gondolas, one at either end, via free swinging trunnions 
equidistant at 30 ft, (9.14m) radius from the axis of rotation. On 
rotation the gondolas swing out to take up the angle which is the 
resultant between the radial acceleration and the perpendicular gravi­
tational field (figure 1.3).
The motor can accelerate the arm to a maximum rotational speed of
54.2 rpm in 9 seconds, at which the resultant force at the pivot axis of 
the gondolas is equal to 30G. Deceleration follows a mirror image 
pattern of the acceleration profile by virtue of the use of regenerative 
braking except when the speed of the arm has fallen to 4 rpm at which 
point hydraulic brakes are applied. Throughout the experiments to be 
described an onset rate of lGs-1 has been employed and the peak accelera­
tion has not exceeded +6G, applied for a period of 60 seconds.
During human centrifuge runs a medical observer is seated at the 
centre of rotation of the centrifuge and is responsible for the safety 
of the subject. The subject can communicate at any time with the 
observer by an intercom which is always live and close-circuit colour 
television (with optional video recording facilities) enables the ob­
server to keep a close watch for any untoward signs in the subject. If 
an emergency develops, the observer has an emergency stop facility with 
which he can terminate centrifugation.
Each gondola has internal dimensions of 8 ft (2.44m) long, by 4 ft 
(1.22m) wide with maximum headroom of 7ft (2.13m), The middle third of 
the gondola is occupied by the seat which faces in the direction of 
rotation. The particular seat fitted in the gondola depends upon the 
experiment and in the work to be described two different types were used 
- a standard ejection seat and a seat capable of reclination from the 
vertical to the horizontal. Clearly such seats vary in weight and in 
the distribution of that weight. It is therefore necessary to balance
10
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the two gondola cars to within 5 lbs (2.27 Kg), before centrifugation. 
In addition, their centres of gravity must be adjusted to within +/-
0.25 in (63 mm). These constraints have not only to be considered 
for changes in seat type, but also for the weight and position of 
any apparatus placed in the gondola.
Power supplies to the centrifuge a m  are brought up the hollow 
shaft of the main driving motor from slip rings mounted below it. The 
cables pass along the lower longerons of the arm and thence to the 
gondola via flying leads. Signal leads pass from the gondola via 
flying leads to the upper longerons and back to- the centre of rotation 
where they pass up a hollow vertical tube to slip rings in the roof 
space above the centrifuge chamber. Leads from these rings pass to a 
patch panel where appropriate connections may be made to recording 
apparatus located in another part of the. building.
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1.3. The Physiological Effects of +Gz Acceleration
An understanding of the physiological effects of +Gz is vital to 
the future development of methods designed to improve human tolerance to 
such acceleration. The need to develop such methods is emphasised by 
the fact that some military aircraft are now capable of sustained 
acceleration of up to +10 Gz without structural failure. However, at 
such a high level of +Gz, the pilot’s cerebral blood flow may be so 
impaired that he becomes unconscious and thus unable to control the 
aircraft.
In an unprotected, relaxed subject, unconsciousness usually occurs 
between +5 and +6 Gz, the exact level being dependent upon individual 
susceptibility and the rate of onset of G. If this is less than 
2Gs-l, then the subject invariably experiences a well-documented 
sequence of visual symptoms prior to unconsciousness. At about +3 to 
+4 Gz the visual fields become darker followed, 0.5 to +1 Gz later, by 
loss of peripheral vision. From this condition of "grey-out” the 
fields contract further to a state of "black-out” when vision is com­
pletely lost. However, hearing and mental orientation are well 
enough preserved to permit intelligent conversation until consciousness 
is finally lost approximately 0.5 Gz later.. At higher rates of onset, 
unconsciousness usually ensues too rapidly to allow an appreciation of 
these characteristic visual symptoms. The cardinal determinant of these 
effects upon vision and consciousness is cardiovascular. The arterial 
pressure of a fully reclined subject is essentially uniform throughout 
his body, but when he stands, thereby changing the G vector from x to z, 
his circulation becomes subject to the action of hydrostatic forces. As 
Howard (1977) so aptly says: "Man regularly performs the greatest of all 
experiments in gravitational physiology when he rises from his bed".
When upright, the blood in the vessels from the heart to the brain 
constitutes a column of fluid which, at 1 Gz, exerts a hydrostatic 
pressure of some 25 mmHg (the pressure exerted by a column of fluid is 
equal to the product of its height, the density of the fluid and the 
gravitational force). A mean arterial pressure of 100 mmHg at heart 
level would thus be decreased to 75 mmHg at the level of the brain. 
Conversely, pressures below the heart are increased by the addition of 
hydrostatic pressure. Based on these figures, one would expect the 
mean arterial pressure at brain level to be reduced to zero at +4 Gz
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since the hydrostatic pressure opposing flow would be increased fourfold 
to 100 mmHg. Consciousness is, however, rarely lost below +5Gz, .sugges­
ting an anomalous situation of perfusion without pressure. In fact, flow 
is maintained because both the cerebrospinal fluid (CSF) and the venous 
system are subject to the same hydrostatic laws as the arterial circula­
tion.
In animals exposed to +Gz it has been shown that CSF and arterial 
pressures fall in unison (Rushmer et al, 1947) so that the pressure 
across the walls of the cerebral vessels may be expected to remain con­
stant during +Gz acceleration. This implies that flow will be deter­
mined solely by the arterio-venous pressure difference. Since venous 
pressure also falls, a pressure gradient will be maintained, even with 
zero arterial pressure, provided that the jugular veins do not collapse 
when their internal pressure falls to sub-atmospheric levels.
Although pressure as low as -40 mmHg have been recorded from deep 
neck veins in man exposed to +4.5 Gz (Henry et al, 1951), the "jugular 
suction effect" cannot completely explain the preservation of conscious­
ness. Undoubtedly cerebral autoregulation is an important factor which 
has been sparsely investigated because of technical difficulties, but 
there is evidence that cortical blood flow is maintained at the expense 
of less vital white matter (Howard and Glaister, 1964).
A selective reduction in blood flow is not, however, the basis of 
the visual symptoms which have a peripheral aetiology, confirmed by 
direct observations on the fundus during +Gz exposure (Duane, 1954).
The intraocular pressure of about 20 mmHg will abolish retinal blood 
flow to cause "black-out" when arterial pressure falls below this value, 
although cerebral perfusion will continue. At the earlier "grey-out" 
stage the peripheral retina becomes hypoxic because of under-perfusion 
due to reduced pressures in the retinal end-arteries.
As a consequence of raised hydrostatic pressures in the vessels 
below the heart, blood pools in the lower limbs and abdomen, thereby 
reducing venous return and impairing cardiac output. The physiological 
changes produced by acceleration resemble those seen in haemorrhage and 
both situations generate similar reflex sympathetic responses, notably 
tachycardia and selective vasoconstriction. In man, the carotid sinus
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reflex is almost certainly responsible for the former, but its role in 
inducing vasoconstriction is probably slight (Roddie and Shepherd, 1957). 
Atrial pressure receptors, mesenteric baroreceptors and local vessel 
response have all been implicated in the stimulation of vasoconstriction 
secondary to haemorrhage in animals, but their role in man has not been 
fully established. The involvement of the endocrine system in cardio­
vascular compensation is discussed in section 2.5,
It is important to realise that hydrostatic pressure gradients 
increase instantaneously with the onset of acceleration, but reflex 
compensation takes at least 6 seconds to become effective and so cannot 
prevent the development of visual symptoms or unconsciousness except at 
very low rates of onset of G, but visual symptoms that are already 
established may be ameliorated.
The pulmonary circulation is also not exempt from the exaggeration 
of hydrostatic pressure gradients by +Gz acceleration. With acceleration, 
perfusion of the lung apex, already poor at +1 Gz (normal gravity), is 
further compromised so that the alveolar dead space is increased. Below 
this point, the rate at which blood flow per unit lung volume rises with 
distance down the lung increases with acceleration. Simultaneously, the 
weight of the lungs rises in proportion to the applied force so that 
apical alveoli are stretched towards their maximum capacity and basal 
alveoli are compressed towards their minimum volume, thus encouraging 
airway closure. The overall effect of these changes is to intensify 
ventilation-perfusion inequalities and to produce large right-to-left 
shunts at the lung base, thereby reducing arterial oxygen saturation and 
aggravating cerebral hypoxia (Glaister, 1970). The measurement of arterial 
oxygen saturation has been applied to the assessment of human tolerance 
to +Gz acceleration and the development of ear oximetry has made its 
accurate and non-invasive measurement possible (Besch et al, 1978). This 
technique has been utilized in experiments to be described in section 6 
of this thesis.
15
1.4. Protection Against +Gz Acceleration
Tolerance to +Gz, as measured by the +Gz levels at which visual 
symptoms develop, may be increased by the pilotfs own voluntary actions 
or by the passive use of purpose-built equipment. The terms "active" 
or "passive" are the two adjectives most commonly used to describe these 
two methods of protection. The author prefers, however, to use the less 
confusing terms "intrinsic" and "extrinsic". For example, the inflation 
of an anti-G suit is an active process but it is a passive method of 
protection.
Present methods of G protection will be described in some detail since 
a considerable portion of this thesis has been devoted to an examination 
of how they may modify endocrine responses to +Gz acceleration.
Intrinsic protection
In the early 1930s it was appreciated by the Germans that the adop­
tion of a crouching posture, in which the head and shoulders are pulled 
down, could increase +Gz tolerance (Harrison and Gibson, 1981). Several 
years later, in early studies at the RAF IAM, it was reported that such 
a method could raise the black-out threshold by 1G (Stewart, 1940a). The 
improvement in tolerance can be explained by the reduction in the length 
of the hydrostatic column between heart and brain. Forward inclination 
Of the trunk to 30° from the vertical can be expected, by simple geometry, 
to raise threshold by about 0.5G. The higher figure produced by Stewart 
is likely to be reflecting the additional benefit created by muscle tensing 
in his subjects. Forcible contraction of the peripheral skeletal and 
abdominal musculature promotes tolerance in a number of ways. Tensing 
of the leg muscles decreases the venous capacitance of the limbs and so 
reduces peripheral pooling of blood. Similar considerations apply to the 
abdominal capacitance vessels but abdominal muscle contraction, by eleva­
tion of the diaphragm, will also tend to prevent the downward displacement 
of the heart during +Gz exposure. The latter effect will be beneficial 
because of the reduction of the hydrostatic column distance described 
above.
Muscle tensing benefits G tolerance immediately, but pooling takes 
time to develop so that other mechanisms must also be operative. The 
most important is that straining usually produces an increase in
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iatrathoracic pressure which is transmitted direct to the arterial 
tree. However, an investigation of the effect of static forearm 
muscular contraction during +Gz exposure showed that tolerance could be 
improved by up to +1 Gz without an increase in intra-thoracic or intra­
abdominal pressure. The handgrip exercise produced elevations in 
systemic pressure, presumably by a reflex mechanism of, as yet, unknown 
origin (Lohrbauer et al, 1972).
Despite Lohrbauer*s findings, respiratory manoeuvres designed to 
raise intra-thoracic pressure play an unequalled role in intrinsic pro­
tection. The Valsalva manoeuvre (forced expiration against a closed 
glottis) has to be used with caution since the initial rise in arterial 
pressure is followed by a steady decline because of a secondary impair­
ment of venous return. Under +Gz acceleration such sequelae can result 
in unconsciousness (Wood and Lambert, 1952), but improvement in tolerance
has been observed with Valsalva manoeuvres lasting for 15s (Shubrooks
\
and Leverett, 1973).
Because of the undesirable effects of hypotension under G, the 
voluntary action of choice is the M-l manoeuvre performed by expiration 
against a partially closed glottis. When performed correctly, it has 
been shown to increase tolerance by up to +2.5 Gz (Wood and Lambert,
1952). It is repeated every 3-5s using rapid inhalations, more appro­
priately termed gasps, of approximately Is duration (Burton et al, 1974). 
The gasp period permits venous return to recover sufficiently to prevent 
cardiovascular collapse but its duration must be short since eye-level 
arterial blood pressure is low during this phase. The correct application 
of the M-l manoeuvre and muscle tensing depends greatly upon the motiva­
tion oJ^-the subject, good teaching and adequate opportunities to practice 
the "art". The disadvantage of these manoeuvres is that they are 
extremely tiring to perform which is not only detrimental to the primary 
task of-flying (especially when they impair communication), but may also 
reduce the efficient performance of the manoeuvres during subsequent 
high G exposures. Physical fitness has been shown to facilitate the 
performance of the M-l manoeuvre (Burton et al, 1974), but has no effect 
on relaxed G tolerance (Copper and Leverett, 1966).
A discussion on intrinsic protection would be incomplete without 
mention of certain environmental and other factors which should be 
avoided by those who require to be able to tolerate high G. In the
17
experimental situation this is of particular relevance and demands that 
experimental conditions are kept as constant as possible. A stable 
environmental temperature is required since elevations in body tempera­
ture have been shown to reduce tolerance (Allan and Crossley, 1972). 
Subjects should avoid alcohol and hypoglycaemia, both of which have been 
shown to impair tolerance (Browne, 1959a.and b).
Extrinsic protection
The perennial method of extrinsic protection is the anti-G suit 
which is made of inextensible fabric containing interconnecting air 
bladders over the abdomen and legs (figure 1.4). A G-sensitive valve 
inflates the bladders to a pressure of 65 mmHg (8.7 kPa) per G when the 
resultant acceleration exceeds about 2.5 Gz, the exact "cut-in11 G level 
and inflation characteristics being dependent upon the valve type.
Pneumatic anti-G suits were developed from earlier water-filled 
garments and, in particular, that designed by Franks (see review by 
Harrison and Gibson). Such a suit enables the distribution of hydro­
static pressures in the vessels of the abdomen and limbs to be counter­
balanced by the external water pressure gradient, thus reducing peri­
pheral pooling of blood. The Franks suit was reported to increase 
tolerance by up to +3 Gz but other studies have shown that water-filled 
garments are much less efficient - as low as 0.7 Gz improvement in one 
series (Glaister et al, 1976). The suit also suffers from the important 
disadvantages of being cumbersome and time-consuming to put on. A 
further complaint, often voiced by the wearer, is that it induces a 
diuresis. The stimulus to this diuresis (and natriuresis) is likely to 
arise from low-pressure cardiovascular receptors which respond to the 
increase in central blood volume created by the displacement of blood 
from the lower limbs. The mechanism whereby renal sodium handling is 
altered, has taxed the minds of endocrinologists for many years and may 
well depend upon the presence of a natriuretic hormone (Epstein, Duncan 
and Fishman, 1972). Such a hormone has recently been isolated but its 
chemical characteristics have yet to be identified (de Wardener, 1982).
Air-filled anti-G suits are light and convenient to wear and do not 
produce a diuresis because counterpressure is only applied when the sub­
ject is exposed to high G. They afford protection of up to +1.5 Gz but
18
Figure 1.4. The RAF Mk. 6 anti-G suit. Air under pressure is supplied through 
the hose to inter-connecting bladders over the abdomen, thigh and 
calf. The bladders are held in place by inelastic material.
19
their mechanism of action is more complex than might appear at first 
sight. In particular, the effect on tolerance is immediate and cannot 
therefore be explained solely by reduced peripheral pooling of blood as 
sequestration takes some time to develop. Wood and Lambert (1952) 
investigated the effects of inflating the abdominal or limb portions of 
a suit on the relaxed tolerance of 12 subjects, and found an increase of 
+0.6 Gz with abdominal inflation but leg pressure alone produced a benefit 
of only +0.2 Gz. When the whole suit was inflated an increase of +1.2 Gz 
was observed. This synergism has been confirmed at the RAF IAM with 
respective increases of tolerance of +0.5 Gz, +0.5 Gz and +1.5 Gz for 
abdomen only, both legs, and whole suit inflation (Nicholson, 1965). 
Recently, however, Burton and Krutz (1975) could only find a simple 
addition of effects between abdomen only (+0.7 Gz) and legs only (+0.2 Gz).
These studies do, however, confirm that abdominal compression plays 
a vital role in anti-G suit action by constricting the arterial inflow 
to the limbs with consequent increases in peripheral resistance and 
arterial pressure (Wood and Lambert, 1952). In addition, blood is shifted 
into the central circulation and helps to maintain cardiac output. For 
example, acute anti-G suit inflation to 80 mmHg (10.64 kPa) at +1 Gz 
(normal gravity) has been shown to produce immediate, but transient, 
increases in right arterial pressure, systemic blood pressure, and cardiac 
output (Gray et al, 1969). The increase in intra-abdominal pressure 
induced by the abdominal bladder has also been shown to prevent downward 
displacement of the heart. Radiographs taken at +5 Gz have demonstrated 
a reduction of 3 cm in the average distance of heart to the base of the 
skull, which is roughly equivalent to +0.5 Gz protection (Rushmer, 1947).
The greatest increase in G tolerance can be obtained by reclining 
the body away from the vertical so that the axis of the applied accelera­
tion changes from z toward x. Again, it was the Germans who were first 
to investigate this and demonstrated that tolerance to +Gx acceleration 
could be as high as 17 Gx for several seconds (Buhrlen, 1937).
Intermediate angles may also be expected to improve tolerance by 
reducing the distance between heart and brain. Thus, Stewart (Stewart, 
1940b) noted that black-out tolerance was raised by a seat installed at 
45° to the vertical in the rear cockpit of a Gloster aircraft. In one of
20
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the mors comprehensive studies to date, Burns (1975) investigated the 
effects on relaxed G tolerance of seat back angles of 13°, 30°,45°,
55°, 65° and 75° from the vertical. There was no significant difference 
between the control back angle of 13° and that of 30° which was explained 
by the absence of a significant change in calculated eye-to-aorto dis­
tance (29.7 cm and 29.6 cm respectively). However, at 45° there was a 
significant 0.5 G increase in tolerance compared to control and, there­
after, tolerance increased exponentially to 8 G at 75°. These increases 
were significantly related to decreases in the eye-heart hydrostatic 
column. The study also demonstrated that the amount of straining re­
quired to maintain vision during +8 Gz exposures was reduced by reclina­
tion.
The effect of seat reclination is additive to the G-tolerance 
benefits produced by othef extrinsic measures. A standard inflated 
anti-G suit has been shown to increase relaxed G tolerances of subjects 
even at tilt-back angles as great as 75° (Crossley and Glaister, 1971).
In a comprehensive review of the effects of seat reclination upon G 
tolerance, Glaister (1978) has examined the mathematical relationship 
between these two parameters. He concluded that G threshold can be 
predicted from the equation:
G threshold = a +
cos back angle
In unprotected subjects, values for the constants a and b were 2.597 
and 1.010 respectively. This relationship predicts that a back angle of 
59.8° would be required to raise tolerance by 1G but increases of 2.0 
and 3.0G would require angles of 70.4° and 75.4° respectively. Predicted 
back angle values for fully protected subjects (inflated anti-G suit, 
tensing and performing the M-l or breathing under positive pressure) were 
56.4°^and 73.0° for G tolerance improvements of 1.0, 2.0, and 3.0 G.
The beneficial effects of positive pressure breathing (PPB) on G 
tolerance have been investigated in a number of studies. Wood and 
Lambert (1952) suggested that PPB only improved tolerance when combined 
with inflation of an anti-G suit though they did not elaborate on the 
pressure gradients employed in the experiments. A more comprehensive 
study in 9 subjects exposed to 10 G with head and back at 0° from the
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horizontal (+Gx) showed that PPB at 2-3 mmHg per G increased the time for 
which this high acceleration level could be tolerated by an average of 
67% (Watson and Cherniack, 1962).
The effects of PPB during +Gz exposure were also examined in 3 
groups of subjects by Shubrooks (Shubrooks, 1973). He found that PPB 
(25-35 mmHg beginning 20s prior to onset of acceleration) increased +Gz 
tolerance by 0.3 to 1.5 Gz in relaxed subjects. With PPB at 40 mmHg +Gz 
tolerance of straining subjects was up by 0.7-2.2 G (mean 1.2 G), equiva­
lent increases to those produced by M-l procedures in the same subjects.
In the third group, exposed to +8 Gz for 45-60 seconds with an anti-G 
suit, PPB (35-40 mmHg) was as effective as the M-l procedure in maintain­
ing vision but was less fatiguing and produced less of a fall in eye- 
level systemic arterial pressure during inspiration.
Positive pressure breathing can add' a further +1.0 Gz to relaxed 
tolerances obtained with a seat back angled at 75° from the vertical 
(Glaister and Lisher, 1976).
Subjects frequently comment that PPB reduces the effort required to 
breathe under high +Gz acceleration, even when respiratory manoeuvres 
are not required to raise tolerance. The reduction in fatigue associated 
with PPB has been investigated by determining heart rate recovery after 
+Gz exposure (Leverett, Burton et al, 1973). Using this index it was . 
shown that the fatigue developed by subjects using PPB (30 mmHg) at 
+8 Gz was similar to that found for the +6 Gz M-l group suggesting a 
2G advantage for PPB.
Pressure breathing (of oxygen) is primarily regarded as a means of 
protecting subjects against the hypoxia which results from ascent to 
altitude. Its physiological effects have been extensively researched 
at +1 Gz and are comprehensively reviewed by Ernsting (1966). Pressure 
breathing always results in an increased systemic arterial pressure 
though pulse pressure is reduced. The rise in arterial pressure is, 
however, considerably less than the pressure applied by the PPB unless 
it is combined with an equivalent counter-pressure (CP) exerted over the 
body. The arterial pressure then rises progressively with pressure applied 
to chest, trunk, and trunk with limbs, reaching a value which frequently 
exceeds the applied positive breathing pressure.
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pressure so that venous return from unpressurized regions of the body, 
such as the.limbs, ceases until local pressure exceeds the central 
pressure. This produces a reduction in effective blood volume which can, 
if PPB is continued for long enough, lead to vasovagal syncope. The 
displacement of blood into the lower limbs may be countered by the use 
of an anti-G suit and provides a physiological explanation of Wood and 
LambertsT original observation that PPB is only effective in raising 
G tolerance when an anti-G suit is also used. The use of an anti-G suit 
will be of even more import if CP is applied to the trunk. CP to the 
upper limbs has only been found necessary at breathing pressures greater 
than 107 mmHg (14.23 kPa) because of pain in the arms and cardiovascular 
collapse (Ernsting, 1966).
A recent Canadian study has indicated that the RAF Mk 5 jerkin 
(applying trunk CP) and RAF Mk 7 anti-G suit afford the best protection 
against the adverse physiological effects of PPB when compared to 
Canadian and Swedish systems (Ackles, Porlier et al, 1978). In the 
experiments to be described in section 6, an RAF Mk 4 pressure jerkin 
(figure 1.5) was used to apply trunk CP.
Despite the potential advantages of CP combined with PPB it has 
been sparsely investigated in +Gz tolerance studies, although it is to 
receive considerable attention in the future at the USAF School of Aero­
space Medicine (Burns and Balldin, 1982). In a preliminary study no 
difference was observed in the effects of unassisted or assisted (i.e. 
plus CP) PPB on tolerance to.gradual onset +Gz accelerations of 0,1 G/s 
(Shaffstall and Burton, 1979). However, the tolerance times for exposure 
to an aerial combat manoeuvre (ACM) profile Alternating 15s duration 
plateaux of +4.5 and +7.0 Gz) were significantly increased by assisted 
PPB when compared to the times achieved with either PPB alone or con­
ventional M-l procedures. The increase in time tolerance was as high 
as 40% when compared to controls using only an anti-G suit.
The final method of extrinsic protection is pharmacological. This 
has received some attention in the past but no specific "therapy” has 
been developed for use in aircrew.
Figure 1. The RAF Mk. 4 pressure jerkin.
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SECTION 2 : STRESS AND THE ENDOCRINE SYSTEM
2.1. Introduction
With the advance in hormone assay techniques, it has been demonstrated 
that "stress11 may be characterised by a number of endocrinological responses 
which are not limited solely to changes in the secretion of catecholamines 
and adrenal steroids. Furthermore, while such responses have previously 
been regarded as "non-specific", it has become clear that certain stressors 
provoke endocrine changes that are remarkably specific. This section 
reviews the extensive literature that has accumulated on this subject but, 
for the sake of brevity, particular attention will be paid to those hormones 
.which have been shown in this thesis, to be secreted in response to +Gz 
acceleration.
+Gz acceleration represents a unique stressor. Although the stress is 
predominantly cardiovascular, secondary effects such as hypoxia develop 
during exposure to acceleration. The contribution of these stressors to 
the observed responses will be discussed under sections 4 to 6. It is rare 
for the investigator to be able to control and quantify experimental stress 
but this is the case with +Gz acceleration. Using the human centrifuge, it 
is possible to exert close control over the rate of onset, duration and 
level of +Gz acceleration while, at the same time, the stress may be 
removed almost instantaneously should problems arise. The prime purpose of 
this thesis has not, however, been to,provide further data for the endo­
crinologist but to see if the information can be of value in the following 
areas of aerospace medicine; /
1. A great deal of individual variation exists in the ability of humans 
to tolerate +Gz acceleration. If hormonal changes can be correlated 
with acceleration tolerance, then they could be used to aid the selec­
tion of aircrew.
2. By defining the optimum hormonal environment for high G tolerance, it 
may be possible to administer hormones or pharmacological agents to 
the aviator in order to improve his tolerance.
3. Many of the devices used to raise tolerance have to be investigated at 
levels of +Gz acceleration which exceed those at which visual end­
points may be used to assess tolerance. Endocrine studies may give
an insight into the efficacy of these methods by assessing their 
ability to reduce stress in the subject.
4. The hormonal changes induced by weightlessness ("zero G") have not 
been defined completely, although they are partly responsible for 
the reduction in +Gz tolerance seen after space flight. It may be 
possible to predict these changes by extrapolation from known hor­
monal effects of increased G. Such a method has, for example, been 
used to predict heart rate under "zero G" (Glaister and Lisher,
1977).
5. The extent to which hormones play a part in the cardiovascular com­
pensation seen in response to +Gz acceleration has not been fully 
assessed. Such studies may be of relevance to normogravic. cardio­
vascular control e.g. in an understanding of orthostatic hypotension.
This review begins with the sympathetic nervous system since the 
adrenal medullae were the first "endosecretory glands" to be recognised 
as being of importance in stress reactions (Cannon, 1914).
2.2. The Sympathetic Nervous System
Three catecholamines are synthesized in the human body: dopamine, 
noradrenaline and adrenaline. Each compound has in common a catechol 
(dihydroxybenzene) nucleus and an amine-containing side chain. The 
synthetic pathway is illustrated in figure 2.1, but it is important to 
realise that no single cell carries out all of the reactions shown. For 
example, the only mammalian cells which produce adrenaline are the chromaf­
fin cells, found predominantly in the adrenal medullae. Thus the blood 
level of adrenaline may be used to reflect adrenal medullary activity. 
Noradrenaline, by contrast, is produced by postganglionic adrenergic 
neurones so that its level may be regarded as a relatively specific index 
of adrenergic nerve activity. It is only a semi-quantitive estimate of 
the amount of noradrenaline released by neural activity because most of 
the noradrenaline is taken back into the adrenergic neurone by an active 
uptake process (uptake 1) or taken up into extraneuronal tissue (uptake 2) 
(Iversen, 1973). Rises in plasma noradrenaline must therefore be regarded 
as "leakage11 into the circulation rather than true secretion of a normally 
active agent. Interpretation of results may also be complicated by errors 
derived from poor sample storage and insensitive methods of measurement, 
factors which are discussed below and in Section 3.3.
Dopamine is predominantly a neurotransmitter within the central ner­
vous system (CNS) and has been particularly implicated in the control of 
the secretion of growth hormone (GH), prolactin (PRL) and, possibly, 
arginine vasopressin (AVP). Highly selective receptors for dopamine have 
also been identified in the peripheral and mesenteric arterioles, the 
sympathetic ganglia and the renal circulation. It has been shown to be 
produced in the kidney where it has been implicated as a natriuretic hor­
mone because it inhibits the tubular transport of sodium (Lee, 1982). 
However, it is the two other catecholamines which are of particular rele­
vance to stress.
The physiological effects of noradrenaline and adrenaline are deter­
mined by the receptors to which they bind. These have been classified 
into two main groups, alpha and beta. Beta receptors have been divided 
into two types, 1 and 2 (Lands et al, 1967) and there is recent evidence 
to suggest that a similar classification should be applied to the alpha 
receptors (Berthelsen and Pettinger, 1977). Noradrenaline is almost 
exclusively an alpha-adrenergic agonist whereas adrenaline stimulates 
both alpha and beta receptors. The many actions mediated by these
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receptors are reviewed by Jenkinson (1973) but the most important, from 
the point of view of stress, are those with cardiovascular and metabolic 
effects.
The cardiac effects of the catecholamines include the induction of 
a tachycardia and increases in cardiac contractility, ventricular excita­
bility and coronary blood flow (beta effects). At the same time there is 
an alpha-adrenergic induction of cutaneous and splanchnic vasoconstriction 
which increases peripheral resistance, but an increase in blood flow to 
skeletal muscle due to selective vasodilation also occurs as a result of 
beta stimulation. •
Adrenaline and noradrenaline induce hyperglycaemia by activating 
glyco'genolysis and, most importantly, by inhibiting insulin secretion (an 
alpha adrenergic action) (Porte, 1969). In fact, these actions are pro­
bably dependent upon noradrenaline release at nerve terminals in the liver 
and pancreatic cells rather than the release of adrenaline into the cir­
culation. For example, a comparison between stimulation of the hepatic or 
splanchnic innervations in the dog suggested that, when compared with the 
hepatic innervation, the adrenal medullae "had little part in the control 
of hepatic glycogenolysis under normal conditions" (Edwards and Silver, 
1972). Overall, the role of the sympathetic nervous system in glucose 
homeostasis is difficult to assess but it is likely that the hyperglycaemic 
actions of growth hormone and glucagon are more important than those of the 
catecholamines under normal conditions (Marks, 1981).
The total amount of glucose available for fuel is very limited and it 
is generally■agreed that fatty acids and ketones are important sources of 
energy. Ketones, by virtue of their water solubility, are more accessible 
to transport into the CNS where they are an important source of energy.
They are produced exclusively in the liver and their rate of production 
is determined by the concentration of non-esterified fatty acids in the 
circulation. The catecholamines play a fundamental role in the mobiliza­
tion of fatty acids by the stimulation of adenyl cyclase, thereby increas­
ing the cyclic AMP content of fat cells. The increased cyclic AMP is then 
thought to stimulate triglyceride lipase which releases non-esterified 
fatty acids into the circulation (Newsholme and Start, 1976).
The- question of a direct action of the catecholamines upon the CNS 
remains controversial but adrenaline has been shown to cross the blood- 
brain barrier in the region of the hypothalamus (Weil-Malherbe et al,
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1959). The possible role of the catecholamines in behaviour is discussed 
below.
In unstressed subjects the plasma concentration of adrenaline is 
less than 10% of that of noradrenaline (Peuler and Johnson, 1977) when 
measured by single isotope radioenzymatic assay. The much lower basal 
adrenaline levels therefore require sensitive assays for their measurement 
and, as will become apparent, many of the older fluorimetric assays (upon 
which several "firm11 conclusions about catecholamine secretion have been 
based) do not possess such sensitivity. Catecholamine levels are subject 
to circadian periodicity, being higher during the day than at night 
(Turton and Deegan, 1974).
The original description of adrenaline as a stress hormone was that 
of Cannon (1914) from his experiments on cats exposed to barking dogs. He 
formulated the "emergency-function" theory of adrenal medullary activity 
based on the view that many of the physiological effects of adrenaline 
serve the goal of preparing the organism to meet threatening situations 
involving fear, rage or pain (often referred to as "fight-flight 
reactions"). Numerous investigators have subsequently demonstrated rises 
in noradrenaline and adrenaline to a host of stressors. These may be 
broadly divided into psychological and physical stimuli.
Psychological stimuli
Conditions characterized by novelty, anticipation, unpredictability 
and change produce a rise in adrenaline output which correlates with the 
degree of arousal evoked by the stressor (Frankenhauser, 1975). If a 
subject then gains control over the situation by virtue of repeated 
exposure to the same stimuli, adrenaline excretion falls. This was demon­
strated by Frankenhauser and Rissler C1970) in humans exposed to unpredict­
able and uncontrollable electric shocks which increased urinary adrenaline 
excretion three-fold when compared to control, resting, conditions. If 
the subject performed a task to prevent the shocks, adrenaline excretion 
was reduced, but noradrenaline excretion remained elevated as long as the 
subject was involved in attention-demanding activity. The increases in 
noradrenaline were, however, only about 50% above control values at rest.
Repeated exposure does not always reduce adrenaline output. For 
example it is elevated as much in highly experienced parachutists as in 
trainee parachutists following parachute jumps (Bloom et al, 1963). These
observations also hold true for noradrenaline excretion. Work such as 
this has raised the question of whether differences in adrenaline and 
noradrenaline excretion may predict personality traits or reflect differ­
ent emotions. Overall, the results of a number of studies have often 
been conflicting, but it does appear that adrenaline has a lower threshold 
for release than noradrenaline in a number of emotional states, including 
fear and anger (Frankenhauser, 1975).
An elegant study which demonstrates this difference was performed by 
Lundberg (1976) who looked at urinary catecholamines in commuters, making 
two train journeys to town. The first journey was not crowded, but the 
second was on a busy line. He found that only adrenaline excretion was 
affected by the increase in crowdedness. It has been suggested that situa­
tions arise where noradrenaline may be released preferentially. In 
Taggart et al's study (1969) on 9 competitive motor racing drivers, all 
showed considerable increases in plasma noradrenaline, but only one had 
adrenaline values greater than those obtained during a tranquil control 
period. Care must be exercised in the interpretation of these results 
because the fluorimetric method used by Taggart et al was insensitive.
Basal^adrenaline levels were between 300-530 pgml considerably higher 
than, for example, the control levels of adrenaline measured in this 
thesis by a single isotope method (see Sections 5 and 6).
The advantages of catecholamine.production in response to psycholo­
gical stress are not entirely clear. Experiments on infusions of cate­
cholamines into human subjects have suggested that performance of certain 
tasks may be improved, particularly by adrenaline (Frankenhauser and 
Jarpe, 1963). Among normal healthy individuals, those who have relatively 
high catecholamine excretion levels tend to perform better in terms of 
speed, accuracy and endurance than those who have lower levels. The rela­
tionship appears to be particularly marked for adrenaline but also appears 
true for noradrenaline (Frankenhauser, 1975).
Physical' stimuli
Various forms of exercise have been shown to cause the secretion of 
catecholamines, an effect which is dependent upon the intensity and dura­
tion of the activity. For example, Galbo et al (1975) measured plasma 
catecholamines during, and following, graded (44, 77 and 100% maximal 
oxygen uptake) and prolonged treadmill running. At 44% V02inax, no signi­
ficant changes were observed but at the higher work loads, sixfold increases
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in both noradrenaline and adrenaline were seen. Prolonged work also caused 
significant increases in both catecholamines with a further rise at 
exhaustion.
This study confirmed those of many other authors, the only notable 
exception being Haggendal et al (1970) who investigated graded bicycle 
ergometer exercise and arterial, rather than venous, catecholamine levels. 
Noradrenaline increased slowly up to work levels of 75% VO^max, beyond 
which the levels increased rapidly. However, no adrenaline was detected 
in any of the samples and the authors therefore suggested that exercise 
did not stimulate the adrenal medullae. They also indicated that one of 
the five subjects was well-trained and had lower values for noradrenaline 
than the remaining unconditioned subjects.. The differences between this 
study and that of Galbo et al (1975) may reflect the different assays used 
by each group. Galbo et al used a double-isotope derivative assay (see 
Section 3.3) which is undoubtedly more sensitive and specific; than the 
fluorimetric method employed by Haggendal. For example, a.comparison of 
control values for noradrenaline in the two studies indicates at least a 
twenty-fold increase in sensitivity with the double-isotope method. The 
inability to detect adrenaline certainly does not exclude the possibility 
of adrenal activation but does reflect poor assay sensitivity.
The influence of fitness upon exercise-induced changes in catechola­
mines has been investigated by a number of researchers. Bloom et al (1976) 
looked at differences in the hormonal response to graded bicycle ergometer 
exercise between 6 well-trained cyclists and 6 untrained subjects. Plasma 
catecholamines rose in both in relation to the severity of the exercise, 
but noradrenaline was more sensitive than adrenaline which may well reflect 
the relatively poor sensitivity of the fluorimetric assay employed. The 
trained group produced lower responses than the untrained group, particularly 
in adrenaline levels. The pre-exercise,concentrations of noradrenaline were 
lower in the'racing cyclists than the untrained group but there were no dif­
ferences in adrenaline between groups Cthis again may reflect assay sensi­
tivity). Similar results were obtained by Davies et al (1977) who investi­
gated the effects of a training programme on the urinary excretion of cate­
cholamines; noradrenaline excretion was reduced in the trained group under 
both exercise and resting conditions whereas adrenaline levels were reduced 
only in the exercise condition.
Under certain conditions, mental strain may accompany physical strain 
(eg competitive sport). Elmadjian et al 0-957) compared urinary catecholamine
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excretion in hockey players, some of whom took part in active competition 
while others observed a game. The results showed large increases in nor­
adrenaline and smaller increases in adrenaline in active participants 
whereas only adrenaline increased in the audience. This finding tends to 
suggest that adrenaline increases in exercise are related to subjective 
changes, such as the discomfort perceived during heavy physical work.
However, Opstad et al (1980), using a single isotope assay on plasma, 
showed that noradrenaline and adrenaline responses to ergometer exercise 
were both elevated substantially when exercise testing was repeated after 
107 hours of continuous activity (a ranger training course) which permitted 
only 2 hours sleep. It therefore appears, as with psychological stressors, 
’that clear distinctions between noradrenaline and adrenaline secretion may 
not always exist in response to physical stressors. A great deal of caution 
has to be used in the interpretation of plasma and urinary catecholamine 
results because sensitive methods for differential determination of nor­
adrenaline and adrenaline have only recently become available. It has to 
be stressed again that it is not always possible to make definite conclusions 
about differential secretion of the catecholamines, particularly when studies 
have employed fluorimetric methods of analysis. Further observations on 
these methods are outlined in Section 3.3.
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2.3. The Anterior Pituitary
Adrenocorticotrophic hormone (ACTH)
In the late 1940s and early 1950s the idea was emerging, largely 
under Seyle!s influence, that all noxious stimuli resulted in the initia­
tion of a series of metabolic changes in the exposed organism, prominent 
among which was the stimulation of the adrenal cortex. The adrenal cor­
tical hypertrophy which occurred in animals subjected to a variety of 
stressors could be prevented by hypophysectomy or duplicated by the use 
of pituitary extracts containing corticotrophin. Seyle emphasised that, 
irrespective of the alarming stimulus used, the adrenal changes were 
essentially the same and were non-specific reactions to the general 
stimulus (Seyle, 1950). It was not long before studies were extended to 
include humans, rather than animals, in experiments designed to examine 
adrenal cortical responsiveness to stressors which can again be broadly 
defined as physical or psychological.
As early as 1945, Venning had shown,by direct bioassay of urine 
extracts, that quite considerable rises in excretion of-adrenal'cortical 
hormones occur under surgical operations and exercise. was even able 
to detect rises in response to the dressing of an operation wound (see 
Cope, 1965). The assay techniques whichshe used were extremely laborious 
to perform and most workers at that time preferred to use loss of circula­
ting eosinophils as an indirect, but highly sensitive, method of assessing 
increased adrenal cortical activity. Thus, Renold et al Q.951) demonstra­
ted large falls in eosinophils after a trial race and the actual race in 
the Harvard crew participating in the Harvard-Yale regatta. Of particular 
interest was the observation that the coxswain and coach had similar falls, 
suggesting that anxiety and tension were as important as muscular activity 
in determining the adrenal cortical response to stress.
A more recent study by Bloom et al (1976) has, however, demonstrated 
that, following an initial fall in plasma cortisol, prolonged exercise 
resulted in substantial increases in cortisol which reflected the severity 
of the exercise as measured by VC^max. An initial fall of plasma cortisol 
in response to exercise has also been demonstrated by Few (1974) in males 
subjected to various exercise regimes. He attributed this reduction to 
increased peripheral tissue binding of cortisol and further demonstrated 
that exercise reduced the half life of injected tritium-labelled cortisol: 
the more intense the exercise, the greater the reduction. Beyond a certain
work load, cortisol secretion was stimulated but this enhanced adrenal 
cortical activity could not be explained simply by the initial drop in 
cortisol acting on the pituitary via the closed-loop negative feedback 
system since low cortisol levels were maintained at'low work loads. The 
suggestion that higher work loads might stimulate cortisol production via 
enhanced noradrenaline secretion was not supported by Few's finding that 
noradrenaline infusions failed to release cortisol.
The apparent lack of importance of the negative feed-back" mechanism 
in the control of"stress-induced activation of the adrenal pituitary axis 
had been suggested previously by studies on humans undergoing surgery. 
Shortly after Cooper and Nelson (1962) first described increased plasma 
ACTH levels in surgically stressed patients, Estep et al (1963) demon­
strated that prior treatment of patients with dexamethasone or cortisol 
did not prevent surgically-induced rises in ACTH. ACTH release is itself 
stimulated by corticotrophin releasing factor (CRF) from the median emi­
nence of the.hypothalamus. Recent advances in the isolation of CRF are 
described below but there is evidence from rats to suggest that an extra- 
hypothalamic, cr "tissue", CRF may be released by surgery. This CRF 
appears to have a longer course of action and higher potency than hypo­
thalamic CRF (Lymangrover and Brodish, 1973);
Other physical, stimuli that have been reported to stimulate the human 
pituitary-adrenal axis include acute cold exposure (Gale et al, 1975), 
motion sickness (Eversmann et al, 1978), insulin induced hypoglycaemia 
(Greenwood et al, 1966) and pyrogen administration (Kohler et al, 1967).
Psychoendocrine research on the pituitary-adrenal cortical system has 
demonstrated that elements of novelty, uncertainty or unpredictability are 
particularly potent in eliciting enhanced adrenal cortical activity (Mason, 
1968). Such situations are essentially the same as those which affect 
adrenaline release and, as with adrenaline, large individual variations 
are observed. Individual differences may depend upon subtle factors such 
as the degree of responsibility expected of the subject during the exposure 
to stress. For example,. Bourne et al (1968) demonstrated greater increases 
in urinary 17-hydroxycorticosteroid excretion in an officer than in any of 
the enlisted men under his charge when they were under combat conditions in 
Vietnam.
The exact importance of the release of glucocorticoid hormones in 
response to stress remains unknown. From the metabolic point of view they
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increase the rate of gluconeogenesis by a mechanism which may depend upon 
a "permissive role" which somehow increases the response of the gluconeo­
genic pathway to cyclic AMP (Newsholme and Start, 1976). The glucocorti­
coids do not, however, appear to be of importance in the restoration of 
normoglycaemia following insulin induced- hypoglycaemia. .
The release of ACTH has been shown to be accompanied in rats by the 
secretion of beta-endorphin (Guillemin et al, 1977), both peptides being 
cleaved, presumably by the action of CRF, from the larger precursor mole­
cule beta lipotropin (beta-LPH) (Mains et al, 1977). Beta-endorphin has 
been shown to have potent analgesic properties in animals (Loh et al,
1976), to be present in human cerebrospinal fluid (Jeffcoate et al, 1978) 
and to be associated with the analgesia produced in humans by electrical 
stimulation of the brain (Akil et al, 1978). Two further endorphins, alpha 
and gamma, with morphinomimetic activity have also been identified as 
derivatives from beta-LPH (Ling et al, 1976). It is therefore likely that 
the stimulation of the pituitary-adrenal axis is associated with the release 
of endogenous opiates which have behavioural effects of benefit to the 
stressed organism.
The control of ACTH secretion by CRF has received considerable atten­
tion and, indeed, CRF was the first of the postulated hypothalamic factors 
controlling the release of pituitary hormones to be demonstrated biologically. 
Despite the successful identification of the hypothalamic peptides control­
ling the release of thyrotropin, the gonadotrophins and growth hormone, the 
chemical identification of CRF has proved an elusive goal.
Studies in rats have demonstrated that prior administration of AVP in 
subthreshold doses i.e. doses which did not release ACTH, could at least 
double the adreno-cortical response to crude ovine CRF given immediately 
after the AVP (Yates et al, 1971). Subsequently Gillies and Lowry 0.979) 
reported the existence of hypothalamic factors with weak CRF activity which 
potentiate the CRF activity of AVP to give it full agonistic properties 
indistinguishable from crude extracts of rat stalk median eminence (SME).
They proposed that CRF is vasopressin modulated by other hypothalamic fac­
tors i.e. vasopressin is the major component of a multi-factor system.
Such a proposal is attractive since it might explain the variety of s.tres- 
sors which result in ACTH secretion.
Very recently, Vale et al (1981) have described a 41 residue ovine 
hypothalamic peptide which releases ACTH in rats in a dose related manner.
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This CRF has now been synthesised and the effects of an intravenous dose 
of 100 microgrammes has been investigated in 6 normal men by Grossman 
et al (1982). They demonstrated significant rises in circulating ACTH 
and cortisol levels in response to this CRF but not to saline. The new 
CRF appeared to be specific for ACTH since it did not release prolactin, 
thyrotropin, growth hormone or the gonadotrophins.
At first sight such a peptide would appear to exclude a role for AVP 
in ACTH release. However, Gillies et al (1982) have demonstrated that, 
although the new CRF was more potent than AVP in releasing ACTH from rat 
pituitary cells in vitro, it was not as potent as the rat SME used by 
Gillies and Lowry (1979). Further chromatographic analysis of rat SME has 
shown at least three different CRFs, one of which is identical to vaso­
pressin. When the new CRF was added to SME, potentiation of CRF activity 
was observed which could be reduced considerably by prior administration 
of AVP antiserum. This suggested a synergism between vasopressin and the 
new CRF and Gillies et al (1982) further deduced from their studies that 
at least one other substance binds vasopressin and the 41-residue CRF to 
ensure full CRF activity. This substance remains to be identified but is 
probably of molecular weight 5,000-8,000 and generated from a higher mole­
cular weight precursor.
Growth hormone (GH)
Many of the circumstances which result in the stimulation of ACTH 
secretion have been shown to release GH. However, the control mechanisms 
for the two hormones are independent since dissociation of these two 
responses has, for example, been observed in man in response to pyrogens, 
acute myocardial infarction, metapyrone administration and insulin induced 
hypoglycaemia (Brown and Reichlin, 1972).
As discussed above, CRF does not release GH and synthetic ACTH has 
also been shown to be ineffective in stimulating GH secretion in man 
(Byyny et al, 1972). There is also little evidence to support a role for 
the endogenous opioid peptides in the control of GH (Wakabayashi et al, 
1980; Morley et al, 1980), but AVP has been shown to stimulate GH secretion 
in humans, an effect which may be prevented by alpha-adrenergic blockade 
(Heidingsfelder and Blackard, 1968). Many other stimuli have also been 
shown to cause GH release via a central adrenergic mechanism thought to 
control the release of GH releasing factor (GRF) and GH-inhibiting hormone 
(GHIH) (Martin, 1973). Thus GRF appears to be stimulated by an alpha, and
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inhibited by a beta, receptor mechanism. Despite these findings, it has 
been demonstrated that parenteral administration of adrenaline is not 
associated with GH Release (Roth et al, 1963; Schalch, 1967).
The major metabolic factor determining GH release is the blood 
glucose level. Glick. et al (1965) have demonstrated in normal subjects 
that GH secretion is stimulated by:
1. Hypoglycaemia induced by insulin when the increase in GH secretion 
occurs 15-30 minutes after the nadir in blood glucose concentration- 
is reached and persists for several hours.
2. The administration of 2-deoxy-D~glucose, an inhibitor of intra­
cellular glucose utilization which produces cerebral hypoglycaemia.
3. A rapidly falling blood glucose concentration even in the absence of 
hypoglycaemia. -
4. Prolonged fasting i.e. beyond 12-15 hours.
A reduction in blood glucose does not appear to be the factor which 
stimulates GH release during exercise, but glucose administration can 
reduce the response (Glick et al, 1965) and also resting levels (Hunter 
and Greenwood, 1964). The response to exercise has a latent period of 
about 10.minutes from the start of exercise and this period is increased 
with reduced workload. The peak responses increase with increased work­
load and are greater in untrained subjects (Buckler, 1972; Bloom et al, 
1976). '
Hypoglycaemia is also not the stimulus to GH secretion in response 
to pyrogen administration (Kohler et al, 1967).
The release of GH in response to psychological stimuli was originally 
demonstrated by Greenwood and Landon (1966) who gave a volunteer an injec­
tion of saline but told him that he had been given a dose of insulin suffi­
cient to produce severe hypoglycaemia. Despite normal blood glucose levels, 
both plasma GH and cortisol rose but saline injection in four other control 
subjects, without prior suggestion, produced no changes. This single 
observation on a single subject is one of the most widely quoted examples 
of psychological induction of GH secretion, yet it might have resulted from 
spontaneous GH release which is known to occur under resting conditions 
(Buckler JMH, 1970).
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Subsequent studies nave indicated that. GH release is not an inevi­
table response to psychological stressors ana, in fact, only occurs in 
about one third of subjects. It would appear that GH responders have 
significantly higher "egotism" than non-responders (Brown and Heninger,
1976). The release of GH, for example, in response to suspense or erotic 
films, has been shown to be independent of cortisol release and again to 
be dependent upon individual personality (Brora and Heninger, 1975).,
The function of GH secretion in response to stress is still unclear, 
but in exercise it is likely to be of value since it leads to mobiliza­
tion of lipid from fat and conserves glucose by restricting entry of the 
, metabolite into muscle and fat cells (Brown and Reich1in, 1972) .
Prolactin (PRL) ,.>••. . •r
Many studies have shown that human PRL levels increase rapidly in 
response to various stressors in both males and females. The functional 
importance of this release, particularly in men, remains obscure since 
the essential actions of PRL are mammotrophic and lactogenic. In large 
doses it has similar metabolic actions to growth hormone although hyper- 
prolactinaemic patients do not develop acromegaly. Because it is known 
to be an important osmoregulatory hormone in fish, it has been suggested 
that such a role exists for human PRL. Baumann et al (1977) were, how­
ever, unable to demonstrate any effect of water loading or hypertonic 
saline infusion upon PRL in 6 normal patients and 8 with chronic prolac- 
tinaemia, results which support those of an earlier study by Adler et al 
(1975).
Prolactin release during surgery has been well documented by Noel Vs 
group. In one study (Noel et al, 1972), major surgery involving general 
anaesthesia resulted in PRL increases of up.to five’-fold in 26 patients. 
Increases were, however, more marked in females than males. Minor pro­
cedures such as gastroscopy and proctoscopy were also associated with 
significant PRL elevations but the rises were considerably smaller and 
showed no significant differences between sexes. Although GH was also 
stimulated by major surgery, it was unresponsive to minor surgery. This 
is of considerable interest since strenuous exercise, although associated 
with small elevations in PRL, predominantly stimulates GH (Noel et al, 
1972). This differential effect of exercise, has been confirmed by Frewin 
et al (1976) and lends support to the concept that endocrine responses 
to stress may be quite specific. Thus, hypoglycaemia has been shown to
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release PRL but the reductions in blood glucose have to be more severe 
than those needed to release GH (Noel et al, 1972).
In a preliminary report on the effects of surgery, Frantz et al 
(1972) had noted that some patients had high PRL levels 24 hours prior 
to surgery. The importance of psychological factors has also been 
suggested by Noel et al (1976) who demonstrated significant increases in 
plasma PRL.in novice parachutists following their first jump. There was 
also a significant correlation between post-jump heart rates and PRL 
levels. A more formal evaluation of the effects of psychological stress 
(Miyabo et al, 1977) using a mirror drawing test failed to demonstrate 
PRL secretion in 11 male and 9 female subjects with normal personality 
but elevations in plasma PRL were observed in 3 out of 12 neurotic females 
(but not in neurotic males). Arato et al (1980) showed that electro- 
convulsive therapy (ECT) resulted in large increases in serum PRL in 14 
schizophrenic males but simulated ECT did not produce significant responses. 
It would therefore appear, as with physical stimuli, that psychological 
stressors may provoke specific endocrine responses.
The gonadotrophins
There is little evidence to suggest that the gonadotropins are affected 
by stress. Charters et al (1969) were, however, able to demonstrate signi­
ficant reductions in plasma luteinising hormone (LH) and follicle stimula­
ting hormone (FSH) on the first and second days following surgery in five 
postmenopausal females and in seven out of 8 subjects with normal gonadal 
function. In the latter group there were five females and three males but 
the authors do not state the sex of the "non-responder". If the subject 
were male then doubt must be cast on the significance of these findings to 
males. A role for these hormones in the immediate response to stress is 
not suggested and this is supported by Stearns et al (1973) who failed to 
demonstrate any effect of coitus upon serum levels of LH and FSH in six 
married couples.
Thyrotropin (TSH)
Studies in animals have suggested that the secretion of TSH is inhi­
bited by stress, probably by the inhibitory effect of the glucocorticoids 
upon the pituitary and/or hypothalamus. This suppressive effect of the 
glucocorticoids has been demonstrated upon the TSH response to thyrotropin 
releasing factor (TRF) in man (Otsuki et al, 1973) but there is no clear 
cut evidence to suggest that stress per se has this effect in humans. For
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example, the study by Charters et al (1969) failed to demonstrate changes 
in TSH levels either during, or after, surgery and pyrogen did not affect 
TSH secretion in any of 17 normal subjects to whom it was administered 
(Kohler et al, 1967).
A small but significant increase, rather than decrease, in plasma TSH 
was observed by Noel et al (1976) immediately after a first parachute jump 
in 14 men and they concluded that psychic stress was the predominant stimu­
lus to TSH secretion. Mason et al (1973) demonstrated small but consistent 
increases in TSH levels in 8 men immediately before they participated in a 
bicycle ergometer experiment designed to exercise them to exhaustion. When 
the experiment was repeated after a seven week period of intensive training, 
the responses were absent, again suggesting that psychological factors are 
of importance in TSH secretion. No psychological testing was employed to 
assess subjective stress so that this association is by no means proven.
The authors did not examine changes during or after exercise but Terjung 
and Tipton (1971) found no changes in plasma TSH concentrations in 7 males 
during or after bicycle ergometer exercise for 30 minutes at 60% VO^max. 
Similar TSH results have been obtained by Berchtold et al (1977) on both 
healthy and diabetic subjects exposed to exhaustive or mild prolonged 
exercise.
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2.4. The Posterior Pituitary
The neurohypophysis contains a number of hormones, including arginine 
vasopressin, oxytocin, neurophysins, enkephalins, thyrotropin-releasing 
hormone, vasoactive intestinal polypeptide, somatostatin and some analogues 
of vasopressin. Of all these hormones, AVP has been studied in this thesis 
because of its role in blood volume regulation, its postulated role in the 
control of ACTH secretion and its activity as a vasopressor agent. More 
recently there has been an accumulation of evidence to suggest that it has 
a number of CNS functions, particularly in the control of memory.
The major role of AVP is in the control of renal water excretion and, 
indeed, AVP is often referred to as antidiuretic hormone (ADH). Its con­
centration in plasma is dependent upon changes in blood osmolality as 
originally demonstrated in the dog by Verney (1947) who formulated the con­
cept of a hypothalamic "osmoreceptor". Since then, much work has been 
carried out on the effects of osmolality upon AVP secretion in a variety 
of species and a number of reviews have been written on the subject (Bie, 
1980; Weitzman, 1979; Robertson, 1977). In healthy humans there are large 
individual differences in osmoreceptor threshold but, on average, the level 
of osmolality at which increases in AVP appear to begin is about 280 mosmol Kg 
(Robertson, 1977). It is also possible that the osmoreceptors monitor and 
respond to rate of change of osmolality (Schrier, et al, 1979).
The nature of the "osmoreceptor" itself remains controversial. Recently 
it has been suggested by work in the goat that there is a specific periven­
tricular sodium receptor for the control of AVP release (Andersson and 
Olsen, 1977), since the effect of intraventricular sodium upon AVP secretion 
may be abolished by inhibitors of Na+ K+ -ATP-ase. Injection of a hypero­
smotic solution into the carotid artery (as used by Verney) is proposed to 
act by inducing a water shift across the blood-brain barrier so producing a 
rise in cerobrospinal fluid Na+ concentration and stimulation of AVP secre­
tion.
Further complications have also been added by the possibility that 
there are extra-cerebral osmoreceptors in the liver and the gastrointestinal 
tract (Bie, 1980), but the evidence is indirect, scanty and, as yet, only 
based on animal studies.
Unlike osmolality, there has been some uncertainty as to the importance 
of changes in blood volume and pressure in the control of AVP secretion. 
Bioassay studies in animals have suggested that blood volume reductions of
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between 8 to 10% result in significant increases in antidiuretic activity. 
However, a sensitive radioimmunoassay used by Robertson1s group (Robertson,
1977) failed to demonstrate changes in plasma AVP when blood volume was 
reduced by 6-9% by phlebotomy in recumbent humans. ' Significant changes 
only occurred when phlebotomy was combined with upright posture, suggesting 
a "threshold" reduction in blood volume of between 10 and 20%, at which 
values sharp falls may occur in systemic blood pressure.
Nonosmotic release of AVP without a fall in systemic arterial pressure 
might occur by decreasing the activity of low-pressure, left atrial baro- 
receptors. Early work by Henry, Gauer and Reeves (1956) demonstrated that, 
in anaesthetised dogs, distension of the left atrium by an intra-atrial 
balloon induced a diuresis. Similar experiments on dogs have since con­
firmed that a fall in bioassayable AVP results from left atrial distension 
(Johnson et al, 1969). Conversely, falls in left atrial pressure are 
associated with increases in radioimmunoassay titres of AVP (Yaran and 
Bennett, 1978). Despite these findings and those of other workers (Schrier 
et al, 1979) which implicate left atrial receptors in the control of AVP 
secretion, some researchers have questioned these results and have suggested 
that a blood borne agent other than AVP is responsible for the renal effects 
of left atrial distension (Knapp et al, 1981); Whatever the actual effects 
of left atrial receptors, it is still not clear that they have an important 
role to play in the control of human AVP secretion since Robertson's -study 
above was also associated with reductions in pressure in the high pressure 
circulation.
Robertson et al (1973) investigated the effects of a short infusion of 
a ganglion blocking drug (trimethaphan) upon plasma AVP levels in 3 subjects. 
The'details of the experiment are incomplete since it was a minor part of a 
much larger study to define the effectiveness of a new AVP radioimmunoassay. 
In one subject, who was certainly waterloaded, the drug produced a rapid 
fall in mean arterial pressure of about 25% and a marked rise in plasma AVP 
from 1.5 pgml  ^ to 30 pgml  ^but osmolality remained at 280 mosmol kg  ^or 
less throughout the experiment. In the two other subjects, presumably also 
waterloaded (but not actually stated), mean arterial pressure was reduced 
by about 12 and 5% and the resultant rises in AVP were proportionately 
smaller at 4.8 and 1.8 pgml  ^ respectively. If small falls in arterial 
pressure, do release AVP then this would be of particular relevance since 
much of the work of Henry and Gauer assumed that, in terms of stimulus to 
AVP secretion, small changes in arterial pressure were insignificant when
compared to changes in atrial pressure (Henry, Gauer and Sieker, 1956).
For example, a 20% loss of blood in 12 anaesthetised dogs resulted in a 
fall of 8 mmHg from a control arterial pressure of 113 mmHg - such a 
change (7%) could be significant.
There is a considerable body of evidence to implicate the arterial 
baroreceptors in the control of AVP secretion. Share and Levy (1962) 
showed in anaesthetised dogs that bilateral carotid occlusion.per se did 
not result in elevated AVP levels, as measured in a water loaded rat bio­
assay system. If 'cervical vagotomy was performed, AVP titres rose approxi­
mately threefold but then, if the carotid arteries were occluded, there was 
an immediate further twofold increase in AVP. These effects on AVP secre­
tion would explain the reduction in free water clearance observed following 
cervical vagotomy in anaesthetised dogs by Schrier and Berl (1972). T h e - 
antidiuresis was due to afferent parasympathetic fibres since atropinic 
blockade of efferent fibres in intact animals did not result in changes in 
free water clearance. They further demonstrated that cervical vagotomy was 
ineffective in hypophysectomised animals indicating that the effects of the 
parasympathetic system were not mediated by changes in AVP metabolism. The 
explanation of these findings is that low pressure receptors exert an inhi­
bitory influence, via the vagus, upon information from the high pressure 
baroreceptors, a mechanism also implicated in the control of cortisol secre­
tion following haemorrhage and hypotension (Cryer and Gann, 1973 and 1974) .
The sympathetic nervous system has also been implicated in the control 
of AVP release, since infusions of noradrenaline have been shown to suppress 
AVP release in experimental animals and man (Baldwin et al, 1963), It 
appears that this action of noradrenaline is dependent upon the integrity 
of the carotid baroreceptors since it is not seen in baroreceptor-denervated 
animals (Berl et al, 1974a). This action is alpha-receptor mediated and, by 
contrast, beta-adrenergic stimulation is associated with the production of 
an antidiuresis (Berl et al, 1974b).
The relative importance of volume/pressure receptors and osmoreceptors 
in the control of AVP secretion remains undecided, especially in humans.
The importance of AVP in the normal control of human blood pressure has 
not been defined. Despite the demonstration in experimental animals that 
the administration of AVP can increase blood pressure by peripheral and, 
possibly, central mechanisms (Rettig et al, 1982), this does not appear to 
occur in normal humans. Padfield et al (1976) were unable to raise blood
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pressure in 5 normal subjects who'were infused with sufficient AVP to produce 
plasma concentrations of up to five times the highest value measured in a 
group of patients with malignant hypertension. However, AVP has been 
implicated in the pathogenesis of essential hypertension (Khokar and Slater, 
1976), but elevated AVP levels in malignant hypertension have been attri­
buted to changes in plasma volume that occur in this state i.e. a secondary 
effect, rather than the cause, of hypertension (Padfield et al, 1976). 
Hypertension is not associated with the syndrome of inappropriate AVP secre­
tion (Padfield et al, 1981) although, as emphasised by Gitelman and Blythe 
(1981), this might be explained by oversecretion of a cross-reacting, non­
pressor form of AVP i.e._an AVP analogue with immunonological activity in 
current RIA systems but no biological activity. This argument could, of 
course, be resolved rapidly by using one of the original bioassay systems 
for AVP which depended upon the blood pressure response of an anaesthetised 
dog or rat.
The role of stress in the secretion of AVP has received considerable 
attention, more recently because of its potential role in the control of 
ACTH secretion. Brennan et al (1975) studied the effects of stressful 
situations in rats: light ether anaesthesia, water immersion, or pain pro­
duced by intra-peritoneal injections of isotonic saline. Surprisingly, 
none of these stresses had any detectable effect upon plasma AVP even 
though all three resulted in very large increases in corticosterone.
Further work by this group indicated that osmotic stimulation of AVP secre­
tion in the rat is not associated with enhanced corticosterone secretion.
In humans, a decrease in urine flow with surgery was observed as early 
as 1859 by Bernard (see Weitzman, 1979). Later studies, employing bioassay 
in water-loaded rats, suggested that this effect was produced by increased 
AVP activity (Moran et al, 1964). This group also demonstrated that AVP 
secretion was particularly sensitive to visceral traction, an effect which 
is thought to depend upon the spinal afferent system since the response 
can occur independently of osmotic or haemodynamic changes. It has also 
been demonstrated in rats that morphine inhibits traction-induced AVP 
release, an effect which may be reversed by naloxone (Ukai and Okumura,
1980). This raises the question of whether the endogenous opiate peptides 
may be involved in the control of AVP secretion. Support for this in man 
comes from work by Grossman et al (1980) who showed that the injection of 
1 mg of a long-acting analogue of met enkephalin, DAMME, into water-deprived 
subjects produced a diuresis which was attenuated by naloxone. AVP levels 
also failed to rise after hypertonic saline infusion when DAMME had been 
administered, prior to the infusion.
46 .
Other stressors associated with elevations in plasma AVP include 
those which induce nausea and vomiting. This has been demonstrated in 
humans given emetic doses of apomorphine (Rowe et al, 1979) where nausea, 
but not necessarily vomiting, is required to elicit this response. The 
authors ascribed the effects of apomorphine to dopaminergic stimulation 
of the supra-optic nucleus since the effect could be prevented by prior 
administration of dopamine antagonists. Non-pharmacologically induced 
sickness may stimulate AVP secretion as shown by studies on sickness 
induced on a rotary chair (Eversmann et al, 1978). The degree of stimula­
tion of A W  secretion appeared to correlate well with the severity of the 
stress.
AVP has also been shown to be influenced by heat and cold stress.
Segar and Moore (1968) demonstrated reductions in plasma levels of AVP by 
bioassay (waterloaded rat) in response to 60 minutes of exposure to 13°C 
and elevations when ambient temperature was increased to 50°C for 2 hours. 
These changes were attributed to alterations in central blood volume 
induced by the environmental conditions. It is difficult to know what 
reliance can be put on the finding of a reduction in AVP by bioassay since, 
even with highly sensitive RIAs, normal levels of AVP are very much at the 
lower limits of detection in the assay system. In Segar and Moore’s assay 
the potency of their standard was not compared against a reference standard 
so that it is not possible to relate biological activity to actual concen­
tration. By their own admission, "a- significant error in absolute values 
may have been introduced”.
Exercise stimulates AVP secretion but, as appears to be the case with 
the catecholamines, the change in plasma AVP is correlated with the inten­
sity of the workload and its duration (Wade and Claybaugh, 1980). AVP 
stimulation under such conditions is probably dependent upon changes in 
osmolality, as suggested by a high correlation between plasma Na+ concen­
tration and changes in AVP during exercise (Convertino et al, 1981). 
Hypovolaemia is likely to be a secondary stimulus.
The possible effects of hypoxia upon AVP secretion will be discussed 
in Section 6.
Although the primary effects of AVP are upon the kidney and cardio­
vascular system, there has been considerable interest in the behavioural 
effects of the hormone which have been reviewed recently by Koob and Bloom 
C1982). In particular, animal experiments have suggested a role for A W
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m  the enhancement of both consolidation and tetrieval of memOiy. W e m -  
gartner et al (1981) have investigated the effects of administering DDAVP 
(l~desamino-8-D“AVP) on human memory functions. The results, when compared 
to those obtained with placebo, suggested significant improvements in 
healthy subjects treated with DDAVP, and similar changes in 3 out of 4 
patients suffering from endogenous mood disturbance with cognitive 
impairment.
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2.5. Current knowledge on hormonal changes induced by acceleration
Few studies have been carried out on the effects of acceleration upon 
endocrine function. Those that have been reported are based upon measure­
ments made either under conditions where a number of stressors may be 
acting (e.g. in aerobatic flight), or during exposure to acceleration pro­
files rarely encountered during operational flight (e.g. +3 Gz for 20 
minutes is a commonly used, but unrealistic, profile). No study has yet 
been comprehensive enough to provide the type of "dose-response" data 
necessary to meet some of the objectives outlined in Section 2.1.
The sympathetic nervous system
It is reasonable to suppose that increased +Gz acceleration will elicit 
the secretion of catecholamines, since the.act of standing up from a lying 
position, i.e. a change of G vector from x to z, is associated with enhanced 
sympathetic activity. In a comprehensive study Sundin (1958) showed that 
tilting of 22 healthy subjects, from recumbency to a head-up position of 
+75°, induced up to fourfold increases in the urinary excretion of both 
noradrenaline and adrenaline. If the postganglionic vasomotor nerves were 
blocked with Mecamylamine, the increases in noradrenaline, but not adrena­
line, were abolished. Sundin concluded that the increased noradrenaline 
excretion reflected the enhanced sympathetic activity necessary to prevent 
postural hypotension and that the increase in adrenaline excretion reflected 
the general stress of the procedure.
A preliminary study by Goodall and Meehan (1956) attempted to correlate 
urinary catecholamine levels with high or low G tolerance in an unspecified 
number of subjects. All subjects showed elevated urinary excretion of adrena­
line. and noradrenaline but the time course of excretion differed between the 
two. In the pre-run period it was mainly adrenaline that was increased, 
suggesting that its production was related to the anxiety of anticipating 
the centrifuge runs (the levels of acceleration employed were not specified). 
Noradrenaline increased mainly in the post-run period and was therefore pro­
bably related to the physiological changes induced by acceleration. Subjects 
with a high G tolerance showed a higher noradrenaline output during centri­
fugation and pre-run than did low G tolerance subjects and, when high toler­
ance subjects were exposed to different G levels (again not specified), the 
noradrenaline output was greater with higher G loads but this association did 
not hold true for adrenaline.
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In a more comprehensive study (Goodall and Berman, 1960), nine 
healthy male volunteers were either centrifuged at 12G (rate of onset of 
0.2G.S  ^ and maximum duration of 3 minutes) or given a mock ride in which 
the centrifuge was spun at 2 rpm for 3 minutes. The subjects were unaware 
of the condition to which they would be exposed and were placed in a seat, 
which was at an angle of 78° from the vertical (so that exposure was pre­
dominantly Gx). Urine samples were collected 1 hour before and 10 minutes 
before centrifugation; post-run samples were collected 30 and 60 minutes 
after centrifugation. Adrenaline excretion increased by similar amounts 
(60% and 51%) prior to actual or mock centrifugation and similar levels 
were observed post-run. By contrast, noradrenaline was not significantly 
altered by mock centrifugation but increased significantly following actual 
centrifugation. This experiment gave further support to the concept that 
adrenaline excretion was influenced by emotional factors and that noradrena­
line release was more closely related to the physical, haemodynamic changes 
produced by acceleration.
Goodall (1962) was able to confirm these different patterns of excre­
tion in a further study where his subjects were exposed to ten 15 second 
centrifuge runs at "subthreshold blackout levels", each run being separated 
by a 3 minute rest period. Noradrenaline excretion was also found to be 
higher in repeated +4Gz runs than in repeated +2Gz runs, although, in con­
trast to his earlier study with Meehan CGoodall and Meehan, 1956), there 
was no significant difference in noradrenaline output when subjects with 
different G tolerances received the same centrifugation pattern of repeated 
+2.5Gz exposures.
The association between the psychological stress of centrifugation and 
adrenaline excretion has been confirmed by Frankenhauser et al (1962). These 
workers were able to demonstrate that repeated exposures of novice subjects 
to +3Gz acceleration reduced both subjective stress and urinary adrenaline 
excretion and that there was good correlation between these two parameters.
The only other centrifuge studies of relevance to the catecholamines 
are those of Harrison. When subjects were exposed to +3Gx for 20 minutes, 
significant elevations in plasma free fatty acids (FFA) were observed follow­
ing centrifugation (Harrison, 1973a). These changes were attributed.to a 
catecholamine-induced lipolysis but catecholamine levels were not measured. 
However, in a subsequent study (Harrison, 1973b) the beta-blocker oxprenolol 
abolished increases in FFA seen in subjects receiving placebo when both 
groups were exposed to consecutive accelerations of +2Gz for one.minute,
+3Gz for one minute and acceleration to grey-out.
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No'studies have yet been undertaken to measure the effects of +Gz 
acceleration upon levels of catecholamines in plasma. This is particu­
larly necessary since the information that can be gained from urine studies 
is limited (see Section 3.3) and the fluorimetric methods of analysis used 
in all the above studies (except Goodallrs: see page 103) are not as sensi­
tive as the metaods now-available-for plasma catecholamine measurement.
Further urinary catecholamine measurements have been carried out on 
pilots executing a pre-arranged sequence of 60-minutes aerobatic flight, 
involving accelerations of between -1.8Gz and *5.5Gz (Pinter, 1974).
Urinary vanilmandelic acid (VMA) excretion was found to increase in anti­
cipation of, but not in response to, the flight. Since VMA is produced by 
the metabolism of both catecholamines, it is not possible to define this 
response in terms of adrenaline or noradrenaline. The failure of this type 
of flight to increase VMA excretion is surprising since centrifugation 
(+6Gz for 3 minutes in a seat inclined 65° from the vertical) has been 
associated with tenfold increases in the excretion of this metabolite 
(Berman, 1959). This difference may be accounted for partly by .the longer 
sampling interval in the aerobatic study which would tend to damp any 
responses.
Simulated 12-hour flights have been reported (Hale et al, 1965) to 
increase the urinary excretion of adrenaline (A) and noradrenaline (NA), 
although the ratio of NA/A fell significantly. This would again support 
the concept that psychological factors influence adrenaline excretion more 
than noradrenaline. In another study, involving actual and simulated air­
craft sorties (Krahenbuhl et al, 1980), both urinary adrenaline and nor­
adrenaline excretion rates were increased following the sorties. The rela­
tive proportions of adrenaline and noradrenaline remained similar across 
all but the final trials in both simulator and aircraft, where noradrenaline 
began to increase while adrenaline decreased. This change in excretion 
pattern was attributed to the acquisition of competence and control 
(cf. Frankenhauser, 1975).
Finally, urinary catecholamines have been measured prior to, and 
following, mock and actual impact deceleration at +20Gx (Foster and 
Sonntag, 1969). Before impact and mock exposure, both adrenaline and nor­
adrenaline excretion increased significantly (approximately 100% and 50% 
respectively). No further changes were observed in noradrenaline after 
either exposure condition, but adrenaline increased about 5-fold from con­
trol after actual impact and a smaller increase was observed after mock runs.
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A Russian study has a.lso demonstrated that adrenalme is produced in pr6“ 
ference to noradrenaline when subjects are impacted (Vyazitskii, 1977). 
These findings again support the concept that adrenaline is particularly 
influenced by psychological stressors.
The anterior pituitary
Very little attention appears to have been directed towards the effect 
of +Gz acceleration upon anterior pituitary function. Wegmann et al (1966) 
investigated the effects of exposure to +2.5Gz for 30 minutes upon peri­
pheral blood levels of free 17-hydroxy-corticosteroid in 12 novice male 
subjects. At the end of centrifugation the mean levels had risen by about 
40% but, unfortunately, no further samples were taken until 90 minutes 
after exposure by which time values were virtually back at control levels. 
The authors did not find a correlation between the increased production of 
corticosteroid and tolerance to +Gz as determined by black-out.
Lipman et al (1970) were unable to find significant changes in the 
plasma cortisol of 8 fasting males during acute or chronic exposures to 
an acceleration profile of up to +4Gz for 30 seconds. The authors do not 
state,whether an anti-G suit was worn - if the subjects were protected in 
this way, acceleration stress would be minimal using this profile.
In a more recent study Vernikos-Danellis et al (1978) demonstrated 
a correlation between plasma ACTH levels and tolerance (time to grey-out) 
in 8 centrifuge-experienced women. Although cortisol was also increased, 
a correlation with tolerance was not observed. However, the samples were 
taken 10 minutes after the run and would certainly not have reached peak 
values at the time.
Harrison (1973a) observed increases in plasma 11-hydroxycorticosteroid 
levels in some subjects exposed to 3G for 20 minutes in the less stressful 
anterior-posterior force vector (+Gx). In a study on aerobatic flight 
(exposure to +2.8 to +5.5Gz), significant increases in serum corticoster­
oids were observed (Pinter, 1974), but changes were attributed mainly to 
emotional factors. No study has been undertaken to define clearly the 
relationship between blood levels of cortisol and the degree of accelera­
tion stress.
In Pinter’s study (1974) serum growth hormone was markedly increased 
over pre-flight levels at 0, 40 and 80 minutes post-flight. The change in 
GH was. greatest in experienced pilots where workload was most demanding and
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the author concluded that the changes In GH were related to workload 
intensity rather than to anxiety since pre-flight levels were unchanged.
The contribution of accelerative loads was not discussed.
Lipman et al (1970) investigated the effects of acute and chronic 
acceleration on the metabolic responses of 8 fasted males to intravenous 
infusion of 2-deoxy-D-glucose (2DG) which is known to stimulate GH release.
The expected increases in GH occurred, but acceleration had no effect on this 
response. Control experiments with acceleration, but no infusion, failed to 
demonstrate changes in GH levels, but the charcoal radioimmunoassay employed 
was of poor sensitivity.
No studies appear to have been carried out on the effects of +Gz 
acceleration on TSH, PRL, LH or FSH.
The posterior pituitary
Although it had been known for many years that when a normal person 
assumes the erect posture, his rate of urine production is reduced, it was 
not until comparitively recently that this was shown to be due to enhanced 
AVP secretion. Thus, Segar and Moore (1968) used a water-loaded rat 
bioassay to demonstrate threefold increases in blood ADH levels in humans 
who changed from a recumbent to a seated posture. A change to a standing 
posture resulted in levels 8 times higher than in recumbency. Compared to 
later studies these changes are rather dramatic and since, as discussed 
above, Segar and Moore’s assay was poorly standardized, the results may have 
been exaggerated by poor analytical technique.
More recently, it has been possible to measure AVP levels by radio­
immunoassays such as the one employed by Baylis and Heath (1977), They 
were unable to demonstrate a change in plasma AVP concentrations after 40 
minutes of orthostasis (from recumbency) in normally hydrated subjects but, 
after 12 hours dehydration, small but significant rises were observed when 
the experiment was repeated. In five normally hydrated subjects who developed 
presyncopal symptoms during orthostasis, extremely high plasma AVP levels 
(up to more than llOpgml” )^ were measured within one minute of the development 
of symptoms. Osmolality was unchanged by orthostasis in all groups so that, 
although not discussed by the authors, it is reasonable to assume that 
increased AVP secretion was initiated by the stimulation of cardiovascular 
receptors.
gradients seen on standing, it might be expected to stimulate AVP secretion. 
Early studies concentrated on the effects of acceleration upon urine flow. 
Stauffer and Errebo-Knudsen (1951) investigated urine output and specific 
gravity (SG) in ten water-loaded male subjects under three conditions: control 
centrifugation at +lGz, unprotected exposure to +3Gz for one minute and 
exposure to +5Gz for one minute with anti-G suit protection. Urine output 
increased and SG decreased during the water-loading period but, following 
centrifugation, the water diuresis was reduced and SG increased compared to 
control conditions. The changes were greater for +5Gz than +3Gz exposure.
Two of the subjects blacked out during the 5G runs and had to be brought down 
early, but it is not possible to gauge how important their contribution was 
to the average results quoted in the paper since individual variation was 
not discussed. This is an important consideration since the anti-G suit 
might be expected to reduce A W  secretion in response to +Gz acceleration.
The authors attributed the changes to either altered renal haemodynamics or 
increased AVP secretion, or both. Clearly their experiments did not provide 
information on mechanisms.
A subsequent study by Piemme et al (1966) on 5 water-loaded subjects, 
showed that urine volume was decreased in all subjects following 90 minutes 
at +3Gz, when compared to the same length of exposure at +lGz or +2Gz. Since 
the glomerular filtration rate was unchanged and there was a concommitant 
fall in free water clearance, the authors proposed that the results demon­
strated an AVP-induced antidiuresis.
One minute exposures to acceleration in the x axis have been reported to 
produce no changes in urine output (Stauffer, 1951) until a level of +7Gx was 
reached, when an antidiuresis occurred. On the other hand, Watson and Rapp 
(1962) reported a diuresis after 4Gx for 10 minutes and they'attributed this 
to a shift of blood into the thorax which, by stimulating central volume 
receptors, suppressed AVP output, but AVP levels were not assayed. Indeed, 
few attempts have actually been made to measure AVP levels in humans who 
have been accelerated. Noble and Taylor. (1953) failed to find any AVP in 
the urine of 9 subjects who had blacked out after gradual onset +Gz runs. 
However, the samples were sent from Toronto to the "University of Western 
Ontario and some activity may well have been lost in transit. The exact 
conditions of sample storage were not discussed in their paper and the authors 
also seem to have been confused by acceleration terminology as they equated
black-out with unconsciousness. This confusion is also suggested by the 
levels of +Gz which were said to have produced unconsciousness i.e. +4 to 
+6.5Gz, the former level indicating very low tolerance since gradual onset 
runs were employed.
Garrow (1960) obtained variable results in a study on 3 water-loaded 
subjects exposed to +2Gz for 10 minutes. Only one subject, who was actually 
the author, consistently produced an antidiuresis with an associated increase 
in urinary ADH as measured by rat bioassay. One subject showed an elevated 
ADH level on one out of two occasions and the other showed no changes at all.
A rat bioassay was also used by Rogge et al (1967) to investigate the 
effects of +2Gz and +2Gx acceleration for 30 minutes on peripheral venous ADH 
levels in 9 male volunteers. The subjects were not waterrloaded and the 
protocol adopted may have encouraged dehydration although this was not clear 
from the authors* description. Each subject showed a rise in ADH concentration 
in samples taken immediately after +2Gz acceleration: a mean increase of 
2.97±0.93yUml~^- from a mean control value of under 2yUml” -^ (conversion to 
absolute concentrations is not possible from the assay information supplied 
in the paper). The rises were abolished, in all but 2 subjects, by the use 
of an anti-G suit, inflated to 60 mmHg during repeat runs and exposures 
to +2Gx acceleration resulted in significant reductions in ADH concentration 
(a mean fall of about 50% though this cannot be calculated accurately from 
the figures provided in the paper). Again, for the reasons outlined above, 
the reliance that one can put on the finding of reduced AVP levels in this 
bioassay system is questionable. However, since rises in concentration were 
abolished by the anti-G suit and rises were not seen when the acceleration 
was acting in the x vector, the results do suggest that cardiovascular 
receptors may be important in the release of AVP by +Gz acceleration.
Greenleaf et al (1977) have recently used a radioimmunoassay to measure 
AVP levels during experiments that were designed principally to investigate 
the effects of dehydration on G tolerance. Large increases in AVP were 
recorded in response to black-out levels of acceleration and these rises 
were associated with loss of plasma volume but not changes in osmotic 
concentrations.
No studies appear to have been carried out on the secretion of oxytocin 
in response to "high G".
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SECTION 3 : HORMONE ASSAY TECHNIQUES
3.1, Introduction
3.2, Radioimmunoassay
3.3, The Assay of Catecholamines
56
O T?r»nr»TO V  o  • T j r m ^ jr n v T ?  a c c a v  T O n m ' r T A T T r oojjuxJLw lN  j> • r iU ra ,ivM/ i \ i j  n.ooi\I x iL u ii.i> ixyu x jQ
3*1. Introduction
Until the last decade only a limited number of hormone assays were 
available and they .fell into two broad types: biological and chemical.
Bioassay depends upon measurement of a characteristic biological 
action of the hormone, using either tissue or whole animal preparations.
Thus, prolactin may be measured by a histological assessment of the 
secretory activity of cultures of breast tissue from 8-9 day pregnant 
mice (Kleinberg and Krantz, 1971) but the sensitivity of such an assay will 
only be close to that of immunoassay when it is in expert hands. Bioassay 
is labour intensive,•and may lack specificity because other hormones with 
similar biological activity may be inadvertently measured. For example, 
the prolactin assay described above requires the addition of antisera to 
human GH because the lactogenic activity of GH may give rise to spurious 
results.
The measurement of biological activity does, however, avoid difficulties 
that may arise in immunoassay due to circulating fragments with immunological, 
but not,biological, activity. This is of particular relevance in the measure­
ment of ACTH (Besser, 1973) and has led to development of a sensitive, but 
time-consuming, cytochemical assay using sections of guinea-pig adrenal 
(Alaghband-Zadeh et al, 1974). Lack of specificity is one reason why ACTH 
was not measured in the experiments to- be described, cortisol levels being 
employed as an indirect measure of ACTH secretion. As Besser (1973) states: 
"plasma cortisol measurement is as satisfactory as measurement of plasma ACTH 
when assaying the activity of the pituitary-adrenal axis and is much simpler 
to perform".
Chemical methods, based on the determination of a functional group on 
the hormone molecule with characteristic light absorption or fluorescence 
have .been used extensively in the past for the measurement of steroids e.g. . 
11-hydroxycorticosteroids. These methods also lack specificity and are 
extremely time-consuming.
The development of binding assays has been a major advance in hormone 
measurement. Such assays depend upon the detection of the hormone by a 
binding protein, which may be naturally occurring, e.g. thyroxine-binding 
globulin or, more commonly, by an.antiserum raised in animals. Indeed, any
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slibstance to whxch antxbodxes can bo r ax s ed can, xn prxncxple , bo dotoctod 
by immunoassay. The most commonly used form of immunoassay, and that 
used in this thesis, is radioimmunoassay.
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3.2. Rad.ioimmunoas s ay
Historically, radioiodinated antigens and antibodies were first used 
to study antibody-antigen reactions. With such technique^ BersonTs group 
was able to demonstrate circulating anti-insulin antibodies in diabetics 
treated with animal insulins and also in non-diabetic patients receiving 
insulin hypoglycaemia therapy. The foundation for the first radio­
immunoassay (RIA) was laid when it was demonstrated, in vitro, that 
unlabelled insulin could displace 1-131 labelled insulin bound to these 
human anti-insulin antibodies. In the insulin RIA (Yalow and Berson, 1960), 
antibody (raised in guinea-pigs) wTas restricted to a quantity that would 
bind about 50% of a fixed aliquot of labelled hormone. Addition of unknown, 
or known, amounts of- unlabelled insulin reduced the amount of bound label to 
a degree determined by the concentration of unlabelled hormone. Bound (B) 
and free (F) fractions of label were then separated by chromatoelectrophoresis 
and the radioactivity counted to construct a standard curve of the B/F ratio 
against concentration. The technique could measure levels of insulin as 
low as lyUml~^.
The general concept of Yalow and BersonTs assay has been applied with 
great syccess to the measurement of a wide range of hormones and other 
antigens. Improvements have been made in separation techniques and 1-125 
is now used instead of 1-131 because of its longer half-life (60 days instead 
of 8 days) and because it can be counted about twice as efficiently as 1-131. 
However, the basic equation common to all RIAs remains:
K1
Ag AgAb Ag (where Ag* is labelled antigen)
+Ab +
Ag* <- Ag*Ab Ag*
K2
Most antisera will display a high avidity of binding to their respective 
antigens (ie K1»K2) so that, providing the antibody (Ab) is in limited 
concentration, the concentration of Ag is proportional to:
[ Ag*Ab] _ B> . Bound ,
[Ag*] F 1,e* Free
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The distribution of radioactivity maj^  equally well be expressed as 
the ratio F:B or as the percentage of total counts, bound or free.
One of the most attractive features of RIA is its sensitivity which 
permits the measurement of exceedingly low concentrations of hormone. 
Sensitivity is mainly a function of the avidity of binding (Kav=Kl/K2) 
between the antiserum and its respective antigen. The importance of this 
relationship is illustrated by the following equation:
- [Ab.Ag]
K3V [Ab] [Ag]
If 50% of the antigen is bound to antibody, Ab.Ag=Ag so that:
1
Kav =
[Ab]
Thus, if the Kav of the antibody is 1x10^ 1 mole-1, the antibody
concentration required for 50% binding will be about lxl0~6 and the 
sensitivity should be in the low micromole, high nanomole range. But if the 
Kav is above 1x10 1 mole-1, sensitivity will extend into the picomole
range.
In practice, what is being measured is the overall avidity of a 
mixture of different antibodies for the protein as a whole. The value for*
Kav is greatly influenced by other factors such as ionic strength, pH and 
temperature. For example, Kav increases as temperature is lowered and antigen 
binding is usually maximal at or near 4°C, the temperature at which most of 
the RIAs used in this thesis were incubated (see section 9). The sensitivity 
of the assay will also be increased by reducing the amount of labelled hormone 
used as much as possible since less unlabelled hormone will be needed to 
induce a significant decrease in antibody-label binding. The minimum 
detectable level of label will be dependent upon its specific activity i.e. 
radioactivity per unit mass.
Optimum assay conditions for sensitivity are derived from intensive 
laboratory assessment. The determination of these conditions was beyond the 
scope of this thesis which utilised RIAs which had been fully established by 
outside authorities (see section 9 for assay protocols). The AVP assay did, 
however, require the production of labelled hormone and its laboratory 
assessment.
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The preparation of labelled hormone is achieved by oxidation of 
radioactive iodine to atomic iodine and its incorporation into the peptide.
For the AVP assay, chloramine T was used as the oxidising agent in-a 
method based on that originally described by Greenwood et al (1963) and 
outlined in section 9.
The final stage in any E.IA is the physical separation of bound and free 
fractions of antigen. Under perfect conditions, the separation should be 
complete but in practice it is not, because some of the free labelled antigen 
always separates out with the bound fraction due to trapping in the precipitate 
(or on the walls of the assay tubes), tracer inpurities and incompleteness 
of separation. Some- separating media, such as charcoal, may also encourage 
dissociation of the bound antigen-antibody complex.
The most- commonly used separation technique is the double antibody 
method involving precipitation using antibody directed against the first, 
hormone-binding, antibody. This second antibody is specific to the 
gammaglobulin of the species in which the first antibody was raised e.g. if 
the first antibody was from a rabbit,.a second antibody may be raised in a 
donkey.^ Precipitation reactions only occur at high antibody/antigen concen­
trations so that a large amount of second antibody is required plus a large 
amount of inactivated serum from the species in which the first antibody 
was raised.
Optimum concentrations again require considerable laboratory assess­
ment to determine the minimum quantities of second antibody and carrier 
serum which result in completeness of separation and low assay blanks. The 
method is efficient and simple to perform but requires additional incubation 
periods.
In the cortisol assay separation was more easily achieved because the 
antiserum was immobilized on the surface of polymer particles of uniform 
diameter (Amerlex antibody suspension). This solid phase system permits 
virtually-complete separation with excellent reproducibility and precision.
The third system used in this thesis employed charcoal adsorption of 
free ligand, so that, in contrast to the above techniques, the bound complex 
remains in the liquid phase i.e. the supernatant. The technique is rapid,
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simple to perform and cheap. However, it is relatively inefficient as some 
absorption of bound complex is unavoidable and dissociation ("stripping") 
of complexes may occur because the charcoal competes with antibody for the 
ligand. Thus control of molarity, temperature, pH and timing of centri­
fugation is important.
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Estimation in urine
Only a small fraction (between 1 to 4%) of the noradrenaline and 
adrenaline which enter the circulation appears in the urine as free 
catecholamines. The majority of the remainder is metabolised to metane- 
phrines and VMA which appear, in conjugated form, in the urine. Their 
rate of appearance is slow and therefore less likely to be useful if one 
wants to measure sympatho-adrenal responses to short term stress. Conjugated 
noradrenaline and adrenaline in the urine are derived, in part, from dietary 
sources so that spurious results may be obtained if diet is not closely 
controlled. Most investigators therefore assay free catecholamines using 
fluorimetric methods.
Such a technique was used in section 4 of this thesis and was based on 
the method described by Crout (1968). It consists basically of extraction 
of the catecholamines by absorption on to alumina at pH 8.4, followed by 
elution with acetic acid and fluorimetric estimation of the.fluorophores 
produced by oxidation of the eluate. Differential analysis is possible because 
only adrenaline is oxidised by iodine to its corresponding fluorophore when 
the reaction is carried out at pH 3.5. When the pH is then increased to 6.5, 
noradrenaline is also oxidised. The method is time-consuming, but reliable 
results and accurate separation of the two catecholamines can be achieved.
Estimation in plasma -
The sympathetic nervous system1s response to stress is rapid and 
basal catecholamine values are soon restored after cessation of the stress.
In order to guarantee success, urine sampling has to be frequent when the 
stress is applied for a short time, lest the rises in urinary catecholamine 
levels are swamped by dilution with urine taken when the subject has returned 
to the control situation. If the stress is also associated with oliguria 
then urinary estimations of catecholamines are no longer a practical method 
of appraising sympatho-adrenal activity. This, in fact, was the case with 
the initial studies in section 4 and it was therefore necessary to consider 
the use of assays to determine the blood levels of noradrenaline and 
adrenaline.
The principal methods at present available for measuring plasma 
catecholamines are either those employing high performance liquid chroma­
tography (HPLC), with fluorimetric or electrochemical detection, or
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radioenzymatic methods. The latter assays are based either on the use of 
two isotopes or a single one, the advantages of the single isotope being a 
significant reduction (up to ten-fold) in the assay time, improved sensiti­
vity and greatly reduced sample volume (Johnson et al, 1980). Compared to 
HPLC methods, the radioenzymatic assays do not require investment in 
expensive, equipment and, in good hands, are undoubtedly more sensitive.
However, the method is more time-consuming than with HPLC and the running 
costs are higher.
With these considerations in mind, it was decided to employ Peuler and 
Johnson’s (1977) single isotope radioenzymatic assay to measure plasma 
catecholamines. Full details of the methodology are described in section 9, 
but the basic features are as follows:
•1. The use of the enzyme, catecho1-0-methyltransferase (COMT), to transfer 
a radioactive methyl group from S-adenosyl-methionine (SAM) to an 
endogenous catecholamine acceptor molecule to form a radioactive 
0-methyl derivative. Maximal production of 3H-0-methyl catecholamine 
is achieved at a SAM concentration of 3.0 - 4.0ymol L*"^  at which 
concentration the enzyme is saturated so that the reaction is zero order,
2. Extraction and separation of the radioactive 0-methyl derivatives 
from the incubation mixture and excess radioactive SAM.
3. Thin layer chromatographic (TLC) separation of the radioactive 
0-methyl catecholamines. A typical plate is illustrated as figure
3.1. This TLC step permits simultaneous determination of noradrenaline 
and adrenaline from the same incubation mixture.
4. Oxidation of the susceptible radioactive metanephrines with periodate 
to form radiactive vanillin which is then measured by scintillation 
counting. The oxidation further helps purification of the derivatives 
-and reduces radioactivity in the blanks.
The single isotope assay does not have a measure of recovery in each 
assay unlike double isotope assays where, for example, tritiated noradrena­
line is added to the incubation mixture to provide such a measure. In order to 
overcome this limitation, an internal standard is incorporated into an 
incubation mixture containing a duplicate plasma sample. This is an import­
ant step since COMT activity in the presence of an aliquot of plasma may 
vary slightly with each subject.
Figure 3.1. TLC separation of 3-methoxytyramine (top), metanephrine (middle) 
and normetanephrine (bottom). The picture has been taken under 
ultra-violet light.
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A major advantage of this assay is that it is possible to include 
plasma directly into the incubation mixture without prior deproteinization. 
However, due to the instability of catecholamines in plasma, an antioxidant 
has to be added. In the experiments to be discussed, reduced glutathione 
(GSH) was used for this purpose in conjunction with the anticoagulant,
EGTA, which was employed to inhibit non-enzymatic methylation by Ca2+ ions 
prior to analysis. It is also important to ensure rapid separation of plasma 
and minimal delay in freezing specimens, since even quite short delays at 
this stage could reduce catecholamine content (Carruthers et al, 1970). 
Because catecholamines, even when prepared in EGTA/GSH, will deteriorate at a 
rate of approximately 5% per month when stored at -20°C, the samples were 
stored at -70°C, a temperature low enough to prevent deterioration (Johnson 
et al, 1980). Repeated thawing and refreezing was avoided by preparing 
multiple aliquots at the time of the experiments.
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SECTION 4 : ENDOCRINE RESPONSES TO +Gz ACCELERATION: UNPROTECTED SUBJECTS
4.1. Introduction
4.2. Materials and Methods
4.3. Results
4.4. Discussion
4.5. Preliminary observations on AVP release following +Gz acceleration
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SECTION 4 : ENDOCRINE RESPONSES TO +Gz ACCELERATION: UNPROTECTED SUBJECTS
4.1. Introduction
It is apparent from the discussion in section 2.5. that there is very 
little information on the effect of +Gz acceleration upon anterior pituitary 
function, with the exception of strong evidence for activation of the 
pituitary-adrenal axis. Other studies have supported the postulated 
stimulation of noradrenaline and AVP release in response to the exaggeration
of circulatory pressure gradients by +Gz acceleration.
If such observations are to be of value in an endocrinological 
examination of the efficacy of G protective devices, then there is a need 
for "dose-response", information. Unfortunately, none of the investigations 
described in section 2.5 have produced information that could be of value 
in this way and, in general, unrealistic acceleration profiles have been 
employed.
This study has, therefore, been designed to investigate the effects of 
varying levels of +Gz acceleration upon the peripheral plasma concentration 
of various hormones in unprotected human volunteers. The levels and duration 
of acceleration exposure employed are realistic in terms of the operational
characteristics of modern fighter aircraft.
4.2. -Materials and Methods
Five healthy male non-aircrew subjects (age 21-46) volunteered for the 
study. Although all subjects had previous centrifuge experience, practice 
runs were held daily in the week prior to the experimental period to ensure 
that each subject could tolerate accelerations of up to +6Gz for one minute.
Four +Gz levels, all applied at a rate of onset.of IGs-l and with 
peak G lasting for one minute, were investigated-: +3Gz, +4Gz, +5Gz and
+6Gz. A +1Gz control, in which the centrifuge rotated very slowly for one
minute, was also included in the study in order to monitor changes due to 
effects other than acceleration.
Each subject was exposed to a single G level on each of five 
experimental days and was unaware of the level to which he would be exposed 
before any run. Since no extrinsic protection was afforded to the subjects,
they were required to use voluntary G protective manoeuvres to protect
themselves against unconsciousness at the higher G levels.
Subjects refrained from alcohol or strenuous exercise the evening 
before the runs and each ate a standard breakfast 3 hours prior to 
centrifugation. All experiments began in the medical room (about 10m from 
the centrifuge) at 0900 hours with the insertion of a catheter (Venflon,
Viggo AB, Helsingborg, Sweden) into the brachial vein. Subjects remained 
seated throughout the experimental period and were transferred by wheelchair 
to, and from, the centrifuge chamber. Each subject was lifted in.a portable 
seat from the wheelchair to the gondola and removed by the same process once 
the 31 minute sample had been taken. Blood samples were taken at the 
following times (with centrifugation starting at time zero): -60, -2, +1,
+3, +6, +11, +21, +31, +61, +91, +121 and +181 minutes. The catheters were 
kept patent by intermittent flushing with dilute citrate solution.
The samples were immediately analysed in quadruplicate for haematocrit 
(Hct; measurement error +/- 0.5%) and haemoglobin concentration ([Hb]; 
measurement error +/- 1.0%) using the cyanomethaemoglobin method. Percentage 
changes in plasma volume (%APV) were then calculated using the following 
equation derived from Dill and Costill (1974).
%APV « {£(lHb]c/[Hb]t) x (100-Hctt)/(100-Hctc)]-1} x 100
4
6ST
The subscript c refers to control calues for Hct and LHb] determined before 
a change in PV occurs and the subscript t refers to subsequent test values.
The equation assumes that all changes in Hct and [HbJ can be attributed to 
loss or gain of plasma or red cell water by the intravascular space.
This assumption is only valid, however, if the total number- of red cells 
within the intravascular space remains constant.
Errors introduced into the calculation of %APV by neglecting effects 
of plasma trapping or of an assumed constant difference between the whole 
body Hct and the Hct at the blood sampling site are negligible, when compared 
with measurement error, and may be ignored (Cochrane et al, 1981). Therefore, 
for the purpose of this experiment no correction was made for either of these 
factors.
Percentage changes in blood.volume may also be calculated from the 
equation:
%ABV = ( ([Hb]c/rHb]t)-l) x 100
The remaining blood was allowed to clot on ice and the serum stored at 
-20°C prior to hormone estimation. PEL, GH, LH, FSH, TSH and cortisol were 
measured by radioimmunoassay (see section 9 for protocols) . The average 
coefficients of variation, based on low, medium and high quality control 
(QC) samples, were as follows:
Within-assay CV (%) Between-Assay CV (%)
PRL 11.4 13.9
GH 9.0 - 12.9
LH 8.2 9.1
FSH 6.9 9.5
TSH 7.9 9.3
Cortisol 6.4 (medium QC sample only) 8.6
Serum glucose was measured by the neocuproine method (methodological 
error +/- 2%). Reagents were supplied by Technicon (Technicon Method 
No SE4-0002FF4).
Because observed changes in hormone concentration might only be 
reflecting the effects of haemoconcentration or haemodilution, the measured 
hormone concentrations were corrected according to the equation:
[corrected] = [measured ^ -_x (100 + %APV)/100..
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In addition to the blood samples, urine was collected from the subjects 
for later catecholamine assay. Each subject had been requested to empty his 
bladder following breakfast and to note the time. He was then requested to 
produce samples just before I/V catheterization, before and 30 minutes after 
centrifugation and finally at the end of the experiment. Adrenaline and 
noradrenaline content were assayed by Crout’s method, as described in 
Section 3.3. .
Mixed model analysis of variance was then applied to the data. The 
factors examined were subjects (S), time (T), and acceleration levels (G) where 
S was treated as a random effect and G and T were treated as defined effects.
In particular, changes in concentration during the experiment were identified 
primarily by consideration of the T by G interaction.
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4.3. Results
All subjects were able to withstand +3Gz without straining, but had 
to start voluntary protective manoeuvres at +4Gz and above to prevent loss 
of vision. During the +6Gz run, subjects experienced either complete visual 
loss or complete peripheral visual loss despite straining and performing 
M-l manoeuvres. The higher G runs were regarded by the subjects as being 
physically demanding but painless.
Unfortunately, it was not possible to collect all of the required 
urine samples. Out of a possible 100 samples, only 64 were collected and, 
of the missing 36, 26 should have been collected either just before or at 30 
minutes after centrifugation. Although all samples were prepared and 
analysed for noradrenaline and adrenaline the resultant lack of data made 
it impossible to draw any conclusions about catecholamine excretion.
Figure 4.1 shows mean percentage changes in plasma volume over the 
first hour of the experiment. The changes induced by acceleration over the 
time of the experiment were significant (p<0.001). The maximum reduction 
in plasma volume occurred immediately after centrifugation,, the first 
significant response being at +4Gz when compared to the +lGz control (p<0.05). 
The haemoconcentration was followed in all cases by a rebound haemodilution 
but its magnitude was unrelated to the level of +Gz exposure. This finding 
contrasted with the direct relationship between haemoconcentration and 
acceleration level. Haemodilution was also a feature of the +lGz control 
and was significant (p<0.01) at 31 minutes from the start of the control 
acceleration.
Centrifugation also resulted in a rise (p<0.001) in the serum cortisol 
concentration over the experimental period. Mean corrected cortisol values 
are illustrated in figure 4.2. The peak cortisol concentration was seen in 
the sample taken 20 minutes after centrifugation and the first significant 
response from the +lGz control was seen at +4Gz (p<0.05). There were no 
significant changes seen in the +lGz control cortisol levels over the 
experimental period. Although not shown in this figure, the variability 
of cortisol values obtained at -60 minutes was the same as that at -2 minutes. 
There was also no significant difference between these values compared between 
times and between acceleration levels.
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Figure 4.2. Effect of varying levels of. +Gz acceleration, applied 
for one minute, on the mean serum cortisol of five 
subjects. Least significant differences (LSD, p<0.05) 
shown are for: A) comparison of times within a specified 
gravity level and B) comparison' between gravity levels at 
a specified time.
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Figure 4.3. Effect of varying levels of +Gz acceleration, applied.
for one minute, on the mean serum prolactin of five 
subjects. Least significant differences (LSD, p<0.05) 
shown are for: A) comparison of times within a specified 
gravity level and B) comparison between gravity levels 
at a specified time. The sample taken at one minute 
was taken at the end of centrifugation.
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No effect of increased gravity was seen on the levels of PPJL (figure 
4.3), TSH (figure 4.4) or FSH (figure 4.5). The analysis of variance did 
suggest an (p<0.05) effect of acceleration level per se on the levels of 
LH (figure 4.6). However, no significant G-T interaction or G-T-S 
interaction was demonstrated in the analysis.
No effect of acceleration was observed on the concentration of GH. 
The results obtained are shown in table 10.6 in section 10. One subject, 
EL, showed no changes in GH level at all and because of this he underwent 
full pituitary function tests at St Luke's Hospital, Guildford. These 
confirmed a low, but normal, basal GH level (0.4mIUL‘r'^ ) and he responded 
normally to insulin-induced hypoglycaemia. The remaining subjects showed 
extremely variable results.
Serum glucose (figure 4.7) increased (p<0.001) over the time of the 
experiment but there was no significant effect of acceleration upon the 
changes.
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Figure 4.4. Effect of varying levels of +Gz acceleration, applied for one
minute, on the mean serum TSH of five subjects. Least signifi­
cant differences (LSD, p<0.05) shown are for: A) comparison of 
times within a specified gravity level and B) comparison between 
gravity levels at a specified time. The sample taken at one 
minute was taken at the end of centrifugation.
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Figure 4.5. Effect of varying levels of +Gz acceleration on the mean serum
concentration of FSH in five male subjects. Least significant
differences (LSD, p<0.05) shown are for: A) comparison of times 
within a specified gravity level and B) comparison between 
gravity levels at a specified time. The sample, taken at one 
minute was taken at the end of acceleration.
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Figure 4.6. Effect of varying levels of +Gz acceleration on the mean serum 
concentration of LH in five male subjects. Least significant 
differences (LSD, p<0.05) shown are for; A) comparison of times 
within a specified gravity level and B) comparison between gravity 
levels at a specified time. The sample taken at one minute was 
taken at the end of centrifugation.
77
Serum Glucose 
mg %
LSD
(P<0*05)
110
-o-o.7 105
100
fo-o 3 G
4 G 
5G  
6G
181121
Time (min)
Figure 4.7. Effect of varying levels of +Gz acceleration, applied for 
one minute, on the mean serum glucose of five subjects.
Least significant differences (LSD, p<0.05) shown are for:
A) comparison of times within a specified gravity level and
B) comparison between gravity levels at a specified time. 
*The sample taken at one minute was taken at the end of 
centrifugation. (lmg% = 0.055 mmol L”l).
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4.4. Discussion
The combination of the haemodynamic changes produced by +Gz 
acceleration and the performance of protective manoeuvres represents a 
unique physical stress. Psychological stress was unlikely to have been 
a factor in these experiments since experienced, rather than novice, 
subjects were used. Subjects were unaware of the +Gz level to which they 
would be exposed so that any anticipatory effect upon hormone levels would 
have been seen in the +lGz control, but no significant changes were, in 
fact, observed. This control experiment was, however, performed without 
demanding the subjects to mimic the straining manoeuvres which were required 
at the higher G levels. Thus it is not possible to estimate the relative 
importance of exercise in the observed cortisol responses and, for this 
reason, such an experiment was included in the protocol to be described 
in the next section.
Acceleration stress, as applied in the above conditions, produced 
an endocrine response of remarkable specificity. In particular, the absence 
of significant changes in GH or PRL was not in accord with the evidence 
outlined in section 2, which has implicated them in the endocrine response 
to a number of stressors. The relatively short duration of exposure to 
the accelerations employed and the absence of psychological stimuli (such as 
pain) may explain the lack of response, particularly in PRL. The large 
fluctuations in GH secretion which were observed in some subjects are likely 
to reflect the pulsatile and spontaneous nature of GH secretion which has 
been well documented (Buckler, 1970; Spitz et al, 1972). The differences 
in GH secretion between subjects support the view of Spitz et al (1972) that 
subjects may be divided into two distinct groups: "non-responders", whose 
GH levels remain low throughout an experiment, and "responders" whose GH 
levels are subject to spontaneous elevations. In Spitz et al!s study on 
the effects of repeated saline infusions on 12 male volunteers, 8 were non­
responders and 5 were responders. The rises in the responders were of 
similar magnitude and abruptness to those seen in the present study and 
were also not momentary but persisted for 24 to 100 minutes. Five of the 
non-responders in Spitz et al's study also failed to demonstrate any rise 
in serum GH in response to single or repeated pulses of arginine*
The failure of +Gz acceleration to release GH has not been documented 
before. However a recent study by the Swedish Air Force (Hans Hjort, personal 
communication 1982) has compared human endocrine responses to +Gz accelera­
tion with those produced in pilots undergoing flight simulator assessment.
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There was no evidence to support GH release with acceleration but it was 
observed during the simulator phase when pilots were under considerable 
psychological stress. Prolactin results- were extremely variable between 
the two conditions and no firm conclusions could be made about its secretion. 
Hjort's observations on GH secretion during simulated flight support Pinter’s 
(1974) finding that GH secretion is related to workload (see section 2.5).
The serum cortisol level does, however, appear to be a good indicator 
of the severity of the gravitational stress. The first significant cortisol 
peak occurred at +4Gz, i.e. at a level when subjects began to tense. The 
higher G levels, which were increasingly demanding were associated with 
larger cortisol responses. The timing of the peak cortisol response is 
suggestive of activation of the pituitary-adrenal axis (Landon et al, 1964), 
although ACTH was not actually measured in this study. A'reduction in the 
metabolic clearance rate of cortisol could not explain the abruptness of 
the changes, since the plasma half life of cortisol is about 75 minutes 
(Few, 1974). . '
In contrast to the cortisol changes, serum glucose increased by 
similar amounts under all +Gz conditions and no significant effect of G 
was observed in the statistical analysis. This lack of G dependence and 
the fact that the glucose changes occurred at an earlier time than the 
cortisol response, suggest that the hyperglycaemia resulted from other
influences. Since the response was also seen under control
conditions, it may reflect activation of the sympathetic nervous system
in anticipation of the stress. The lack of data from the urinary catecho­
lamine studies made it impossible to test this hypothesis.
.The reduction in plasma volume after centrifugation has been observed 
in other studies (Greenleaf et al, 1977; van Beaumont et al, 1974), and is 
likely to be caused by capillary pressures exceeding the plasma oncotic 
pressure with a resultant net loss of fluid into the interstitial space-.
Since +Gz acceleration accentuates the normal circulatory pressure gradients 
that exist in the upright position, a similar response may be expected and, 
indeed, is observed on moving from a supine to an erect position (Hagan et al, 
1978). ~
The rebound haemodilution following centrifugation appears not to have 
been documented before. Subjects remained seated throughout the experimental 
period and it is interesting to note that haemodilution was also a feature
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of the control group. Movement from an initial standing to a supine position 
has been reported to result in haemodilution (Hagen et al, 1978), although 
haemoconcentration appears to be a feature of prolonged recumbency (van 
Beaumont et al, 1974). The haemodilution produced by sitting presumably 
reflects a reduction in circulatory pressure gradients from those existing 
in the erect position. The reduction is more pronounced following exposure
to increased +Gz acceleration.
A possible mechanism underlying enhanced ACTH secretion may be 
increased secretion of AVP in response to the sudden hypotension and 
hypovolaemia produced by centrifugation. Although Rogge et al (1967) have 
shown that AVP is released in.response to +2Gz for 30 minutes, no studies 
have demonstrated its release following short, exposures to increased 
acceleration. In order to see whether this was indeed the case, a 
preliminary study was undertaken and is described in the following sub­
section.
Three of the subjects who had been used in the previous experiment 
were exposed to +6Gz for one minute. The conditions for the study were 
essentially the same as before except that the subjects were informed 
of the G level and blood samples were taken less frequently: at -2, +1,
+30 and +120 minutes, with centrifugation at time zero. One subject, IH, 
became unconscious after about 50 seconds at peak G and was "brought down" 
immediately.- The other.two subjects tolerated the acceleration without 
incident.
The blood samples, which had been collected into chilled lithium 
heparin tubes (see section 9.6), were analysed for haemoglobin and haema- 
tocrit and then centrifuged at 4°C. Prior to. storage of plasma at -70°C, 
one aliquot was used to measure osmolality by freezing point depression 
(Fisons 3R Osmometer). Deep frozen plasma was subsequently transferred 
to Leeds General Infirmary where AVP levels were measured by radioimmunoassay.
Subject
Time
(mins) %APV
Osmolality
(mosmolkg”^ )
AVP
(pgml”1)
DG -2 control 295.8 1.5
+1 -5.27 304.3 13.9
+30 -0.3 292.1 1.4
+120 -0.26 292.2 1.0
AD -2 control 293.6 2.0
+1 -12.29 299.9 6.1
+30 +2.38 288.7 1.4
+120 +2.0 290.0 1.0
IH -2 control 294.3 0.2
+1 -10.08 298.8 233.1
+30 -3.14 292.4 5.6
+120 -1.0 290.7 1.8
Table 4.1. Plasma AVP levels measured in three unprotected 
subjects exposed to +6Gz for one minute at 
time zero.
The results (Table 4.1) demonstrated clearly that acceleration was a 
potent stimulus to AVP secretion in the three subjects. The response was 
exceptionally rapid and that of subject IH was remarkable, presumably 
reflecting the severity of the cerebral hypotension resulting from accelera­
tion whichjin his case, led to unconsciousness. It is interesting to note 
that his plasma volume response was no more severe than that of subject AD
control of AVP secretion. This preliminary study demonstrated that AVP 
measurement would have to be an essential part of any further investigations 
into human endocrine responses to +Gz acceleration.
SECTION 5 : ENDOCRINE RESPONSES TO +Gz ACCELERATION: PROTECTED SUBJECTS
PART 1 : ANTI-G SUIT AND RECLINED SEAT
5.1. Introduction
5.2. Materials and Methods
5.3. Results
5.4. Discussion
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SECTION 5 : ENDOCRINE RESPONSES TO +Gz ACCELERATION: PROTECTED SUBJECTS
PART 1 : ANTI-G SUIT AND RECLINED SEAT
5.1. Introduction
The present study has been designed to see how the "dose-related1 
changes in cortisol seen in response to +Gz acceleration may be modified 
by two well-established methods of extrinsic protection: the anti-G suit 
and the reclined seat. Their effects upon G tolerance, as measured by 
visual criteria, have been described in Section 1 but visual endpoints 
are of limited use if the acceleration levels exceed visual threshold or 
are maintained for long periods. Under such circumstances they cannot 
provide useful information about the degree of stress imposed upon the 
subject. The study of hormonal correlates of stress would seem to be a 
logical method of answering this need. -
The study in Section 4.5 also indicated that AVP is released rapidly 
by acceleration so that this study has also been designed to investigate 
changes in this hormone. In addition to AVP, evidence has been presented 
to show that +Gz acceleration results in activation of the sympathetic 
nervous system. The failure to obtain sufficient data on urinary cate­
cholamine excretion in the previous study has been remedied by the use of 
a single isotope radioenzymatic method to measure catecholamine levels in 
plasma. This has therefore made it possible to assess the usefulness of 
catecholamines in defining the severity of the G stress imposed in this 
study.
The +lGz control experiment in Section 4 was conducted under resting 
conditions and did not take account of the possible role of exercise in 
releasing cortisol. A suitable control designed to make subjects undertake 
the equivalent of an M-l procedure at +lGz has therefore been included.
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5.2. Materials and Methods
The five subjects who volunteered for the study in Section 4 also 
volunteered for this study.
A prototype Martin Baker reclining seat was used to provide back 
angles of 35°, 45° and 80° from the vertical which were compared with an 
angle of 15° from the vertical provided by a standard Martin Baker Mk 4 
ejection seat. The volunteers were subjected to centrifugation at each of 
the four angles, with and without the use of an anti-G suit (RAF Mark 6C), 
making a total of eight possible conditions. The anti-G suit was inflated 
to 6.5 psi at +6Gz (cut-in: 2 +/- 0.25Gz).
Each subject was exposed to one of the eight conditions on each of
eight experimental days in a randomized trial. The acceleration level used
-1in all runs was +6Gz for one minute applied at a rate of onset of 1 G s 
Subjects abstained from alcohol and strenuous exercise the night before the 
experimental runs and each ate a standard breakfast three hours prior to 
centrifugation. Subjects were allowed coffee with their breakfasts but not 
again until after completion of the dayfs experiment.
All experiments began at 0900 hours with the insertion of a catheter 
into a brachial vein one hour prior to centrifugation. Blood samples were 
taken and collected into chilled heparinised tubes at the following times 
(with centrifugation at time zero):
-2, +1> +11> +21, +61 and +121 minutes.
After estimation of haemoglobin and haematocrit, the remaining blood was 
centrifuged at +4°C and aliquots of plasma were stored at -70°C. Aliquots 
for catecholamine assay had EGTA/glutathione added as described in Section 9.7,
Following completion of all the experimental runs the subjects parti­
cipated in a +lGz control study designed to mimic the straining and M-l 
procedures required of them under the most demanding condition i.e. 15° 
seat without an anti-G suit. Each subject expired against a mercury column 
in order to maintain the height of the column as near to lOOmmHg as possible 
for one minute. The tubing which connected the subject to the manometer was 
punctured in order to create an expiratory loss which necessitated regular 
inspirations every 4-5 seconds. Conditions for blood sampling were identical 
to those of the +6Gz experiments.-
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Plasma cortisol and AVP were estimated by the radioimmunoassays 
described in Section 9. Plasma noradrenaline and adrenaline were assayed 
using the single isotope radioenzymatic method, also outlined in Section 9. 
The mean coefficients of variation for the assays were as follows:
Within assay Between assay 
CV (%) CV (%)
Cortisol 3.8 6.2
AVP 6.9 11.4
Noradrenaline 8.5 20.4
Adrenaline 13.8 20.1
The mean recovery of AVP from plasma "spiked" with AVP (see Section 
9.6) was 77.6% + 7.8 (n =7).
\
Measured cortisol concentrations were corrected for the effect of 
plasma volume changes as in Section 4. AVP, noradrenaline and adrenaline 
were not corrected for plasma volume changes. Analyses of,variance (ANOVA) 
were used to investigate the separate and interactive effects of seat back 
angle and anti-G suit upon the plasma hormone concentrations. Because ANOVA 
demands that the data satisfy a series of assumptions, particularly homo­
geneity and normality for the observations, it is sometimes necessary to 
apply a transformation to the data so that this technique may be employed 
correctly. This was found to be necessary for the AVP and catecholamine 
measurements after scatter plots of residual against fitted values were 
examined. After considering a range of possible transformations it was 
concluded that adrenaline could be transformed using ln(x+10) and nor­
adrenaline by ln(x+50) (Box and Cox, 1964). AVP values were transformed 
using ln(x+0.25).
In a final study, the relaxed G threshold of each subject was ascer­
tained at each back angle using peripheral light loss as an end point.
Runs were performed without the use of an anti-G suit at an onset rate of 
1 G s  ^with peak G lasting 15 seconds. The G thresholds were subtracted 
from +6Gz to give an indication (AG) of the additional effort required of 
each subject to tolerate the +6Gz runs. Values for AG at each angle were 
then compared with the +6Gz A cortisol values (peak minus control values) 
for unprotected subjects at each back angle.
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5.3. Resuits
All subjects had to perform active straining manoeuvres in order to 
maintain vision when exposed to +6Gz without an anti-G suit at all angles 
except 80°. There was general agreement amongst the volunteers that the 
35° seat back angle required more subjective effort than the 15° angle 
and that the 45° angle required less effort than either of these. Runs 
undertaken with an anti-G suit were all considered less fatiguing. The 
+lGz straining experiment was felt to be physically demanding but was not, 
subjectively, as stressful as the +6Gz runs.
Plasma volume (PV) changes were similar to those seen in the unpro­
tected subjects in the previous study with an initial decrease occurring 
immediately after acceleration followed by a rebound haemodilution. Seat 
back angle had a significant effect (p <0.001) on the magnitude of this 
response and, in particular, the size of the initial haemoconcentration was 
reduced by seat back angle, with the exception of the 35° angle which was 
associated with the largest haemoconcentration.whether an anti-G suit was 
worn or not. The results obtained at a seat back angle of 35° were not, 
however, significantly different from those at an angle of 15°.
Use of an anti-G suit did not affect plasma volume changes following 
centrifugation when compared with runs performed without an anti-G suit so 
that the data for PV changes were combined for both anti-G suit conditions. 
These results are shown as figure 5.1. Straining against a column of mer­
cury at +lGz produced a 6.1% fall (p <0.001) in PV at the end of the experi­
mental period but this had recovered to control levels by the 11 minute 
sample.
■ Peak plasma cortisol levels occurred 20 minutes after acceleration as 
in the previous study. Figure 5.2 demonstrates the mean plasma cortisol 
levels for subjects without anti-G suit protection at the various back 
angles' used in the study. The effect of back angle on this response was 
significant (p < 0.001) over the period of the experiment, the maximum cor­
tisol level being reached at an angle of 15° and the minimum at an angle 
of 80° from the vertical. There was no difference between peak plasma cor­
tisol levels at 15° and 35° but the peaks at 45° and 80° were lower (p<0.05 
and p <0.001 respectively) than the 15° peak cortisol value.
Figure 5.3 compares mean plasma cortisol levels for subjects protected 
by an anti-G suit at the experimental back angles. As in unprotected sub­
jects, back angle had a significant (p <0.001) effect on cortisol levels
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Figure 5.1. Effect of seat back angles, as indicated, on plasma volume
changes, meaned for both anti-G suit conditions, in 5 subjects 
exposed to +6Gz for 1 minute. Least significant differences 
CLSD p<0.05) shown are for: A) Comparison between angles at
a specified time and B) Comparison of times at a specified 
angle.
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Figure 5.2. Effect of indicated seat back angles on the mean plasma cor­
tisol of 5 subjects exposed, without anti-G suit protection, 
to +6Gz for 1 minute. LSDs shown are for: A) Comparison between 
angles at a specified time and B) Comparison of times at a 
specified angle.
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Figure 5.3. Effect of indicated seat back angles on the mean plasma cor­
tisol of 5 subjects exposed, with anti-G suit protection, 
to +6Gz for 1 minute. LSDs shown are for: A) Comparison between 
angles at a specified time and B) Comparison of times at a 
specified angle.
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Figure 5.4. Plasma cortisol levels of 5 subjects meaned for all back
angles with, and without, the use of an anti-G suit during 
exposure to +6Gz for one minute. LSDs shown are for:
A) Comparison between anti-G suit conditions at a specified 
time and B) Comparison of times for a specified anti-G suit 
condition.
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over the experimental period. The largest response was seen with the 
35° seat angle but this was not significantly different from the 15° peak 
value. Seat angles of 45° and 80° produced peaks at 21 minutes that 
were smaller (p<0.01 and p <0.001) than those obtained with the 35° seat.
The most obvious feature of figure 5.3 is the reduction in overall 
response compared to figure 5.2 and reflects the protective action of the 
anti-G suit which reduced (p <0.001) the rise in plasma cortisol levels 
at all back angles. This action of the anti-G suit was independent of 
seat back angle and is summarised in figure 5.4.
Examination of the relationship between changes in plasma volume and 
of plasma cortisol levels during the experiment showed a significant rela­
tionship (p < 0.01) between them when the subjects were unprotected by an 
anti-G suit, but there was no significant correlation in suited subjects.
There were no significant differences in mean plasma cortisol concen­
trations during the +lGz straining experiment (for values see table 10.8).
Mean values for plasma noradrenaline, back transformed and corrected 
for transformation bias (John and Quenouille, 1977) have been plotted in 
figure 5.5 (subjects without anti-G suit) and in figure 5.6 (subjects 
with anti-G suit). The values have been plotted on a log scale so that 
the error term is genuinely constant over the range of values. The LSD 
shown in the diagrams is derived from a general error term for making com­
parisons of meaned subject values for all conditions. For both anti-G suit 
conditions, the analysis showed a significant (p <0.001) effect of time 
-with peak values occurring in the sample obtained immediately after centri­
fugation. The anti-G suit reduced this response (p <0.001), and the absence 
of a significant interaction between anti-G suit and seat angle in the 
ANOVA suggested that this effect was independent of back angle.
The effect of seat angle upon noradrenaline levels was more complex. 
Although the effect of angle was significant (p < 0.05) on the sample taken 
immediately post-centrifugation, it was not possible to distinguish the 
effects of individual seat angles on an a posteori basis. At an angle of 
80° there was no significant difference between times.
Mean values for adrenaline, similarly backtransformed and plotted, are 
shown in figure 5.7 (without anti-G suit) and figure 5.8 (with anti-G suit). 
As with noradrenaline, the analysis showed a significant (p < 0.001) effect 
of time with peak values occurring immediately after centrifugation.
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Figure 5.5. Effect of indicated seat angles on the mean plasma noradrenaline 
of 5 subjects exposed, without anti-G suit protection, to +6Gz 
for 1 minute. The least significant difference (LSD, p<0.05) 
shown permits comparisons between angles at a specified time and 
comparisons between times at a specified angle. Note that nor­
adrenaline values are plotted on a log scale (see text)..
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Figure 5.6. Effect of indicated seat angles on the mean plasma noradrenaline 
of 5.subjects exposed, with-anti-G protection, to +6Gz for 1 
minute. The least significant difference (LSD, p<0.05) shown 
permits comparisons between angles at a specified time and com­
parisons between times at a specified angle. Note that nor­
adrenaline values are plotted on a log scale (see text).
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Figure 5.7. Effect of indicated seat angles on the mean plasma adrenaline of 
5 subjects exposed, without anti-*G suit protection, to +6Gz for 
1 minute. The least significant difference (LSD, p<0.05) shown 
permits comparisons between angles at a specified time and com­
parisons between times at a specified angle. Note that adrena­
line values are plotted on a log scale (see text).
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Figure 5.8. Effect of indicated seat angles on the mean plasma adrenaline of 
5 subjects exposed, with anti-G suit protection, to +6Gz for 1 
minute. The least significant difference ( L S D ,  p<0.05) shown 
permits comparisons between angles at a specified time and com­
parisons between times at a specified angle. Note that adrena­
line values are plotted on a log scale (see text).
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Although the anti-G suit reduced the response, this effect was only sig­
nificant at the p <0.05 level. In addition, this effect of an anti-G 
suit did not appear to be completely independent of back angle since an 
interaction between anti-G suit and seat angle was observed in the ANOVA 
although this was of marginal significance (p = 0.05). Further analysis 
demonstrated that there was an effect of anti-G suit at 15° (p<0.05),
35° (p <0.05), 45° (p<0.01) but no effect at 80°.
Examination of angles within time showed, as with noradrenaline, that 
the only time at which there.was a difference between seat angles was 
immediately after centrifugation (p<0.05). However, it was again not 
• possible to resolve the individual seat angles on an a posteopi- basis.
Plasma noradrenaline and adrenaline values for the static straining 
control are-shown in Tables 10,10 and 10.11 respectively. For adrenaline, 
the changes were not significant but, for noradrenaline, there was an 
increase (p <0.05) in the mean .value of the samples taken immediately after
the straining period (time: +1 min) when compared to the mean control 
value (time: -2 mins).
Plasma AVP values, meaned for subjects, are shown in figures 5,9 and 
5.10. A log scale has again been employed to allow the error term to be 
constant over the range of values. Only the results of the first 3 timed 
samples have been plotted as the concentrations measured in the final 3 
samples were back to control levels. Overall, the analyses indicated that 
acceleration resulted in increases (p <0.05) in AVP levels in the samples 
taken immediately after centrifugation. Use of an anti-G suit reduced 
(p <0.001) this response but the effect was not completely independent of 
seat back angle as there was an interaction (p<0.01) between these two 
factors in the ANOVA. The effect of seat back angle was to diminish the 
AVP response (p<0.05). The maximum response was seen in unprotected sub­
jects at an angle of 35° but this did not differ significantly from that 
at 45°. These two seat angles did, however, produce greater responses 
(p<0.05) than those observed at angles of 15° and 80° for subjects who 
were not wearing anti-G suits. The responses at these latter two angles 
were not significantly different. In subjects protected by an anti-G suit, 
the maximum response was seen at an angle of 15°. This was not signifi­
cantly different from the response at 35° but was greater (p < 0.05) than 
the responses seen at angles of 45° and 80°.
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9. Effect of indicated seat angles on the mean plasma AVP 
of 5 subjects exposed, without anti-G suit protection, to 
+6Gz for 1 minute. The least significant difference (LSD, 
p<0.05) shown permits comparisons between angles at a 
specified time and comparisons between times at a specified 
angle. Note that AVP values are plotted on a log scale 
(see text).
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>.10. Effect of indicated seat angles on the mean plasma AVP 
of 5 subjects exposed, with anti-G suit protection, to 
+6Gz for 1 minute. The least significant difference (LSD, 
p<0.05) shown permits comparisons between angles at a 
specified time and comparisons between times at a specified 
angle. Note that AVP values are plotted on a log scale 
(see text).
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No significant relationship could be demonstrated between plasma 
AVP and cortisol levels during the experiment.
No changes were observed in AVP levels after the control experiment.
Mean relaxed G thresholds obtained at each back angle are shown in 
Table 5.1. Analysis of variance indicated that seat angle had a significant 
(p<0.001) effect on the G threshold. This effect was accounted for mainly 
by the large increase at an angle of 80°. There was also a significant 
(p<0.01) relationship between AG and Aplasma cortisol i.e. the larger 
the value for AG, the larger the value for Aplasma cortisol, (see Figure 5.11)
Seat Angle Mean 
G Threshold
1 5° 3 - 8 8
3 5 ° 3-56
oLO 4*06
oo00 6*52
LSD ( P <  0*05)  = 0 * 3 0
Table 5.1. Mean relaxed +Gz thresholds of 5 subjects at the indicated 
- seat back angles. G applied at a rate of lGs*“l.
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5.4. Discussion
The relaxed G thresholds observed at the back angles used in this 
study were all within the range delineated by Glaister (1978) in his 
review of a total of 234 rapid onset G threshold values obtained in 
relaxed, unprotected subjects by a number of authors. The reduction in 
mean threshold seen at an angle of 35° was not an unexpected finding since 
the eye-heart distance is similar at this angle and at 15°. Although the 
reduction of 0.32G was statistically significant (p<0.05), it is impor­
tant to appreciate that, on the RAF LAM centrifuge, it is only possible to 
measure G threshold to within +/- 0.2G in individual subjects. This may 
explain the discrepancy between this study and that of Burns (1975) who 
was unable to demonstrate any significant difference in relaxed thresholds 
between these two angles.
The increase observed in mean threshold at an angle of 45° was not 
significant. Although Burns demonstrated a mean benefit of 0.5G (p <0.05) 
in his subjects x^hen this angle was compared to 13°, the mean threshold of 
+4.06Gz observed in the present study was in the upper limits of Glaister's 
range of values for this angle. The increase to +6.5Gz at an angle of 80° 
also compared favourably with Glaisterls observations.
As emphasised earlier, visual endpoints are of limited application 
when acceleration levels exceed visual threshold. In addition, the infor­
mation from such measurements may be a poor prognostic indicator of a 
subject's ability to withstand higher levels of acceleration. For example, 
Burton and Shaffstall (1980) found, in 7 acceleration-experienced males, 
that relaxed G tolerances were not significantly correlated with the 
ability of the subjects to withstand an ACM centrifuge profile (see page 23), 
as determined by subjective fatigue or black-out. These findings corro­
borate those of Burton et al (1973) who demonstrated, again in 7 subjects, 
that their relaxed tolerances were not significantly correlated with the 
length of time for which they could withstand +8Gz by straining.
The significant relationship between AG and A cortisol in this study 
suggests that the plasma concentration of cortisol is a useful measure of 
the additional stress imposed upon subjects when they are accelerated at 
a level which exceeds their relaxed visual threshold.
It remains, however, to define the nature of the stressor which has 
stimulated the secretion of cortisol. From the studies in Section 4 it 
was concluded, particularly on the basis of "mock" centrifugation runs,
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that psychological stress was not an important factor in stimulating 
cortisol release in the subjects who were centrifuge-experienced. In 
the present study, using the same subjects, plasma adrenaline levels 
prior to centrifugation were not elevated greatly above normal supine 
values (0-65 pgml and would therefore tend to support this assumption - 
(cf. discussion below).
Although physical exercise has been shown to release cortisol, as 
discussed in Section 2.3, and physical effort was undoubtedly induced in 
the subjects by +Gz exposure, enhanced cortisol production was not a 
feature of the control experiment. Even though it has to be admitted 
that this experiment was not subjectively as stressful as actual centri­
fugation, it would be reasonable to conclude that intense straining for 
one minute was not the prime stimulus to cortisol production under 
"high G".
The stress of +Gz acceleration is mainly cardiovascular and this is 
reflected by the alterations in plasma volume seen in this, and the pre­
vious, study. The influence of seat' back angle on the degree of hypo- 
volaemia induced by +6Gz was to be expected since the G vector tended 
towards x with increasing angles, leading to a reduction in circulatory 
pressure gradients and a consequent reduction in peripheral pooling of 
blood. This relationship was not affected by the wearing of an anti-G 
suit, which suggested that voluntary muscle straining was as effective as
anti-G suit inflation in restricting peripheral pooling.
In experimental animals, hypovolaemia induced by haemorrhage has been 
shown to cause concomitant reductions in the pressures of both right and 
left atria (Henry, Gauer and Sieker, 1956). Since central venous pressures
also fall in response to haemorrhage in man (Gauer, Henry and Sieker, 1956)
it might be postulated that +Gz-induced hypovolaemia will stimulate AVP 
release by reducing left atrial pressure. AVP might then be responsible 
for cortisol release because of its CRF-like activity which has been 
described in animals (Yates et al, 1971). However there was no significant 
relationship between AVP and cortisol levels in this study, although AVP 
levels were shown to be increased by acceleration. Since CRF has now been 
identified as a 41 residue peptide, synthesized and shown to be effective 
in releasing ACTH in man Csee pages 37-38), this lack of relationship 
between AVP and cortisol is, perhaps, not so surprising. However, the 
results do not necessarily exclude the possibility that AVP enhances the 
activity of CRF, as suggested by Gillies et al (1982). *
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Hypovolaemia, induced by haemorrhage, has been shown to promote cor­
tisol secretion (as determined by radioimmunoassay on adrenal venous 
blood) in dogs and this effect was reduced considerably by inflation of 
a balloon in the right atrium (Cryer and Gann, 1974). The haemorrhage 
rate of 5 ml Kg  ^ over 3 minutes might also have been expected to release 
AVP because, although AVP levels were not measured in Cryer and Gann's 
study, the same rate of haemorrhage in dogs has been shown to be an 
effective stimulus to AVP release (Claybaugh and Share, 1973). Since the 
presence of a right atrial balloon would have further reduced left atrial 
pressure and AVP secretion should have been augmented, the implication of 
Cryer and Gann's study (regrettably not made "watertight” by AVP measure­
ment) was that AVP could not be of primary importance in the control of 
ACTH-cortisol secretion and that right atrial receptors mediate the 
release of cortisol seen in dogs subjected to low grade haemorrhage.
If these observations are extrapolated to man then they could provide 
a basis for explaining the observed reductions in cortisol secretion with 
seat reclination - thus increased back angle, by reducing acceleration- 
induced hypovolaemia,might be expected to reduce the stimulation of these 
right,atrial receptors and therefore reduce cortisol secretion.
Examination of the relationship between changes in PV and of cortisol 
showed a significant correlation (p <0.01) when subjects were not protected 
by an anti-G suit but there was no correlation when an anti-G suit was 
worn. That the anti-G suit reduced the cortisol response without amelioration 
of hypovolaemia suggests that some other factor additional to hypovolaemia 
is responsible for the secretion of cortisol in response to +Gz acceleration.
A further cardiovascular effect of +Gz is to reduce arterial pressure 
above the heart. In dogs, aortic constriction has been shown to stimulate 
cortisol release if the resulting drop in arterial pressure was greater 
than 20 mm Hg (Cryer and Gann, 1973). If the fall was less than 20 mm Hg, 
the increased cortisol secretion was only seen after prior vagotomy. The 
results‘of vagotomy have been interpreted as due to the abolition of the 
inhibitory influence of right atrial receptors which have responded to 
the opposing stimulus of a slight rise in right atrial pressure created by 
aortic constriction. Thus both high and low pressure receptors have been 
implicated in the control of cortisol secretion in dogs.
If similar control mechanisms operate .in man then the different effects 
of straining and an anti-G suit upon cortisol secretion might reflect
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different responses from high pressure receptors. The major physiological 
action of the anti-G suit is to increase peripheral resistance and thereby 
raise arterial pressure but the increase in arterial pressure seen with 
straining and the M-l procedure is intermittent. These voluntary manoeuvres 
might not, therefore, be as effective as anti-G suit inflation in inhibiting 
the high pressure receptors„ The inhibition of these receptors might also 
explain the absence of a cortisol response in the straining experiment where 
a significant fall in PV occurred. Under normal gravity, straining will 
produce cerebral hypertension whereas at +6Gz it cannot prevent a degree of 
cerebral hypotension.
The results indicated that the reduction in cortisol response observed 
with the anti-G suit was independent of back angle. This is of interest 
since it supports the additive effect of anti-G suit and back angle on 
visual threshold as.shown'by Dorman and Lawton C1956) and confirmed by 
Crossley and Glaister (1971). This addition was also suggested by the 
results for noradrenaline and, to a lesser extent, adrenaline.
The increases in both noradrenaline and adrenaline in response to 
acceleration reflect the activation of the sympathetic nervous system in 
an attempt to compensate for the sudden change in cardiovascular dynamics 
produced by acceleration. Although Goodall and Berman (I960) demonstrated 
that urinary adrenaline excretion was raised by the anticipation of centri­
fugation, the plasma adrenaline levels measured just prior to centrifuga­
tion in the present study were within normal limits and, furthermore, were 
not significantly different from the values obtained two hours after com­
pletion of the centrifuge runs, i.e. after a period when the subjects had 
been able to relax completely. Goodall and Berman (I960) used 9 Air Force 
subjects in their study but they did not state how experienced they were 
or, indeed, whether or not familiarisation runs were undertaken prior to 
their experiment. This is particularly relevant since the subjects used 
in the present study were all highly experienced and were "trained up" 
daily in the week prior to the study. Familiarization with repeated cen­
trifugation runs has been shown to reduce urinary adrenaline excretion 
(Frankenhauser et al, 1962) in novice subjects so that doubt must be cast 
on the validity of Goodall and Berman’s findings.
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Support for this challenge comes, surprisingly, from a critical 
analysis of one of a series of experiments conducted by Goodall (1962) 
on Air Force personnel who were centrifuge-experienced and "had been 
previously classified as low, intermediate or high tolerance subjects". He 
exposed six high tolerance subjects to 10 consecutive rapid onset +2Gz or 
+4Gz runs over one hour (on any one experimental day, each subject was 
exposed blind to only one of these repeated +Gz levels). Urine collections 
were made at the end of a 3-hour pre-run period, at the end of the hour long 
centrifugation period and at l.hour and 3 hours following centrifugation. 
Urinary noradrenaline and adrenaline were assayed by bioassay (cat blood 
pressure and relaxation of fowl rectal caecum respectively). Noradrenaline 
output was "significantly elevated during the run period and the degree of 
elevation paralleled the G exposure i.e. the greater the G exposure, the 
greater the noradrenaline output". Goodall appears however to have failed 
to calculate the adrenaline results (shown in Table II in his paper) which 
actually showed a mean increase of 33% between 2 and 4G exposure. This 
equates with a 36% mean increase for noradrenaline so that one must conclude 
that adrenaline excretion was also related to G level - not necessarily, 
as Goodall again concluded, to anticipation of acceleration.
It is reasonable to suppose that seat reclination, by reducing cerebral 
hypotension will decrease baroceptor-initiated stimulation of the sympathetic 
nervous system and thus reduce the enhanced catecholamine secretion seen in
response to +Gz acceleration. Burns (1975) and Glaister and Lisher (1977)
have indeed shown that rises in heart rate associated with +Gz exposure are 
reduced by reclination. In Glaister and Lisherfs study, for example, the 
average heart rate recorded at +8Gz in a 65° reclined seat corresponded to 
the rate observed at +5Gz in an upright seat.
In the present study, the secretion of both catecholamihes was reduced 
by reclination but it was not possible to differentiate the effects of 
individual seat back angles. Much of the observed significance of the 
effect of back angle was due to the large reduction in response obtained 
at an angle of 80°. In Burns1 study (1975) reduction in heart rate occurred
with angles of less than 45°, but only when subjects were relaxed. In
subjects exposed to high sustained G (>+8Gz), and therefore required to 
strain, significant reductions did not occur until angles of 55° and 65° from 
the vertical were attained. Failure to show reductions in heart rate in 
straining subjects exposed to high G at angles of less than 45° was also a
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feature of a study by Burton et al (1975). Since the subjects in the 
present study were required to strain, the findings provide endocrinological 
support for these observations on heart rate. However it must be emphasised 
that the frequency of blood sampling in the present study was limited by 
the need to obtain a minimum of 10. ml of blood for the AVP assay (a total 
of 80 ml of blood per experiment had been set as a limit). If more frequent 
sampling had been undertaken, then differences in catecholamine responses 
at the various angles may have been demonstrated. Thus, peak catecholamine 
levels might have occurred at different times for each angle. Since the 
half-life of both catecholamines is under one minute (Marks, 1981), it is 
not possible to identify such differences from the results that have been 
obtained e.g. the values at +11 minutes for noradrenaline were not signifi­
cantly different for each angle. In addition, this short half-life makes 
even slight differences in the time taken to obtain a sample significant 
when attempting to compare catecholamine levels between subjects.
Although a baroreceptor mechanism must be of prime importance in the 
stimulation of catecholamine production under +Gz acceleration, cerebral 
hypotension also necessitated the performance of straining manoeuvres by 
the subjects. Intense exercise, as discussed in Section 2.2, may stimulate 
catecholamine production so that the reduced secretion of catecholamines at 
an angle of 80° and with the use of an anti-G suit, may have also reflected 
the reduced straining requirements of the subjects when these protective 
measures were employed under high G. The relative contribution of these 
two factors i.e. cerebral hypotension and straining, to the stimulation of 
catecholamine secretion cannot be assessed from the results although the 
+lGz straining experiment produced a significant increase in plasma noradrena­
line levels in the subjects. No significant changes in adrenaline levels 
were observed which tends to support the concept that noradrenaline secretion 
is more sensitive than adrenaline to exercise in trained subjects (Bloom 
et al, 1976; Davies et al, 1977). This might afford an explanation of the 
effects of anti-G suit inflation upon adrenaline levels which were not com­
pletely independent of back angle. Further conjecture on mechanisms must 
however be limited because only five subjects were used in this study and 
sampling times have not necessarily been ideal.
The present experiment has also confirmed that AVP secretion, as 
with the catecholamines, is increased rapidly in response to +Gz accelera­
tion. Although the statistical significance of this effect was reported
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as p<0.05 it should be remembered that this significance level was derived 
by analysis of variance from data combined for both anti-G suit conditions. 
This is an important consideration since use of an anti-G suit virtually 
abolished the responses seen when subjects were not protected in this way.
The stimulus to AVP secretion was again likely to have been cardio­
vascular. No significant changes in plasma AVP were produced by the control 
straining experiment and therefore suggested that exercise was not an 
important aetiological factor. It is also interesting to note that straining 
produced a 6.1% fall in plasma volume yet AVP was not stimulated. This 
finding supports Robertson’s (1977) observation that no changes in plasma 
AVP occurred in humans when blood volume was reduced by 6-9% by phlebotomy, 
unless the experiment also produced hypotension. In the present study 
straining would have increased arterial pressure and would therefore have 
been expected to inhibit the high-pressure baroreceptors which have been 
implicated in the control of AVP secretion.
Osmolality was not measured on the samples obtained in this study 
because of the persistent unreliability of the osmometer (Fisons 3R). It 
is therefore not possible to exclude osmotic change induced by acceleration 
as a stimulus to AVP secretion in these experiments. However, this mechanism 
would seem to be unlikely when one considers the results of other studies 
which have supported the nonosmotic, rather than osmotic, control of AVP ; 
release. In particular, Greenleaf et al (1977) demonstrated that the 
increases in plasma AVP seen in 6 males exposed to black-out levels of +Gz 
acceleration were associated with loss of plasma volume but not change in 
osmotic concentration i.e. there was an iso-osmotic content loss of electro­
lytes together with the loss of plasma volume. In Baylis and Heath’s study 
(1977), high plasma AVP levels were measured in presyncopal subjects during 
orthostasis but these were not associated with changes in osmolality. This 
evidence does not, of course, exclude the well established role of osmotic 
control of AVP release at other times e.g. during dehydration.
Another possible stimulus to AVP secretion is the hypoxia which 
develops from the creation of ventilation:perfusion inequalities by +Gz 
acceleration (this has been described on page 15). Evidence to suggest 
that hypoxia does not stimulate AVP release is reviewed in the next Section 
in which an experiment was also undertaken at +lGz to mimic the hypoxic 
effects of acceleration in order to verify this evidence.
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If cardiovascular receptors are responsible for the secretion of 
AVP in response to +Gz acceleration then similar considerations to those 
which applied to the control of cortisol secretion must also be applied to 
AVP. In particular, the reductions in AVP responses produced by the anti-G 
suit occurred without significant improvement in hypovolaemia. Evidence 
from animals has already been presented (see page 45) which implicated low 
and high pressure receptors in the control of AVP secretion. The low 
pressure receptors exert an inhibitory influence upon the high pressure 
receptors (Share and Levy, 1962) in a similar manner, to that described for 
cortisol secretion (Cryer and Gann, 1973 and 1974) . However, the low 
pressure receptors implicated in AVP secretion are left atrial whereas 
those for cortisol control are right atrial. If similar control mechanisms 
for AVP exist in man, as implied by the work of Robertson!s group (Robert­
son, 1977; Robertson et al, 1973), then the action of the anti-G suit upon 
AVP secretion*could be explained, as for its effects upon cortisol secretion, 
by different responses from high pressure receptors.
The effect of seat angle upon AVP secretion in subjects without anti-G 
suit protection was not as one might have expected when the effects of 
angle on the plasma volume responses are considered. In particular, the 
response at 15° was not significantly different from that at 80° and the 
two intermediate angles of 35° and 45° produced larger peak AVP levels.
The physiological significance of these results is difficult, to determine 
since infrequent sampling may have again meant that true peak values were 
missed. The half-life of AVP is also short, about 6 minutes (Fabian et al, 
1969), so that return to control values will be relatively rapid. There is 
a suggestion (from figure 5.9, page 96) that the mean peak AVP value for 
the 15° angle was higher than measured since the 11 minute value was very 
similar to the 11 minute values for 35° and 45°.
It would be tempting to attribute the reduction in response at 15° 
to the tendency of subjects to crouch forward at this angle while they were 
under high G. At 35° and 45° the mechanics of the seat were such to make 
it difficult for the subjects to alter their posture in this way. The 
adoption of a crouched posture can significantly reduce the cerebral hypo­
tension that results from +Gz acceleration and so might be expected to 
reduce AVP secretion by decreasing the stimulation of high pressure receptors. 
However if this were the case, then a similar pattern would be expected for
106
cortisol but this was not demonstrated. Overall the interpretation of 
the AVP results is made difficult by the sampling intervals and also by 
the relatively small amount of data which lacked homogeneity between 
subjects.
The AVP results in suited subjects suggested that an angle of 15° 
produced a mean peak response that was significantly greater than that at 
45°. This result is again in conflict with the cortisol results for 
subjects wearing an anti-G suit. Closer examination of the AVP.results 
(figure 5.10, page 97) does however show that the mean peak AVP value for. 
the 15° angle was not significantly greater than the control value at this 
angle. Control values were similar between 15° and 45° but there was then 
a fall in AVP level after acceleration at 45°. Although this was not 
different from the control value at 45°, it. was sufficient to produce a 
statistically significant difference from the post-acceleration value at 
15°. This difference must therefore be interpreted with care especially 
since the sensitivity of the AVP assay was not sufficient to place great 
reliance on the measurement of such small falls in concentration. The 
apparent dependence of the anti-G suit effect upon seat back angle must also 
be interpreted with care for these reasons. Nevertheless the results have 
confirmed those of Regge et al (1967) that use of an anti-G suit may 
abolish the AVP response to +Gz acceleration.
The physiological function of the hormones in relation to their 
release under +Gz acceleration is discussed in Section 7.
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SECTION 6 : ENDOCRINE RESPONSES TO +Gz ACCELERATION : PROTECTED SUBJECTS
PART 2 : POSITIVE PRESSURE BREATHING (PPB) AND COUNTERPRESSURE (CP)
6.1. Introduction
The final method of extrinsic protection to be investigated in this 
thesis is the use of positive pressure breathing (PPB). The physiological 
effects of PPB have been discussed in Section 1 (pages 21-23) where it was 
concluded that PPB will usually provide an increase in G tolerance which is 
equivalent to that produced by repeated M-l manoeuvres, but without sub­
jective fatigue. It is therefore not surprising that PPB has been described 
as the "automatic M-l manoeuvre" by some authorities.
In the previous section, the effect of one minute of strenuous exercise 
was investigated on the blood levels of several hormones but all subjects 
agreed that this control experiment was not, subjectively, as stressful as 
the +6Gz runs. An investigation of the endocrinological changes produced 
under +Gz while using PPB might therefore provide further information about 
the importance of muscular exercise as an aetiological factor in the 
acceleration-induced secretion of hormones such as cortisol. Although PPB 
may well reduce the muscular effort required under high G and therefore modify 
hormonal responses, it is possible that PPB may itself induce the secretion 
of hormones, particularly AVP. For example, PPB at +lGz results in displace­
ment of blood into the lower limbs which, by reducing atrial pressure, might 
be expected to stimulate AVP secretion.
Drury et al (1947) investigated the effects of PPB for 30 minutes at 
10, 20, 30 and 40 mmHg upon urea clearance (as a measure of renal function) 
in four water-loaded subjects. No counterpressure (CP) was provided and 
they demonstrated a progressive reduction in urea clearance as the breathing 
pressure increased. Drury et al suggested that this was due to posterior 
pituitary stimulation with production of .an antidiuretic substance. It was 
not until 1972 that Khambatta and Baratz showed in 6 conscious subjects that 
plasma AVP levels (measured by bioassay in water-loaded rats) were increased 
by intermittent PPB. The subjects were not overhydrated and no counterpressures 
was provided to the limbs or trunk. Since plasma osmolality had remained 
unchanged throughout the experiment, the authors concluded that PPB had 
stimulated AVP secretion by activation of left atrial stretch receptors. In 
the present study a +lGz control has been included during which subjects have 
been asked to breathe at 30 mmHg pressure for one minute. In addition, an
109
anti-G suit has been worn and inflated to its. equivalent +6Gz pressure, 
in order to provide abdominal and limb CP during PPB. This situation is 
therefore identical to that under +6Gz from the point of view of CP and 
breathing pressures so that any differential effect of high G upon 
endocrine responses may be attributed to the cardiovascular changes which 
accompany high G exposure rather than to effects of PPB/CP. In fact no 
studies appear to have been conducted upon the endocrinological effects of 
abdominal and'limb CP combined with PPB at +lGz, despite the likelihood 
that CP will modify the hormonal responses to PPB.
Because of the possible additional beneficial effects on G tolerance 
of extending CP to include the trunk, this experiment has also investigated 
the effect of combining a pressure jerkin witn’an anti-G .suit during.PPB.
A further result of +Gz acceleration is to create ventilation perfusion 
inequalities which result in reduced arterial oxygenation. It has been 
suggested by work in animals that hypoxia will stimulate the release of 
AVP. For example, Anderson et al (1978) demonstrated that a reduction in 
inspired oxygen from 80 to 34 mmHg for between 30 to 60 minutes resulted 
in considerable increases in radioimmunoassay titres of AVP in anaesthetised 
dogs. This response could be abolished by denervation of the carotid 
baroreceptors but not by denervation of the carotid body chemoreceptors, 
an effect which was interpreted as induction of alterations in afferent 
parasympathetic tone by hypoxia. If hypoxia releases AVP in man then it 
could provide an aetiological basis for the pathogenesis of acute mountain 
sickness (AMS) which is associated with fluid retention leading, in severe 
cases, to pulmonary and/or cerebral oedema.
Forsling and Milledge (1977) found that no significant changes in 
plasma AVP were induced in five altitude'acclimatized males who were 
made to breathe a 10-10.5% oxygen mixture for 4 hours. Similar results, 
using low oxygen gas mixtures, have also been obtained by Baylis, Stockley 
and Heath (1977) although, in this study, the hypoxia induced profound 
hypocapnia. Since hypocapnia results in venoconstriction and thereby 
increases central blood volume, it is possible that this tended to oppose 
any stimulatory effect of hypoxia upon AVP secretion.
A recent and tragic study by Harber et al (1981) involved the 
measurement of AVP in 24 hour urine samples obtained from 8 mountaineers
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during an ascent from 1900 to 5400 m in the Himalayas. Exogenous AVP 
was added to aliquots of the samples and confirmed that the methods 
employed for sample storage reduced AVP losses to a minimum. The results 
indicated that there was generally no correlation between AVP and altitude 
and that this lack of relationship also held true for one member of the 
party who developed AMS and died of cerebral oedema.
No investigators appear to have examined the endocrinological effects 
of short exposures to hypoxia i.e. of a minute or so duration. One of the 
aims of the present study has therefore been to produce levels of arterial 
desaturation at +lGz which are similar to those measured in subjects after 
one minute at +6Gz. The relationship between the induced hypoxia and the 
blood levels of a number of hormones has then been investigated. The 
importance of this study is that, if PPB at +6Gz diminished the hormonal 
response to +6Gz seen in subjects protected only by an anti-G suit, then 
this could possibly be attributed to the amelioration of hypoxia by PPB. 
The latter effect of PPB has been demonstrated during sustained +6Gz 
exposures by Leverett et al (1973).
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6.2. Materials and Methods
Five male subjects, of whom four had been subjects for the experi­
ments described in Sections 4 and 5, volunteered for the present study. 
The new subject (BC), who had replaced subject RE, had been centrifuged 
regularly during the two months prior to the start of the experiments and 
had obtained a satisfactory level of experience, being able to withstand 
+6Gz for one minute without extrinsic protection. All subjects were 
centrifuged daily in the week prior to the study in order to ensure that 
they were familiar with the experimental procedures, including the use of 
PPB and CP under high G.
Five experimental conditions were employed with subjects seated in 
a conventional 15° seat:
1. Exposure-to +6Gz for bne minute (rate of onset : lGs""^) with the
use of an anti-G suit (RAF Mk 6 inflated to the same profile as that
employed in Section 5).
2. As for condition 1, but with the addition of PPB at 5 mmHg G~^
(cut-in : +4Gz). Total PPB pressure was therefore 30 mmHg at +6Gz.
3. As for condition 2, but with the addition of CP provided by an RAF
Mk 4 pressure jerkin, also inflated at 5 mmHg G“^ with a cut-in
of +4Gz.
4. A control run at +lGz with PPB at 30 mmHg (+6Gz equivalent) and 
anti-G suit inflation at 6.5 psi (also +6Gz equivalent) for one 
minute. Trunk CP was NOT provided.
5. Hypoxia at +lGz induced by breathing a 7.6% oxygen, 92.4% nitrogen 
gas mixture. The experiment aimed to reproduce the fall in oxygen 
saturation, as measured by ear oximetry (see below), which had 
occurred in each subject under condition 1.
During the-experiments which involved PPB, mask pressure was monitored 
from a pressure tapping in the subject!s mask and this was connected by 
plastic tubing to a Statham P23b pressure transducer mounted in the 
centrifuge gondola. The transducer was calibrated daily and pressure 
tracings recorded on a Brush pen recorder located in the recording room. 
Prior to each PPB run the subject undertook a short control period of PPB 
at +lGz to ensure that the face seal of his mask was secure from leaks.
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five experimental days. The order of the runs was randomized with the 
single constraint that condition 1 should precede condition 5.
The timing and conditions for the experiments and the timing of 
blood sampling were the same as those described in Section 5. After 
estimation of haemoglobin and haematocrit, samples were stored and analysed 
exactly as described in Section 5. The mean coefficients of variation 
for the assays were as follows:
The mean recovery of AVP from "spiked" plasma was 69.1% ±11,2 (n = 6).
Measured cortisol concentrations were corrected for the effect of 
plasma volume changes as in Section 4. AVP, noradrenaline and adrenaline were 
not corrected for plasma volume changes. ANOVA was used to investigate the 
effects of the conditions upon the plasma concentrations of the hormones.
The values for noradrenaline and adrenaline were transformed as described 
in Section 5 (page 87) but the AVP data did not require transformation.
In addition to the hormonal measurements, the arterial oxygen 
saturation of each subject was measured during all conditions by an 
optoelectronic ear oximeter (Hewlett-Packard model no 47201A). The 
accuracy of this model during high G exposure has been verified by Besch 
et al (1978) who demonstrated an excellent correlation (r = 0.95 ; P<0.001) 
between oxygen saturation (SaC^) measured by the oximeter and SaC>2 
calculated from the oxygen tensions of arterial blood samples drawn at 
the same time as oximeter readings were taken. A similar correlation 
(r = 0.98 ; P<0.001) was also demonstrated during hypoxia induced by 
breathing oxygen-nitrogen gas mixtures of varying composition.
Glaister and Lisher (1977b) have also confirmed that the Hewlett- 
Packard oximeter gave excellent and reproducible results during acceleration 
exposures of up to +8Gz on the RAF IAM centrifuge. Furthermore the oximeter 
was insensitive to changes in ear lobe blood volume which occurred during
Noradrenaline
Adrenaline
AVP
Cortisol
Within-assay CV(%) 
3.6 
9.1 
8.9 
13.5
Between-assay CV(%)
5.6
16.4
24.9
21.8
+Gz acceleration and/or PPis. (Such sensitivity was demonstrated for 
an Atlas ear oximeter and gave rise to spurious results.)
The ear oximeter, which was carried in the gondola car, was 
calibrated prior to each experimental run and its output recorded on the 
Brush pen recorder. From these recordings, the following measurements 
of arterial oxygen saturation were made for conditions 1 to 3 i.e. those 
with exposure to +6Gz.
1. CONTROL values obtained at Is intervals for the 3s immediately prior 
to the start of centrifugation.
2'. "SPIN-UP" values' at Is intervals for the 3s immediately prior to 
attaining plateau level of +6Gz.
3. "SPINNING" values at Is intervals for the last 3s at plateau G.
4. "SPIN-DOWN" values at Is intervals over the 3s immediately prior 
to return to +lGz.
5. "RECOVERY" values obtained at 58, 59 and 60s after return to +lGz.
These measurements were then analysed by ANOVA to determine the 
significance of alterations in oxygen saturation during the +6Gz experi­
ments. The minimum levels of oxygen saturation attained by breathing the 
hypoxic gas mixture were noted but not'included in the analysis. No 
formal analysis was made of the recording of oxygen saturation made during 
Condition 4 (+lGz control with PPB and anti-G suit inflation).
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6,3, Results
All subjects were able to tolerate +6Gz for one minute but straining 
manoeuvres were found to be necessary in order to maintain vision under 
condition 1 i.e. anti-G suit protection only. Positive pressure breathing 
was found to reduce muscular effort and to be comfortable at +6Gz whereas 
during the +lGz control it required expiratory effort and was uncomfortable. 
When CP was combined with PPB there was no subjective feeling of improve­
ment over PPB alone and two subjects complained of arm pain at the end of 
centrifugation. Examination of the mask pressure recordings indicated 
that no mask leaks occurred during PPB and that the pressure supplied under 
all PPB conditions was 30 mmHg.
In the hypoxia experiment all subjects attained a suitable level of 
arterial desaturation in just under one minute of breathing the gas mixture. 
The experiment did not produce any discomfort apart from occasional "light­
headiness".
Typical ear oximeter recordings have been traced out for one subject 
(DG) and are shown as figures 6.1 and 6.2. Figure 6.1 combines the tracings 
for the three +6Gz experiments and shows the falls in Sa02 that occurred 
in this subject with exposure to acceleration. The falls continued after 
cessation of acceleration for about 15s from the end of plateau accelera­
tion, at which point the levels started to recover towards control values.
In figure 6.2, the effect of hypoxia was to reduce the Sa02 in a similar 
manner to that seen with acceleration. Also shorn in this figure is the 
subject’s Sa02 recording during the +lGz control (inflation of the anti-G 
suit and PPB) but no changes in SaC>2 were observed.
Similar tracings were obtained for all the other subjects. The 
meaned subject data from the three +6Gz experiments are presented in 
Table 6.1. For all three conditions acceleration reduced mean SaC>2 values 
(p<0.,001) with minimum values occurring during "spinning” and "spin-down". 
The mean "spin-down" values were lower (p<0.05) than the "spinning" values 
under conditions 1 (anti-G suit only) and 2 (anti-G suit and PPB). However 
with the addition of counter pressure there was no difference between "spin- 
down" and "spinning" values. Comparison of the results between conditions 
indicated that the addition of PPB ameliorated the hypoxia observed with an 
anti-G suit only during both "spinning" (p<0.001) and "spin-down" (p<0.001) .
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Addition of CP further improved the hypoxia seen with unassisted PPB 
during "spin-down" (p<0.05) but not during "spinning” (p=0.05).
During the hypoxia experiments, the minimum Sa02 meaned for all 
subjects was 79.4%. Although not analysed statistically, no changes in 
SaO£ were observed in any of the subjects during condition 4.
TIME
OF
MEASUREMENT
CONDITION
1
(AGS only)
2
(AGS + PPB)
3
(AGS + PPB + CP)
CONTROL 96.1 96.1 96.8
"SPIN-UP" 96.2 95.8 96.6
p<0.001 p=0.05
"SPINNING" 82.2 «- — v 86.9 *---------- ► 88.8
p<0.001 p<0.05
"SPIN-DOWN" 80.1 > 86.2 ■<---------- >• 88.5
"RECOVERY" 94.4 95.1 96.2
Table 6.1. Mean values for arterial oxygen saturation (%) measured by 
ear oximetry on five subjects exposed to +6Gz for one 
minute on three different occasions. For each of the 
exposures different extrinsic protection was afforded to 
the subjects : Condition 1 = anti-G suit (AGS) only;
Condition 2 = AGS + positive pressure breathing (PPB); 
Condition 3 = AGS + PPB + counter pressure (CP). Times 
of measurement relate to time of centrifugation as defined 
in text. Least significant differences (LSDs) for com­
parison between times for a given condition are p<0.05 = 2.9, 
p<0.01 = 4.0, p<0.001 =5.4.
LSDs for comparison between conditions at a given time are 
p<0.05 = 2.0, p<0.01 = 2.7, p<0.001 =3.6.
(Note that the significance levels for some of the latter com~ 
parisons have been marked on the table.)
Plasma volume changes meaned for subjects are shown in figure 6.3. As 
noted before, acceleration resulted in an immediate haemoconcentration 
(p<0.001) followed by a haemodilution. Significant haemoconcentration did 
not occur after either of the +lGz control conditions although haemodilution 
was a feature of the PPB/AGS control (p<0.01 at 21 minutes). There was 
no difference between the results for each of the +6Gz conditions.
%  APV
Acceleration
■ +
121
'— oTIME (min)
- 2
-4
- 6
□---------- □ PPB/AGS +1GZ
+--------- + Hypoxia+1Gz
x ............x AGS only + 6Gz
o-— — o AGS/PPB + 6Gz 
a ----------a AG S/PP B/CP +6G z
-8 LSD 
P < 0 *0 5 )
-10
-12
Figure 6.3. Mean changes in plasma volume (%APV) in five subjects exposed 
to five different conditions: 1) Positive pressure breathing 
(30 mmHg) and anti-G suit inflation for one minute at +lGz 
(PPB/AGS +1Gz ). 2) Hypoxia at +lGz. 3) Exposure to +6Gz for
one minute with anti-G suit protection (AGS only +6Gz).
4) As in 3, but with addition of PPB (AGS/PPB +6Gz) and
5) As in 4 but with addition of counter-pressure (CP) to the 
trunk (AGS/PPB/CP +6Gz).
Least significant differences (LSD p<0.05) shown are for
A) Comparison of times for a specified condition..
B) Comparison between conditions at a specified time.
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Mean plasma cortisol values for the five subjects are shown in figure
6.4. For the +6Gz conditions, peak plasma cortisol levels occured 20 
minutes after acceleration (p<0.001) and although it was not possible to 
differentiate individual +6G conditions they all produced larger responses 
(p<0.001) than those observed in the +lGz control experiments. In the 
latter two conditions, no significant changes in cortisol concentration 
were observed over the time of the experiment.
PLASMA CORTISOL 
n mol/l  
600 r
o----- d  PPB /A G S +1G2
+ ---------+ H y p o x ia + 1 G Z
 ............ * AGS only + 6GZ
o--------- o  A G S/PP B  + 6GZ
* --------- *  A G S /P P B /C P  + SGz
LSD 
( P < 0  05)
500
400
300
200
121
Acceleration TIME (min)
Figure 6.4. Plasma cortisol results, meaned for five subjects under the 
five experimental conditions indicated.
(For legend see figure 6.3).
Least significant differences (LSD p<0.05) shown are for:.
A) Comparison of times for a specified condition.
B) Comparison between conditions at a specified time.
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for transformation bias (see page 92) have been plotted on log scales in 
figures 6.5 and 6.6. Figure 6.5 shows the results for the +6Gz conditions 
and figure 6.6 shows the results for the two +lGz control experiments.
Acceleration at +6Gz resulted in increases in plasma noradrenaline 
(p<0.0.01) which peaked in the sample taken immediately after centrifuga­
tion. It was not possible to differentiate the results between the three 
conditions. For the +lGz control experiments, no significant changes were 
observed. ,
Mean values for plasma adrenaline, similarly back transformed and 
plotted, are shown in figures 6.7 (+6Gz conditions) and 6.8 (+lGz conditions). 
As with-noradrenaline, adrenaline values peaked after acceleration (p<0.001) 
but the peaks for each of the conditions were not significantly different. - 
There were no significant changes in the'adrenaline levels measured during 
the control experiments. '
The results for AVP, meaned for the five subjects are shown for all 
five conditions in figure 6.9. The analysis indicated that there were no 
significant changes under any of the conditions. No significant relation­
ship was found between plasma AVP and plasma cortisol values during the 
experiments.
L S D
( P < 0 * 0 5 )
a a A G S / P P B / C P  + 6G
800
600
200
AccQ
100
121
Time (m in )
Figure 6.5. Mean plasma noradrenaline of 5 subjects exposed to +6Gz for one
minute under 3 different conditions of protection: 1) anti-G suit 
only, 2) anti-G suit and positive pressure breathing (PPB) and 3) 
anti-G suit, PPB and trunk counter pressure (CP). LSD’s (p<0.05) 
shown are for A) Comparison between conditions at a specified time 
and B) Comparison of times for a specified condition. Note that 
the nbradrenaline values are plotted on a log scale.
P la s m a
Noradrenaline
p g /m l
1000
+ ----------+ H y p o x ia +  1Gz
o---- o P P B / A G S +  1G
8 0 0 L S D
( P < 0 * 0 5 )
6 0 0
4 0 0
— C
— +
200
Stimulus
100
2 1 21 61 121
Time (m in )
Figure 6.6. Mean plasma noradrenaline of 5 subjects exposed to two +lGz
control conditions: 1) Hypoxia induced by breathing a 7.6% C^j 
92.4% N2 g^s mixture and 2) PPB at 30 mmHg with' anti-G suit infla­
tion for one minute. LSD’s (p<0.05) shown are for, A)* Comparison 
between conditions at a specified time and B) Comparison of times 
for a specified condition. Note that the noradrenaline values 
are plotted on a log scale.
^ a A G S /P P B /C P  +6G z(P <  0 -0 5 }
AccD
Time (min)
- 2  1 11 21 61 121
Figure 6.7. Mean plasma adrenaline of 5 subjects exposed to +6Gz for one
minute under 3 different conditions of protection: 1) anti-G suit 
only, 2) anti-G suit and positive pressure breathing (PPB) and 3) 
anti-G suit, PPB and trunk counter pressure (CP). LSD’s (p<0,05) 
shown are for A) Comparison between conditions at a specified time 
and B) Comparison of times for a specified condition. Note that 
the adrenaline values are plotted on a log scale.
P las m a
A drenaline
pg/mi
200
+ ---------+ H y p o x ia + 1 G z
□----------□ P P B /A G S + 1 GLS D
(P <  0*05 )
100
Stimulus
20 -
12161-2 1 21
Time (m in )
Figure 6.8. Mean plasma adrenaline of 5 subjects exposed to two +lGz control
conditions: 1) Hypoxia induced by breathing a 7.6% O2, 92.4% N2 gas 
mixture and 2) PPB at 30 mmHg with anti-g suit inflation for one 
minute. LSD’s (p<0.05) shown are for A) Comparison between 
conditions at a specified time and B) Comparison of times for a 
specified condition. Note that the adrenaline values- are plotted 
on a log scale.
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Figure
P lasm a
AVP
p g / m l
x**
Time (m in )
B
LSD 
(P< 0*05)
+ -----------+ H y p o x i a + 1 G Z
x.....-x AGS only+.6 G.2
□-----------a .  PPB/AGS + 1GZ
o----—o AGS/PPB + 6GZ
A AGS/PPB/CP + 6G2
3.9. Plasma AVP results, meaned for 5 subjects exposed to five
different experimental conditions: 1) Hypoxia at +lGz induced 
. by breathing a 7.6% O2, 92.4% N2 gas mixture. 2) PPB at 30 mmHg 
with anti-G suit inflation for one minute at +lGz (PPB/AGS +lGz).
3) +6Gz for one minute protected by an anti-G suit only (AGS only 
+6Gz). 4) As in 3 but with the addition of PPB (AGS/PPB +6Gz).
5) As in 4 but with the addition of trunk counter pressure 
(AGS/PPB/CP +6Gz).
Least significant differences (LSD p<0.05) shown are for 
A) Comparison of times for a specified condition and B) Comparison 
between conditions at a specified time.
124
6.4. Discussion
Measurement of Sa02 in this experiment has confirmed that +Gz accelera­
tion produces arterial oxygen desaturation which has been attributed to the 
development of ventilation:perfusion inequalities (Glaister, 1970). The 
improvement in Sa02 produced by the addition of PPB to the use of an anti-G 
suit has also confirmed earlier results from Leverett et al (1973) who 
demonstrated improved saturation with PPB at 30 mmHg during +6Gz exposures.
Shaffstall and Burton (1979) were, however, unable to confirm this action of 
PPB in.six subjects exposed to "aerial combat manoeuvre" +Gz profiles (ACM: 
see page 23). This conflicting result appears to have been caused by the 
high Sa02 values recorded in the "anti-G suit only" group, although this was 
not discussed by the authors. The values obtained were considerably higher 
than those seen in the present study and by Leverett et al during +6Gz 
exposures. Although it is reasonable to suggest that this is an unfair 
criticism because the +Gz levels employed by Shaffstall and Burton were 
+4.5Gz alternating with +7Gz rather than a steady +6Gz, support for this 
criticism does come from a more recent work by the same authors (Burton:and 
Shaffstall, 1980). In this study they investigated seven G-suited subjects 
exposed to an identical ACM profile at various seat angles. PPB was not 
employed but Sa02 levels were recorded and for conditions equivalent to their 
earlier study, mean Sa02 values were considerably lower e.g. 78.1% mean Sa02 
compared to a mean of 86.2% for the anti-G suit only group at the equivalent 
time in the earlier study. This discrepancy in measurement must therefore 
raise doubt about the validity of the results in the earlier experiment on 
PPB. '
It seems reasonable to suppose that PPB will improve arterial saturation 
by minimising the airway closure that occurs in the dependent lung under high 
G. Further amelioration of the desaturation by the use of trunk counterpressure, 
which was observed in this study, cannot be explained so easily. Indeed, 
counterpressure over the chest might be expected to reverse the effect of PPB 
by counterbalancing the effect of PPB on airway pressures. The significance 
of this beneficial effect was small (p<0.05) and the numbers of subjects 
limited so that verification of these results is required by an extension of 
this work to encompass more subjects exposed to a greater variety of +Gz 
loads.
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In subjects made to breathe a hypoxic gas mixture, the mean minimum 
SaC>2 of 79.4% was similar to the mean minimum value of 80.1% seen under 
+6Gz with anti-G suit only, although the time courses of the falls were 
different between the two conditions. At +lGz the hypoxia did not 
promote secretion of the hormones measured in this study. That hypoxia is 
not the stimulus to the secretion of these hormones under high G is also 
supported by the lack of differences in hormonal responses between the.three 
+6Gz conditions where, as discussed above, differing degrees of arterial 
oxygen desaturation were observed. The results of this experiment therefore 
support previous studies, outlined on page 110, in which hypoxia was not 
associated with AVP release.
In the other normogravic control experiment, PPB failed to stimulate 
release of the measured hormones. However, the use of counterpressure to 
both legs and trunk in this experiment-may have inhibited a response to PPB 
alone but this latter condition was not included in the study. The observa­
tion that intermittent PPB stimulates AVP secretion (Khambatta and Baratz,! 
1972) was made in subjects without counterpressure and was attributed to 
reduced left atrial distension due to peripheral sequestration of blood.
In the present experiment there was no haemoconcentration following PPB, in 
fact, a haemodilution developed. Under +6Gz there was no evidence to suggest 
that PPB promoted AVP secretion and the haemoconcentration produced by 
acceleration was not worsened by PPB, which reflected the protective action 
of the anti-G suit. -
The failure of PPB to modify the hormonal responses observed when an 
anti-G suit was used alone, suggested that muscular exercise, necessary to 
perform M-l manoeuvres, did not act as a stimulus to hormone secretion because 
PPB improved fatigue by reducing muscular effort in all subjects. This 
beneficial effect upon fatigue has also been observed by Leverett et al 
(1973), Shubrooks (1973) and Shaffstall and Burton (1979). The results from 
the present study therefore support.the findings of the control experiment 
in section 5, which suggested that strenuous exercise alone was not the 
stimulus to hormonal secretion under high G.
It was postulated, again in section 5, that the cardiovascular changes 
produced by +Gz acceleration stimulate hormonal secretion via low and high 
pressure baroreceptor mechanisms. In this present study, changes in plasma 
volume during the +6Gz conditions -were not significantly different. Therefore
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it was likely that low pressure cardiovascular receptors were stimulated 
equally during these conditions so that, on this basis alone, one might not 
expect different hormonal responses between conditions. Nevertheless the 
results can only be explained fully on such a cardiovascular model if 
arterial pressure changes were also similar between conditions. After all,v 
the effects of an anti-G suit were attributed in section 5 to reduced 
stimulation of high pressure baroreceptors.
Shubrooks (1973) measured eye-level arterial pressure continuously in 
three subjects during up to 60s of exposure to +8Gz. The recordings suggested 
that PPB (at 40 mmHg) resulted in less respiratory-induced variations in 
arterial pressure than when subjects were required to perform M-l manoeuvres. 
Such a finding would suggest that PPB might be expected to reduce hormonal 
responses to high G by reducing the amount of hypotensive stimulation of high 
pressure baroreceptors.
In a similar study, however, Leverett et al (1973) obtained variable 
results when they monitored eye-level arterial pressure in six subjects 
exposed to +1, +6 or +8Gz using either-PPB (at 30 mmHg) or M-l manoeuvres.
In four subjects, the arterial pressure recordings were similar between the 
two conditions. In one subject the findings corroborated those of Shubrooks 
but, in the final subject, less variation in pressure was observed with M-l 
manoeuvres than with PPB, On the basis of these results significant changes 
in hormonal responses would not be expected between the two conditions.
The experimental conditions employed by Leverett et al were closer to 
those in the present study than those of Shubrooks. In particular, the 
breathing pressure was set at a constant 30 mmHg and the experiment was 
conducted, at least in part, at +6Gz. However neither of these experiments 
made use of counterpressure and in fact there is no information available 
about arterial pressure changes under high G when PPB is "assisted" in this 
way. Firm conclusions about the role of high pressure baroreceptors cannot 
be made from the results of the present study and the current state of know­
ledge in this field.
Another limiting factor in the present study was the level of +Gz 
acceleration employed. +6Gz was not really a severe enough stress to allow 
clear demonstration of changes in hormonal secretion induced by PPB since 
the responses had already been diminished considerably by the use of an anti-G
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suit. As a general rule inhibitory effects are more easily demonstrated 
when maximal rather than sub-maximal stimulation is used as a control.
Since PPB requires the use of an anti-G suit for its beneficial effects upon 
visual tolerance to be demonstrated, it might have been wiser to employ a 
higher level of acceleration, such as +8Gz, in this study. Although ideal, 
some of the subjects might not have been able to tolerate such a high level 
of acceleration and, to be of physiological use, the study would have required 
considerable training for subjects during which time they may have had to 
experience bouts of unconsciousness etc. This was therefore considered to be 
unacceptable.
It remains now to review the work carried out in this thesis and to 
see what conclusions may be drawn about the effects of sustained +Gz 
acceleration upon endocrine function.
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SECTION 7 : DISCUSSION AND CONCLUSIONS
SECTION 7 : DISCUSSION AND CONCLUSIONS
The relationship between stress and endocrinology has been reviewed 
at length in Section 2 of this thesis, where individual hormones were 
examined in relation to a wide variety of stressors. It was emphasised 
that the development, over the last two decades, of new assay techniques 
has permitted hormonal changes to be defined more accurately, and witti 
greater sensitivity, than at any time in the history of medicine. Thus, 
some hormones which were thought of as being "static" and unresponsive, have 
been shown to be labile and responsive, simply because the former belief 
had been based on insensitive methods of measurement.
It is, however, this very lability associated with spontaneous and 
pulsatile secretion, that has led to conflicting results and the important 
requirement that the investigator should exercise close control over experi­
mental conditions. In this thesis the need for frequent blood sampling has 
been emphasised so that conclusions have not been based on a control, and 
single post-stress, samples. Endocrinological studies should ideally include 
an equivalent experiment carried out under resting conditions, in the same 
subjects, without the superimposition of the stressor in case base-line 
fluctuations due to diurnal rhythms, pulsatile secretion etc, produce spurious 
results. The importance of this type of control was discussed in Section 2 
where it was pointed out that the original description of GH as a "stress- 
hormone" was established by the most limited of experiments - a single 
subject exposed on one occasion to an unquantifiable psychological stressor 
(Greenwood and Landon, 1966).
The lability of stress hormones also limits the usefulness of urine 
sampling since the time course of measurement is restricted, even in the 
most optimistic hands, to a minimum of 15 minutes. Thus the extreme rapidity 
of the catecholamine responses to +Gz acceleration which have been demon­
strated in Sections 5 and 6 could not have been predicted from previous 
studies on urinary catecholamines. As a result these latter studies have 
little application in the understanding of physiological processes.
In addition to these general observations on experimental design, it 
is also apparent that there is a need to define the level of experience of 
the subjects - is this their first exposure to the stressor or are they used 
to it? Previous investigators have often failed to do this and, for example,
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it was not possible to compare the catecholamine results obtained in this 
thesis from highly experienced subjects, with the results obtained in earlier 
studies (see pages 102-103). In addition account has to be taken, where 
applicable, of different sub-groups of "non-responder11 and "responders"
(see page 79). In general, therefore, the enhanced sensitivity of assays 
must be matched by increased sophistication in experimental design. In the . 
future it may also be necessary to appreciate that each individual may 
actually demonstrate his or her own individual pattern of hormonal response I
From the experiments conducted in this thesis, it has been established 
that +Gz acceleration produces a specific endocrinological response marked, 
in experienced subjects, by the secretion of cortisol, noradrenaline, 
adrenaline and*AVP. The stimulus to the secretion of these hormones has been 
attributed to the stimulation of high and low pressure cardiovascular 
receptors in response to the sudden development of orthostatic hypotension 
under "high G". From control experiments, it has been demonstrated that 
these changes do not appear to be induced by muscular effort or by the develop­
ment of hypoxia. There was also no clear relationship between the secretion 
of AVP and cortisol which supports the concept that CRF is an entity distinct 
from AVP although a role for AVP may exist in the enhancement of CRF activity 
(see page 100).
The prime function of the release of catecholamines in response to +Gz 
acceleration must be the restoration of cardiovascular homeostasis. The 
increases in catecholamine concentrations are large and occur with extreme 
rapidity. When the stimulus is removed, levels fall off abruptly. The 
importance of such a sudden response to orthostatic hypotension is readily 
apparent to those patients with autonomic dysfunction who faint on assuming 
the upright posture. The catecholamine response to high G was therefore 
predictable but its magnitude had not been defined before.
The exaggeration, by +Gz acceleration, of this postural change in blood 
pressure provides- a model to study and define "normal" hormonal responses to 
a situation that would otherwise only occur under pathological conditions.
The sudden and large AVP response to this stimulus might suggest that AVP 
also has a role-to play in the immediate response to hypotension i.e. a 
pressor rather than an antidiuretic action. As discussed earlier (see pages 
45-46), a ,pressor effect of AVP has not been demonstrated in normal subjects 
and AVP has not been implicated with any certainty in the pathogenesis of
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administration of AVP (v7hole posterior pituitary snuff and infused Pitressin) 
to three subjects with autonomic dysfunction, produced dose-related rises in 
recumbent arterial pressure measured by an invasive method. Such rises 
were not demonstrated with oxytocin or in six normal volunteers exposed to' 
the same doses of AVP or pituitary extract. The study was not combined with 
measurement of plasma AVP levels (although this could only be done at that 
time by one of the early bio-assays) so that one has no idea of whether the 
doses of AVP used produced physiological blood levels of the hormone. Sadly, 
this study has received little attention since it was published, yet it 
implies that such patients have a marked sensitivity to the pressor effect 
of AVP. Could it be that, by some unknown mechanism, the receptors which 
are responsible for the pressor action of AVP are only active during hypo­
tensive states and are inactive under normo- or hypertensive conditions? If 
this were the case then one could envisage an "emergency" role for AVP in 
the body's defence against hypotension created by conditions such as 
haemorrhage or +Gz acceleration. Such a role might also explain the 
anecdotal observation frequently expressed by fighter pilots that the first 
"pull" of the day is always the worst i.e. the initial exposure to high G 
has something missing - could this be the pressor effect of AVP?
The anti-diuretic action of AVP clearly acts to conserve blood volume 
in the longer term and combined pressor and anti-diuretic actions would 
represent the not uncommon "belt and braces" approach that the body adopts, 
under conditions where homeostasis is threatened. The final and less well 
documented action of AVP is on human memory function (see pages A7-48).
Could AVP be acting to protect the facility to retrieve memory under condi­
tions of cerebral hypotension? From the author's own experience, and that of 
others, +Gz induced unconsciousness, which is undoubtedly associated with 
high AVP levels, is also always accompanied by a merciful amnesia! More 
subtle techniques need to be applied if changes in memory retrieval are to 
be elucidated.
The interpretation of the enhanced secretion of cortisol seen in 
response to +Gz acceleration is less clear than that of the catecholamines 
and AVP. It can hardly be regarded as a non-specific "all or nothing" 
response since it is dose-related. The action of cortisol in promoting the 
activity of the catecholamines would at first sight seem an inappropriate 
reason for cortisol secretion since the rise in catecholamine levels occurs
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well before the rise in cortisol. However the body cannot predict when a 
stimulus will be terminated and must be prepared for all eventualities. It 
would be a worthwhile experiment to see if G tolerance could be raised by 
prior administration of hydrocortisone or shown to be increased at twenty 
minutes after an initial high G exposure when the level of cortisol in blood 
is at a peak. In the longer term, caloric homeostasis must be maintained 
to a brain already deprived of nutrition by hypotension. Under such conditions, 
cortisol would also have an important role in ensuring that the brain was 
supplied with metabolic substrate.
One of the aims of this thesis has been to determine whether hormonal 
changes may be correlated with acceleration tolerance and the efficacy of 
extrinsic protection. It was apparent from the experiments in Sections 5 
and 6 that the rapidity of the noradrenaline, adrenaline and AVP responses 
made the precise measurement of the timing of peak levels difficult. Ideally, 
samples would need to be taken at 15s intervals (i.e. continuously) which, 
because of the amount- of plasma required by the assay, would not be practical 
for AVP. A more distinct definition of the timing of the peak catecholamine 
responses could be achieved because of the lower sample volumes required in 
the assay. Peak values might then provide an endocrinological measure of G 
tolerance but with the information available from the present experiments 
it was not possible, for example, to distinguish clearly between the effects 
of different seat back angles upon the catecholamine responses.
The secretion of cortisol with its slower rate of onset and well 
defined peak did give valuable information which was dose-related. Although 
its predictive use was not established in experiments using PPB (Section 6), 
it did appear to provide reliable information about seat back angle and 
tolerance since a significant relationship was demonstrated AG and A cortisol . 
(see page 67).
 ^Finally it was suggested that this study might be useful in the predic­
tion of the endocrine changes that occur under conditions of weightlessness.
An extrapolation to "zero G" from known hormonal effects of increased G is 
a logical approach to the problems inherent in blood sampling under weightless 
conditions. On the Skylab missions blood samples were obtained for a limited 
number of hormone measurements but greater reliance was placed upon the use 
of urine samples, which were easier to collect.
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One might reasonably predict from the results of this thesis that the 
blood levels of AVP, cortisol and the catecholamines would be reduced below 
normal (+lGz) values under "zero G" conditions. From the analysis of daily 
urine samples produced by Skylab crewmen, Leach and Rambaut (1977) concluded 
that AVP levels were high in the first two days of flight but then fell to 
well below control levels until rising again post-flight. The rises at the 
beginning and end of the weightless period presumably reflected stimulation 
of AVP secretion by the accelerative loads imposed by insertion into, and 
re-entry from, orbit coupled with an understandable degree of psychological 
stress.
Urinary adrenaline levels were generally normal or decreased in-flight 
and elevated post-flight, the latter probably again reflecting the degree 
of psychological stress that occurred on return to earth. Urinary noradrena­
line levels were, however, generally raised during flight but one of the 
main aims of the Skylab programme was to see whether high levels of sustained 
exercise could prevent the muscular atrophy known to occur under weightless 
conditions. Thus a reduction in noradrenaline excretion may have been observed 
if the astronauts had not been required to exercise.
Plasma cortisol levels were raised during flight whereas ACTH 
levels were reduced. Leach and Rambaut have interpreted this result 
as due to reduced metabolism of cortisol but their conclusion must be 
viewed with caution as conditions for specimen storage were not ideal 
especially for a hormone of ACTH's lability. Clearly the study of 
endocrinology in weightlessness is in its infancy and the verification 
of the predictions made in this thesis will take several years of 
research and a financial investment that will make the cost of this 
present study look, in NASA's eyes at least, like a "good buy".
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SECTION 9. APPENDIX I: ASSAY PROTOCOLS
9.1. Growth Hormone Radioimmunoassay
9.2. Prolactin Radioimmunoassay
9.3. Luteinising Hormone and Follicle Stimulating Hormone Radioimmunoassays
9.4. Thyroid Stimulating Hormone Radioimmunoassay
9.5. Cortisol Radioimmunoassay
9.6. Arginine Vasopressin Radioimmunoassay
9.7. Single Isotope Radioenzymatic Assay for Catecholamines
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Section 9. Appendix 1: Assay protocols
9.1. Growth Hormone Radioimmunoassay
This is a double antibody RIA originally developed by the University 
of Surrey, Guildford. Unless otherwise stated, all reagents and 
chemicals were obtained from H & W Ltd.
Reagents
Barbitone buffer 0.05M, pH 8.0 with 0.5% human serum albumin (HSA)
HSA is supplied by The Blood Products Laboratory, Lister Institute.
10.31g (0.05M)
3.80g (0.065M)
3.72g (0.01M)
0.10g (0.01%)
Dissolve in approximately 800 ml distilled water. Adjust to pH 8.0 
by titrating with IN HC1 and then make up to 1 litre with distilled 
water. The solution should be stored at 2-4 degrees centigrade. 
Immediately before use add 0.5% (by weight) HSA.
2. Standards
The standard for this assay is the first British Standard (1974) 
preparation of human growth hormone for immunoassay, Code No. 66/217. 
(National Institute for Biological Standards and Control, Holly Hill, 
Hampstead, London NW3 6RB). Each ampoule contains, by definition, 
approx. 175 yg of human GH, equivalent to 0.350 IU HGH.
The contents of one ampoule are dissolved in 35 ml HSA/barbitone 
buffer, giving a solution of 10 mU/ml. This solution is dispensed 
in 1 ml aliquots and stored at -20°C as a stock solution.
A 1 ml aliquot of stock solution is diluted to 10 ml with assay 
buffer, giving a solution of 1 mU/ml (1000 mU/L). This solution is 
dispensed in 0.1 ml aliquots (0.1 mU/tube) into LP3 tubes and stored 
frozen as a working solution. For the assay, take on ampoule of 
working solution and add 0.9 ml assay buffer. This solution now 
contains 0.1 mU/ml (100 mU/L) . Mix well, remove 0.5 ml mixture and 
add to an equal volume of transfusion plasma. This gives a standard
Sodium barbitone 
Sodium chloride 
Disodium EDTA 
Thiomersal
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of 50 mU/L. Cont5.nue to double dilute in this manner to give 
standards of 25, 12.5, 6.25, 3.13, 1.57 and 0.78 mU/L. Use 
25 mU/L as the top standard because the 50 and 100 mU/L standards 
are beyond the limits of the assay.
3. Anti-HGH antiserum
The anti-serum number RD15/RD16 is supplied by Wellcome Reagents Ltd, 
303 Hither Green Lane, London SE13 6TL. It is stored freeze-dried 
at 4 degrees centigrade in 0.5 ml aliquots of a 1:1000 dilution. 
Dissolve the contents of one ampoule and dilute to a final volume 
of 37.5 ml with HSA/barbitone buffer.
4• Label
Iodinated HGH was supplied by Dr. B.D. Thompson, University College 
Hospital, Gower Street, London WC1E 6AU. It is iodinated by the 
Bolton Hunter method and purified by gel filtration on Sephadex 
G-100. Each batch of label lasts about three weeks and should be 
diluted so that 0.1 ml solution contains 50 pg labelled HGH and so 
50 pg label is added to each tube. Details of the specific activity 
and dilution 'factors of the label are usually supplied with each 
batch.
5. Inactivated rabbit serum (IRS)
This is supplied by Wellcome Reagents Ltd as heat-inactivated 
normal rabbit serum. It is diluted 1:500 with HSA/buffer for use 
in the assay.
6. Donkey anti-rabbit globulin
This is supplied by the University of Surrey as freeze dried 1 ml 
aliquots. The contents of one vial should be dissolved in 1 ml of 
distilled water and diluted 1:50 in HSA/buffer for use in the assay.
7. Specimens and quality controls
Use serum in preference to plasma. If necessary, centrifuge samples 
before use. Low, medium and high QC samples were supplied by the 
Dept of Clinical Biochemistry, St Luke’s Hospital, Guildford, Surrey.
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Transfusion plasma was supplied by the Army Blood Supply Depot, 
Aldershot, Hants.
Procedure in Outline
Sample or standard lOOyl
Buffer 500yl
1st antiserum (anti-HGH) lOOyl
Label lOOyl
Normal rabbit serum (NRS) lOOyl
2nd antiserum lOOyl
Total volume lOOOyl
Tube Buffer
Transfusion
plasma
Sample or 
Standard
Anti-HGH Label NRS 2nd Ai
Total - - - 100 - -
NSB 600 100 - - 100 100 100
Max 200 100 - 400 100 100 100
Zero 500 . 100 - 100 100 100 100
Std 500 - 100 100 100 100 100
Sample 500 - 100 100 100 100 100
Set up the assay with all tubes duplicated for standards, samples 
etc.
Procedure
Day 1. Dispense buffer, sample or standard and anti-HGH antiserum into
the appropriate tubes. Mix and incubate at 4°C.
Day 2. Add label to all tubes. Mix and incubate at 4°C.
Day 5. Add NRS and second antiserum to all but total tubes. Mix and
-incubate at 4°C.
Day 6. Centrifuge tubes at 2.500 rpm and 4°C for 30 minutes. Aspirate
the supernatent using a pasteur pipette connected to a vaccuum 
pump. Place the tubes on a Gamma counter and count the total tubes 
to obtain 10-20,000 counts and measure the other tubes for the 
same period. Read the values for each tube directly from the 
calibration curve.
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This is a double antibody RIA developed at St Luke*s Hospital, 
Guildford.
Reagents
1. Phosphate buffered saline. 0.01M, pH 7.4 containing 1% BSA.
Make up stock solutions of potassium dihydrogen phosphate 
(KH2P04; 68g/l) and disodium hydrogen phosphate (Na2H?04.2H20;
89g/l), both containing 0.1% thiomersal and store at 4°C. For use, 
mix 4 ml of the potassium salt with 16 ml of the disodium salt.
Dilute this to 11 and add 9g of NAC1. Store the solution at 4°C.and, 
just prior to use, add 1% BSA.
2. Anti-PRL serum (Guildhay)
The rabbit anti-PRL serum is supplied diluted 1:400 with BSA/ 
phosphate buffer and frozen in 1 ml aliquots. For use dilute each 
aliquot to 120 ml in assay buffer to give a final antiserum dilution 
of 1:96,000. Add NRS to an initial dilution of 1:600.
3. Label
Human prolactin was obtained from the National Pituitary Agency,
310 West Fayette Street, Baltimore, Maryland 21201, U.S.A.
Iodination should be carried out using lactoperoxidase and 1 ml 
aliquots containing about 100,000 counts are stored at 4°C.
4. Second anti-serum (Guildhay)
Use donkey anti-rabbit IgG precipitating serum at an initial dilu­
tion of 1:20 (final dilution of 1:160). Each vial of freeze-dried 
serum must be reconstituted with 1 ml distilled water and diluted 
for use in assay buffer.
5. Standards
The PRL standard used is the first International Preparation of 
Human PRL (Reference No. 75/504) obtained from the National 
Institute for Biological Standards and Control, London NW3 6RB.
Each ampoule has a defined activity of 650 mU PRL and is dissolved 
in 15.5 ml BSA/buffer. Store frozen in lOOyl aliquots. For use
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add 900yl assay buffer to each tube to reproduce the top assay 
standard of 4300 mU/1. Double dilute to produce standards of 
2150, 1075, 537, '268, 134 and 67 mU/1.
6. Standard, control and test sera
Plasma “spiked" with prolactin should be used to.
make low and high internal quality control specimens to be included 
at intervals in each assay, as well as carry over specimens from 
previous assays.
Method
Use polystyrene LP3 tubes for all incubations. Volumes listed 
below are in ylitres.
DAY 1 
TUBES
(Monday or 
CODE
Friday)
STANDARD CONTROL SAMPLE BUFFER 1st Ab LABEL
DAY 4 
2nd Ab
1&2 TOTAL - - - - - 100 -
3&4 4300mU/l 100 - - 300 100 100
5&6 2150mU/l 100 - - - 300 100 100
7&8 1075mU/l ’ 100 - - - 300 100 100
9&10 537 mU/1 100 - - - 300 100 100
11&12 268 mU/1 100 - - - 300 100 100
13&14 134 mU/1 100 - - - 300 100 100
15&16 67 mU/1 100 - - - 300 100 100
17&18 BLA - - 100 300 100 100
19&20 NSB - - 100 300 “ 100 100
21&22 CONTROLS “ 100 - - 300 100 100
23&24 UNKNOWNS - - 100 - 300 100 100
25&0N UNKNOWNS - 100 - 300 100 100
Day 1 (Monday or Friday)
Prepare standards, thaw specimens and controls and make up sufficient 
anti-serum solution. Dispense 100 pi aliquots of plasma and add 300 pi 
of anti-serum. To each tube add 100 p.l of label, vortex mix and incubate 
at 4°C for 72 hours.
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Day 4 (Thursday or Monday)
Add 100 yl of second anti-serum to all tubes except the totals and 
NSBs, vortex mix and incubate at 4°C for 24 hours.
Day 5 (Friday or Tuesday)
Centrifuge all tubes, except for the totals, at 2500 rpm for 30 
minutes. Aspirate the supernatant:; and discard. Place the tubes in a 
gamma .counter and count for a sufficient period to record at least 5000 
counts from the total tubes,. Plot counts against standard concentration 
and read off control's and tests. •
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9.3. Luteinising Hormone and Follicle Stimulating Hormone Radioinnnunoassays
Both LH and FSH were measured by double antibody RIAs developed by 
Dr K Ferguson, Dept of Biochemical Endocrinology, Chelsea Hospital for 
Women, Dovehouse Street, London SW3.
Reagents
1. Phosphate buffered saline. 0.05M, pH 7.4 containing 1% BSA.
Make up stock solutions of potassium dihydrogen phosphate (KH2P04; 
68g/l) and disodium hydrogen phosphate (Na2HP04.2H20; 89g/l), both 
containing 0.1% thiomersal and store at 4°C. For use, mix 20 ml 
of the potassium salt with 80 ml of the disodium salt. Dilute this 
to 11 and add 9g of NAC1. Store the solution at 4°C and just prior 
to use add 1% BSA.
2. Standards
Working standards for LH and FSH, which have been prepared from 
International Reference Preparations 68/40 and 69/104 respectively, 
may be obtained from Dr K Ferguson. Each vial contains sufficient 
material for one assay only and should be stored at 4°C until 
reconstitution with one ml of assay buffer. This will give a 
concentration of 40IU/1 of FSH or 50IU/1 of LH.
3. Antisera
1. Anti-LH antiserum (Code No WRB F87-2) and anti-FSH antiserum 
(Code No WRB M93*r2) were donated by Prof. W.R. Butt, Birmingham.
Vials containing 1 ml of diluted freeze-dried serum are available 
from Dr S.L. Jeffcoate at the Chelsea Hospital for Women. Each vial 
contains sufficient antiserum for 2500 tubes and should be stored
at 4°C until reconstitution with 1 ml distilled water when it should 
be divided into 50yl aliquots and frozen. For each assay dilute 
to 1:250 and use lOOyl per tube.
2. Donkey anti-rabbit gamma globulin serum (University of Surrey).
4. Label
Donated by Dr Ferguson in vials each sufficient for the assay of 
fifty tubes. Using a hypodermic syringe, inject 5 ml of assay 
buffer, through the rubber stopper of the vial, venting the internal
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pressure and shake gently to dissolve the contents. This provides 
the stock solution which should be stored at 4°C.
For use in the assay, remove 1 ml stock solution and transfer 
to a plastic test tube. Add approximately 25 mg Dowex 1 to remove 
free iodide, vortex mix for about thirty seconds, centrifuge 
briefly and aspirate the supernatant. Add the supernatant to 12 ml 
assay buffer and mix thoroughly. lOOyl of this diluted tracer 
will contain 15,000-20,000 cpm or about 150g peptide when fresh.
Assay Procedure
uay x
TUBES CODE STANDARD CONTROL SAMPLE
BSA/
BUFFER
1st
Ab LABEL
2nd
Ab nrs
1&2 TOTAL - - - - - 100 ~ -
3&4 STD 1 100 - - 500 . 100 100 100 100
5&6 STD 2 100 - - 500 100 100 100 100
7&8 STD 3 100 - - 500 100 100 100 100
9&10 STD 4 100 - • - 500 100 100 100 100
11&12 STD 5 100 - “ 500 100 100 100 100
13&14 STD 6 100 - - 500 100 100 100 100
15&16 ZERO - - - 500 100 100 100 100
17&18 NSB - 100 r 600 - 100 100 100
19&20 CONTROL - 100 - 500 100 100 100 100
21&22 UNKNOWN - - 100 500 100 100 100 100
23&24 UNKNOWN - - 100 500 100 100 100 100
DAY 4
Centrifuge all tubes at 2500 rpm for thirty minutes, aspirate the 
supernatant and count the precipitate. Read off the hormone concentra 
tion of the unknowns from the standard curve.
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9.4. TSH radioimmunoassay
The assa}' is based upon the method published by Hall, Amos and 
Ormston (1971). A double antibody separation technique is employed. 
The use of polyethylene glycol (PEG) to assist in the second antibody 
precipitation reduces the final incubation time.
Reagents
1. Borate buffer, 0.13M pH8.2 ■ - ■ ■ ,
Weigh out 8.25g boric acid, 2.70g NaOH and O.lg methiolate. 
Dissolve in about 900 ml distilled water. Adjust to pH8.2 with 
concentrated HC1. Make up to 1 litre and store at 4°C.
2. Rabbit anti-TSH antiserum
The antiserum Code No M168/2 was supplied by the University of 
Surrey. It is used at a dilution of 1:40,000. Each vial of 
freeze-dried'serum is reconstituted with 1 ml distilled water 
and then diluted for use with buffer.
3. Iodinated TSH
■Labelled TSH is supplied by St Lukefs Hospital, Guildford. 1 ml 
aliquots of label are stored at 4°C and used at a dilution such 
that lOOyl of label, when diluted, will contain approximately 
lOOpg TSH.
4. Second antiserum
Donkey anti-rabbit IgG precipitation serum was supplied by 
Guildhay. The batch should normally be diluted 1:100 by recon­
stituting with 1 ml of distilled water and then making up to 
100 ml with EDTA/BSA/buffer.
5. PEG solution
Dissolve 12.5g PEG 6000 in 75 ml distilled water and make up to 
100 ml. Store at room temperature.
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Procedure
DAY 1 
TUBES CODE STANDARD SAMPLE . 1st Ab LABEL
DAY 3 
2nd Ab PEG
1&2 TOTAL - - 100 100 50 100
3&4 128mU/l 200 - 100 100 50 100
5&6 64 mU/1 200 - 100 100 50 100
7&8 32 mU/1 200 - 100 100 50 100
9&10 16 mU/1 200 - 100 100 50 . 100
11&12 8 mU/1 200 - 100 100 50 100
13&14 4 mU/1 200 -■ 100 100 50 100
15&16 2 mU/1 200 - 100 100 50 100
17&18 1 mU/1 200 - 100 100 50 100
19&20 0 200 - 100 ' 100 50 100
21&22 NSB 200 — 100 100 50 100
23&24 UNKNOWNS - 200 100 100 50 100
25&0N UNKNOWNS - 200 100 100 50 100
Day 1
Add 800yl TSH-free plasma to an aliquot of TSH standard ’. 1
200yl of this solution and add 1800iil of plasma to produce a 128mU/l 
solution. Double dilute into TSH-free plasma to produce a range of 
standards from 128 to ImU/l. Reconstitute a sufficient number of vials 
of TSH antiserum.
Set up all tubes in duplicate and dispense 200yl aliquots of 
standard, control or test plasma according to the protocol table. Using 
a Compupet add lOOyl of antiserum to all tubes except the totals and 
lOOyl of label to all. Vortex mix thoroughly and incubate at 4°C for 
48 hours.
Day 3
Make up sufficient second antiserum and add 50yl to all tubes except 
the totals followed by lOOyl of PEG solution. Vortex mix and incubate 
at room temperature for two hours. Centrifuge all tubes except the 
totals for thirty minutes at 2500 rpm and 4°C and aspirate the supernatants.
Count all tubes for a sufficient length of time to record at least 
5000 counts from the zero tubes.
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9.5. Cortisol Radioimmunoassay
Cortisol was measured using Amerlex cortisol RIA kits supplied by 
The Radiochemical Centre, Amersham, Bucks.
The antiserum is immobilized on to the surface of polymer particles 
of uniform diameter (Amerlex antibody suspension) so that separation of 
bound and unbound label is easily effected by centrifugation. In this 
solid phase separation system the amount of label bound by the antibody 
is inversely proportional to the concentration of unlabelled cortisol 
present in the serum.
An important feature of this assay is that cortisol is released 
from transcortin by a chemical blocking agent contained in the ^ 5 j- 
labelled cortisol derivative solution. The total cortisol in the 
sample is then free to compete with the label for binding sites on the 
antibody-coated particles. This therefore means that no heat denatura- 
tion or extraction process is required prior to the assay.
9.6. Arginine Vasopressin Radioimmunoassay
Reagents for this assay were donated by Professor B Morgan, Dept 
of Clinical Biochemistry, Leeds General Infirmary. The assay is based 
on that described by Thomas and Lee (1976) and requires an extraction 
process prior to RIA.
Recommended Procedure for the Collection of Plasma Samples
Since AVP is extremely labile in plasma the following procedure is 
designed to minimise losses prior to estimation. Blood should.be drawn 
into a previously chilled syringe and subsequently transferred to 
heparinised tubes stored on ice. Samples must be thoroughly mixed by 
gentle inversipn. Plasma is separated from the cells in a refrigerated 
centrifuge at 4°C. Mild haemolysis will not affect the results of the 
assay. Plasma must be stored in.plastic tubes at a maximum of ~20°C 
until assayed for AVP. Storage at even lower temperatures is desirable.
The sensitivity of the assay is such that for normal concentrations 
of AVP found, 5 ml of plasma should be used for each extraction. It is 
possible to obtain valid results with less plasma but this can lead to 
the lower limit of the assay being exceeded. Sufficient blood must be 
taken to allow for this.
Reagents
1. Florisil 100-200 mesh from Koch-Light Labs.
a. Place 500 ml Florisil in a large round-bottomed flask.
b. 3/4 fill flask with distilled water, stopper and shake well.
c. Allow the bulk of the Florisil to settle, then discard the 
y'"' supernatant.
d. Repeat steps b and c until the supernatant has been clear for 
three consecutive washes.
e. Pour the Florisil slurry into a shallow tray and place in a 
cold oven. Allow the oven to warm up slowly to 200 degrees 
centigrade and dry the Florisil at this temperature for 48 
hours. This drying step activates the Florisil by increasing 
the pore diameter, thus facilitating absorption. Slow heating 
is necessary to prevent the formation of steam pockets.
f. .Check each batch before use for labelled AVP recovery which 
should be in the region of 90% of added label.
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2. 0.2M Hydrochloric acid
Add 8.7 ml concentrated AnalaR HC1 to distilled water and make up 
to 500 ml.
3. 90% aqueous acetone
Add 100 ml distilled water to 900 ml UltraR acetone (H & W).
4. Repelcote (H & W) for the siliconisation of 4 ml glass tubes.
a. Immerse tubes (SAMC0 soda glass, code G002) in Repelcote for 
24 hours- in a sealed tank.
b. Remove tubes and allow to dry at room temperature in a fume 
cupboard.
c. Wash tubes with distilled water and dry in an oven at 100 
degrees centigrade.
d. Repeat a-c, '
e. Wash tubes in mild Decon solution. Rince in tap water 
followed by distilled water.
f. Dry in the oven.
NB. The wash is important since it is the actual siliconisation step.
5. Inactivated rabbit serum (IRS) (Wellcome).
Extraction procedure
1. Wash test tubes and soak in 10% nitric acid to remove all traces 
of detergent. Rinse thoroughly with good distilled water and dry 
before use.
2. Pipette 3-5 ml fibrin-free plasma into a conical tube noting the 
actual volume.
3. Set up similar control tubes containing high, medium and low 
concentrations of AVP in 5 ml IRS. Suggested concentrations for 
human plasma are given by the addition of 25, 15 or 5yl of the 
1024pg standard in each tube.
4. Add approximately lOOmg Florisil to each tube using a suitable 
measure.
5. Extract the AVP onto Florisil for thirty minutes on a vortex or 
rotary mixer.
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6. Centrifuge briefly to sediment the Florisil.
7. Aspirate and discard the plasma.
8. Wash the Florisil twice with distilled water (2x5 ml),
9. Wash the Florisil with 5 ml acetone (not aqueous), mixing, gently 
by inversion.
10. Discard washings.
11. Acidify Florisil with 0.4 ml of 0.2M HC1. Mix briefly,
12. Add 2 ml 90% acetone and mix for 5-10 seconds.
13. Centrifuge to sediment the Florisil.
14. Transfer eluate to a siliconised glass tube.-
15. Repeat 12 and 13 and combine with the first eluate.
16. Dry down the eluate at 40°C under an air stream (this may take 
up to three hours) and store below 20 degrees.
This should give a recovery of added AVP of >75%.
Radioimmunoassay .
Reagents
Barbitone buffer
1. Weigh out 12.76g sodium barbitone and 1.66g barbitone into a 
1L beaker.
2. Make up to nearly 1L with distilled wTater.
3. Check pH and if necessary adjust to pH 8.6 using the correct
salt. DO NOT ADJUST WITH ACID OR ALKALI.
Human serum albumin (HSA)
Obtained from Sigma Ltd as freeze-dried fraction IV.
HSA-barbitone buffer
Dissolve 0.25g HSA in 200 ml barbitone buffer. Make fresh for 
each assay.
AVP antibody
At present obtained from Leeds Infirmary as 1 ml aliquots of 1:500 
dilution Ab in HSA buffer. This is further diluted to give
approximately 50 percent binding as determined by an Ab dilution
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curve. The antibody is batch k 2 (see Thomas and Lee, 19/6).
Labelled AVP
Pure AVP is flagged with 125-iodine and stored deep frozen.
For use it is diluted in KSA buffer to give 1000-1500 counts 
per minute in 20ul.
The method used to iodinate the AVP is described after the 
radioimmunoassay,
AVP standards
Synthetic AVP is obtained as the pure, dry solid. All stock standards 
are prepared from this as follows. HSA-barbitone buffer is used for all 
dilutions.
Dilution 1. lOOOyg/ml
1 ml of HSA-buffer added to the pure, dry AVP. Stored in 50yl 
aliquots.
Dilution 2. 4yg/ml
40yl of dilution 1 (40yg AVP) diluted to 10 ml. Stored in 
500yl aliquots.
Dilution 3. 2yg/ml
500yl of dilution 2 (2yg AVP) made up to 1 ml. Stored in 
200yl aliquots.
Dilution 4. 64ng/ml
200yl of dilution 3 (400 g AVP) diluted to 6.25 ml. Stored in 
400yl aliquots.
Dilution 5. Working standard of 2560pg/ml
400yl of dilution 4 (25.6ng) diluted to 10 ml. Stored in 
400yl aliquots (1024pg/tube).
The working standard is diluted 1:3 before use to give a final 
concentration of 128pg AVP/200^1. (ie. Add 400yl to 1.2 ml buffer).
This is equivalent to 128pg/ml in the assay of plasma since 5 ml plasma
173
are extracted, dried and then reconstituted to 1 ml. The 1:3 
working standard is then double diluted to give a range of values for 
the standard curve.
Tris-HCl buffer. 0.05M pH 7.5
Dissolve 6.05g Tris (hydroxymetnyl) methylamine [NH2C(CH20H)sj in 
approximately 500 ml distilled water. Adjust pH to 7.5 with 0.1M HC1 . 
(approximately 400 ml). Make up to 1L. Store at 4°C.
Charcoal. Norit grade SX1 or equivalent.
Assay procedure
Reconstitute the dried extracts with 1 ml HSA-buffer and allow to 
stand for two hours with occasional mixing. The samples may be stored in 
this form indefinitely at -4°C. .
Set up the assay as follows:
DAY 1 
TUBES
(Tuesday/Friday)
CODE STANDARD/UNKNOWN HSA/BUFF Ab
DAY 4 (Friday/Monday) 
LABEL
1&2 BLANKS - 620yl - -
3&4 TOTALS - - - 20yl
5&6 128pg STD 200yl 200yl 200yl 20yl
7&8 64pg STD 200yl 200yl 200yl 20yl
9&10 32pg STD 200yl 200yl 200yl 20yl
11&12 16pg STD 200y 1 200yl 200yl 20yl
13&14 8pg STD 200yl 200yl 200yl 20yl
15&16 4pg STD 200yl 200yl 200yl 20yl
17&18 2pg STD 200yl 200yl 200yl 20yl
19&20 Ipg STD 200yl 200yl 200yl 20yl .
21&22 0.5pg STD 200yl 200yl 200yl 20yl
23&24 ZERO • 400yl 200yl 20yl
25&26 UNKNOWNS 400yl - 200yl 20yl
27 ON UNKNOWNS 400yl - 200yl • 20yl
???? RECOVERIES 200yl 200yl 200yl 20yl
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DAY 7 (Monday or Thursday)
1. Weigh out lg charcoal/100 ml Tris buffer.
2. Wash in an excess of buffer.
3. Centrifuge and discard supernatant.
4. Resuspend in required volume of Tris buffer.
5. Add 15 ml IRS/100 ml charcoal mixture and mix for 40 minutes.
6. Identically number a set of LP3 tubes for counting.
7. Remove assay tubes from refrigerator and place on a chill tray.
8. Divide assay into batches of 30-40 tubes. (Choose a multiple
of the centrifuge head capacity.)
9. Add 1 ml charcoal mixture to each tube of the first batch as
rapidly as possible.
10. Mix on vortex mixer and immediately centrifuge to bring down the 
solid and compact it sufficiently to allow decantation of the 
supernatant.
11. Decant supernatant into the correspondingly numbered LP3
tube as soon as possible. .
12. Repeat steps 9-11 with successive batches.
13. Count the supernatant (bound) fractions for 600 seconds.
NB. STEPS 9 AND 10 MUST BE COMPLETED AS FAST AS POSSIBLE.
Iodination procedure
AVP is iodinated'by reaction with 125-iodine using chloramine-T as 
a catalyst. It is purified by separation on an A25 DEAE sephadex 
column followed by further fractionation on a G25 sephadex column.
Equipment:
1. 5 ml plastic syringe and blank male Luer cap.
2. Glass wool.
3. LP3 tubes and stoppers.
4. Pipettes; lyml, lOyl, 5yl.
5. Pasteur pipettes.
6. Two retort stands with boss and clamp.
7. Glass reaction tube.
8. Fraction collector.
9. 5 ml tubes.
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Reagents
1. 0.5M Phosphate buffer pH 7.5.
a. Weigh out 68g potassium dihydrogen orthophosphate (KH2P04) 
and make up to 1L with distilled water in a volumetric flask.
b. Weigh out 71g of disodium hydrogen orthophosphate (NA2HP04) 
and similarly make up to 1L.
c. To prepare the buffer mix together 160 ml of the potassium 
solution and 840 ml of the sodium solution. Adjust to pH7.5 
if necessary using the appropriate solution and store at 4°C.
2. 0.05M Phosphate buffer
Prepared on day of use. Dilute the 0.5M buffer 1 in 10 with 
distilled water.
3. Chloramine-T
Weigh out 20 mg chloramine-T (stored at 4°C) and dissolve in 5 ml
0.05M phosphate buffer. This solution should be preapred just 
before use.
4. Pure AVP for iodination (supplied by Ferring Pharmaceuticals7 Flal.mo,
. (.Sweden)
Stored as 2yg in 5yl distilled water and kept frozen.
5. Tris-HCl buffer pH 7.5 0.05M 
As used for AVP assay.
6. Na. 125-1 (Specific activity 12-17 mCi/yg)
Stored in "Hot" fume cupboard. LABEL CLEARLY.
7. DEAE Sephadex A25
A25 DEAE-Sephadex powder is added to Tris-HCl buffer and left at 
4 degrees centigrade to swell and equilibrate for 24 hours.
Store in fresh Tris-HCl buffer in the refrigerator.
8. Sephadex G25 (Fine)
G25 Sephadex is added to 0.25% acetic acid and allowed to swell and 
equilibrate for 24 hours. This may be packed into a column and used 
repeatedly for fractionation of the A25 eluate providing it is 
washed through thoroughly with 0.25% acetic acid after use.
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9. 1.25g/L human serum albumin in 0.25% acetic acid
Dissolve 0.25g HSA in 200 ml 0.25% acetic acid. . Make fresh for 
each assay.
Method:
1. Allow A25 DEAE-Sephadex to warm to room temperature. Debubble 
by attaching flask to vaccuum pump. Air bubbles trapped in the 
Sephadex will rise to the surface.
2. Use the 5 ml syringe as a column. Glamp the syringe to a retort 
stand and pack with a small amount of glass wool. Fill up to 
the 5 ml mark with A25 DEAE-Sephadex. Continue to wash through 
with Tris-HCL buffer, not allowing the column to run dry.
Seal off the column with the Luer cap, leaving a small amount • 
of buffer on top of the settled column. Allow to equilibrate 
overnight.
3. The iodination procedure must be performed in an area that is 
assigned for the handling of radioactive isotopes. Place the 
small glass reaction tube in a lead container lined with paper 
tissue.
Add 0.5mCi of Na 125-1 (5yl) to the glass tube and mix with 10yl 
phosphate buffer.
Add 2yg AVP in 5yl distilled water and mix again. Start the 
reaction by adding 5yl of chloramine-T solution and mixing.
After 10-15 seconds (not more) add 1 ml of Tris-HCl buffer to 
the mixture and transfer..the resulting solution to the A-25 
coliimn using a pasteur pipette.
Remove the Luer cap.
When the mixture has been absorbed onto the column elute it with 
Tris-HCl buffer and collect about 15 1 ml fractions in LP3 tubes.
Unreacted 125-1 will remain on the column which must be discarded 
in a radioactive waste container.
NB. GREAT CARE'MUST BE TAKEN THROUGHOUT THIS PROCEDURE. ALL EQUIPMENT 
WHICH COMES INTO CONTACT WITH 125-1 MUST BE DISCARDED IN RADIO­
ACTIVE WASTE CONTAINERS STANDING IN THE FUME CUPBOARD.
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Save the peak fraction and the one following for further 
fractionation. Peak tubes are normally numbers 4-6.
Wash the G25 Sephadex column through with HSA-acetic acid.
.(The HSA prevents the labelled AVP from being adsorbed;)
Allow the column to just run dry and apply the peak fractions 
using a pasteur pipette.
Elute the radioactivity with HSA-acetic acid and collect 2 ml 
fractions withvan automatic fraction collector.
Collect about 50 fractions.
Count 10yl of each fraction as before and pool the peak fraction 
with the two following and use these as the pure iodinated AVP.
Aliquot the pool into 5>iCi amounts and store deep frozen.
This label can be used for about three months.
The theoretical basis of this assay is described in section 3.3 and 
is based on that described by Peuler and Johnson (1977).
Preparation of catecho1-0-methyl transferase
1. Remove and weigh the livers of twelve young adult rats.
4. Titrate the supernatant to pH 5 with 1M acetic acid.
5. After 20 minutes spin down the precipitate.
6. Fraction with ammonium sulphate, discarding the 0-30% precipitate 
and resuspending the 30-55% precipitate in water.
7. Add solid ammonium sulphate with constant stirring to give 
55% saturation.
8. Spin down and redissolve the residue in ImM TRIS pH7.4 containing
O.lmM dithiothreitol.
9. Dialyse the solution in 2L of the same TRIS buffer for 24 hours with 
• 2 or 3 buffer changes.
10. Centrifuge the preparation to remove the residue which accumulated 
during dialysis-
11 . Measure the enzyme activity using the standard assay technique with
lOOpg to lOOOpg of the catecholamine standard. Note that aliquot
which first produces maximal activity.
12. Dilute the enzyme accordingly with the TRIS/dithiothreitol buffer 
reduced glutathione and ImM benzyloxyamine hydrochloride.
13. Store the enzyme deep frozen in small aliquots in plastic vials.
Sample Collection
1. Add 20pl of additive solution (95mg EGTA and 60mg glutathione per ml 
at pH 6-7) to the containers to be used for every ml of whole blood 
to be collected. Store the primed tubes at 0-4°C until use.
Perform all the following procedures at 4°C:
2. Homogenise the livers .in 4 Volumes isotonic potassium chloride
3. Centrifuge at 78,OOOg for 30 minutes.
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2. Immediately upon collection mix the sample with the preservatives 
by gentle inversion of the tube.
3. Place the tubes in ice prior.to centrifugation in a refrigerated 
unit to separate the plasma from the cells.
4. Aspirate the plasma and store deep frozen (-70°C) in suitably 
labelled tubes.
Catecholamine assay 
Reagents
TRIS buffer 1.0M of approximate pH 8.4
This consists of 12.114g TRIS, 6.099g MgC12.6H20 and 3.8035g EGTA 
made up to 100 ml. Store frozen at -20°C.
Internal standard
At the start of each week prepare a fresh solution containing lmg 
each of adrenaline and noradrenaline. For daily use dilute this 1 in
10,000 to end up with lOOpg in lOpl.
Basic reaction mixture
This consists of one part each of Tris buffer, water, C0MT and 
tritiated SAM. Fresh basic reaction mixture must be made daily.
S-adenosyl-L-|methyl-3H| methionine was supplied by Amersham Inter­
national; Code TRK 236, l.OmCi/ml C37MBq/ml) and diluted with an 
equal volume of water before use. The unused isotope was stored 
at -70°C.
Stopping solution
This consists of: 800mM boric acid
80mM EDTA.Na2 
4mM metanephrine 
4mM normetanephrine 
4mM methoxytyramine
Dissolve the solids in distilled water, adjust to pHll with approx 
20 ml 10M NaOH and make up to 200 ml. After thorough mixing divide 
into 500jil aliquots and store deep frozen. The solution usually 
requires warming to ensure that all the compounds redissolve as 
precipitation tends to occur on freezing.
Scintillation reagents were supplied by Koch-Light.
9.928g
5.9558g
0.187g
0.176g
0.163g
40% mono amine
The chromatography solvent consists of a mixture of the following:
120 ml t-amyl alcohol
40 ml benzene
15 ml 70% ethylamine
45 ml 25/30% methylamine
Toluene/Isoamyl alcohol 3:2
0.1M acetic acid
EGTA/glutathione solution
Take 20 yl of the additive solution and make this up to 1 ml.
0.5. ammonium hydroxide
4% sodium periodate made fresh, daily.
10% glycerol.
Equipment
Pipettes: 20yl, 50yl, adjustable set at 40yl.
Hamilton dispenser PDII 
12 ml conical tubes 
Scintillation vials 
Centrifuge 
pH meter
Water bath and shaker at 37°C 
Multivortex mixer 
Vortex mixer 
Ethanol/dry ice bath
Chromatography tank and Whatman LK6DF channelled, preloading plates. 
(Whatman Ltd., Springfield Mill, Maidstone, Kent.)
Vacuum pump and aspirator.
Method
1. Thaw all samples at 4°C on a chill tray or in a refrigerator.
2. Any samples which are not clear may be spun down in a refrigerated 
centrifuge to free the plasma of fibrin and any other suspended
' particulate matter.
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3. Set up tubes in. duplicate for unknown and standard and pipette 
50yl plasma into each. To the first set add lOyl of EGTA/ 
glutathione solution and to the second add lOyl of the internal 
standard solution. Also set up blank tubes containing 60yl 
EGTA/glutathione solution.
4. Add 40yl of basic reaction mixture to all tubes to give a total 
volume of lOOyl at pH 8.1-8.3.
5. Mix all tubes, centrifuge to bring down fluid adhering to the tube 
walls and incubate in a shaking water bath at 37°C for 1 hour.
6. Add 50yl stopping solution to each tube.
7. Extract the 3H-0-methy1 derivatives by adding 2 ml of toluene/
isoamyl alcohol and mixing on the multivortex for two minutes.
8. Centrifuge at room temperature for 5 minutes to separate the phases.
9. Freeze the aqueous phase by immersing just the aqueous layer in
an ethanol/dry ice bath for 12-15 seconds and transfer the organic 
fraction into a second tube containing lOOyl of G.1M acetic acid.
10. Multivortex for 10 minutes to back extract the catecholamines into 
the acetic acid and centrifuge at 2000 rpm for 5 minutes.
11. After freezing the aqueous layer, aspirate the organic layer 
using a Pasteur pipette connected to a vacuum pump. Avoid touching 
the ice with the pipette tip.
12. Add 1 ml of toluene/isoamyl alcohol 3:1, mix for two minutes, 
centrifuge and aspirate the organic layer.
13. There should now be about 80yl of the acetic acid extract. Apply
this to the TLC plates and DRY THOROUGHLY.
14. Develop the plate for about 30 minutes until the solvent front
has travelled approximately 10 cm. This may vary between batches
of plates. (The time should be adjusted to give good separation
between bands without too much spreading of bandwidth or streaking
particularly of the Normetanephrine fraction.)
15. Dry the plate under a cold air stream in a fume cupboard and
visualise under UV light. The top zone will contain 3-methoxy- 
tyramine, the middle zone metanephrine and the bottom zone
normetanephrine Csee figure 3.1 in section 3).
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16. Scrape the appropriate fraction and its surrounding matrix from 
the plate and transfer to a scintillation vial.
17. Add 1 ml of 0.05M ammonium hydroxide to elute the catecholamine 
derivative from the silica gel. Shake the vial on the multi­
vortex for a few seconds.
18. To convert the 3H-metanephrine and 3H-normetanephrine to 
3H-vanillin add 50yl of 4% sodium periodate followed 5 minutes 
later by 50yl 10% glycerol.
19. Acidify the solution with. 1 ml of 0.1M acetic acid followed by 
10 ml toluene containing 10% butyl-BPD (by weight).
20. Partition the 3H-vanillin into the organic phase and count.
The samples were counted on an Intertechnique SL30 liquid 
scintillation spectrometer, and the counts min  ^ (CPM) used to calculate 
the concentration of the unknown (in pg ml )^ using the following 
equation:
_______ Mean CPM unknown - mean CPM blank________  _ _ 1 _ r , *i
Mean CPM (int. std + unknown) - mean CPM unknown X 0.05 i-un n0WIU
Quality control samples were included in each assay batch. These 
were obtained from a large volume of plasma taken from an individual 
prior to the first assay.
SECTION 10: APPENDIX 2: DATA TABLES
1. Tables 10.1-10.7 : Section 4
2. Tables 10.8 - 10.11 : Section 5
3. Tables 10.12 - 10.15 : Section 6
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Subject
+lGz DG RE BL IH AD DG RE BL IH a d
Sample
No
1 331.2 115.9 276.0 400.2 358.8 276.0 251.2 717.6 240.1 336.7
2 287.0 218.0 234.6 287.0 143.5 215.3 215.3 543.7 270.5 358.8
3 276.0 138.0 223.6 281.5 2.8.0 259.4 242.9 565.8 262-2 433.3
4 289.8 140.8 242.9 317.4 143.5 215.3 339.5 502.3 320.2 402.9
5 251.2 126.9 231.8 284.3 132.5 264.9 333.9 469.2 262.2 436.1
6 264.9 138.0 248.4 353.3 237.4 309.1 634.8 587.9 400.2 496.8
7 259.4 N.S. 226.3 276.0 193.2 369.8 488.5 648.6 375.4 375.4
8 146.3 124.2 198.7 325.7 143.5 419.5 385.4 690.0 353.3 331.2
9 179.4 218.0 146.3 262.2 162.8 336.7 240.1 309.1 298.8 289.8
10 215.3 204.2 149.0 242.9 168.4 193.2 215.3 469.2 234.6 242.9
11 201.5 220.8 149.0 237.4 198.7 240.1 202.0 400.2 234.6 248.4
12 129.7 276.0 331.2 207.0 118.7 231.8 138.0 259.4 248.4 242.9
+3Gz
1 441.6 276.0 325.7 303.6 372.6 358.8 270.5 400.2 273.2 369.8
2 447.1 289.8 267.7 264.9 273.2 303.6 187.7 510.6 193.2 270.5
3 414.0 284.3 242.9 267.7 248.4 256.7 149.0 345.0 220.8 314.6
4 436.1 289.8 209.8 287.0 253.9 262.2 245.6 303.6 ,220.8 314.6
5 427.8 303.6 231.8 298.1 182.2 253.9 491.3 455.4 209.8 364.3
6 386.4 248.4 325.7 333.9 198.7 430.6 662.4 828.0 325.7 552.0
7 339.5 231.8 215.3 314.6 234.6 634.8 662.4 897.0 347.8 452.6
8 427.8 201.5 182.2 322.9 165.6 469.2 723.1 786.6 383.6 386.4
9 262.2 173.9 231.8 273.2 173.9 391.9 552.0 552.0 248.4 298.1
10 240.1 168.4 231.8 259.4 129.7 270.5 414.0 397.4 168.4 248.4
11 215.3 140.8 •182.2 220.8 149.0- 276.0 313.2 345.0 165.6 259.4
12 204.3 303.6 198.7 215.3 140.8 231.8 151.8 190.4 287.0 231.8
+4Gz
1 253.9 270.5 198.7 284.3 245.6
2 289.8 242.9 195.9 276.0 226.3 TABLE 10. 1
3 270.5 303.6 331.2 386.8 262.2
4 276.0 270.5 292.6 372.6 317.4 Serum cortisol values (nmol/L)
. 5 237.4 289.8 193.2 383.6 325.7 from 5 subjects at 5 levels of
6 264.9 386.4 369.8 474.7 345.0 +Gz acceleration. Values
7 345.0 322.9 427.8 469.0 325.7 uncorrected for plasma volume c'
8 253.9 256.7 292.6 331.2 262.2 (Protocol : Section 4).
9 251.2 267.7 331.2 331.2 262.2
10 264.9 168.4 455.4 524.4 204.2 Normal range : 140-700 nmol/L
11 278.8 339.5 441.6 375.4 193.2 (at 0900 hrs)
12 245.6 273.2 284.3 215.3 331.2
+5Gz
+6Gz
185
supjecc OUUj KCL
+lGz DG RE BL IH AD DG RE BL IH AD +5Gz
Sample
No
1 2.4 3.8 5.5 4.4 6.0 5.0 5.0 6.5 2.9 3.7
2 2.1 6.8 7.2 3.8 3.1 2.0 4.0 7.9 2.9 6.1
3 2.0 4.2 6.6 3.7 3.5 3.9 3.9 11.6 3.4 4.9
4 2.2 5.3 5.5 3.9 3.3 2.0 6.4 10.7 3.8 5.1
5 1.9 6.0 6.4 4.0 3.2 4.6 4.8 11.4 2.9 5.1
6 2.1 4.8 5.4 3.9 3.2 4.6 5.6 9.6 3.5 3.9
7 2.2
No 7.0 -3.0 2.8 5.3 3.4 6.8 2.7 5.6
Sample
8 2.4 4.8 '4.0 2.9 3.5 4.8 5.3 7.6 3.4 3.9
9 3.8 10.0 4.6 4.1 6.7 5.6 5,6 8.4 2.1 5.6
10 3.8 5.7 4.2 "5.0 4.3 3.8 2.7 7.1 3.2 5.5
11 3.7 4.4 3.2 4.0 3.5 8.0 2.1 4.8 1.3 4.6
12 2.4 •3.1 - 5.2 8.0 2.8 6.6 5.8 4.8 5.0 4.6
+3Gz - +6Gz
1 2.5 3.2 3.2 1.9 3.6 6.6 8.2 6.5 6 . 4 6.0
2 2.1 3.4 4.3 1.4 3.1 5.9 5.6 8.6 5.7 3.5
3 1.9 4.2 4.0 1.4 5.0 5.9 4.4 10.9 5.2 4.1
4 2.2 2.8 4.3 1.6 4.1 5.5 5.0 7.0 5.6 4.0
5 2.1 2.6 4.5 1.6 ^4.6 7.6 8.2 8.9 5.8 5.2
6 2.2 2.0 4.7 1.8 4.4 6.4 8.4 9.9 5.3 3.6
. 7 2.0 2.2 4.3 1.7 5.3 3.8 9.2 8.0 5.0 6.6
8 1.5 1.9 6.4 3.9 3.3 5.9 6.8 7.6 4.9 8.0
9 2.1 1.9 7.2 5.5 2.7 5.2 7.1 6.6 4.1 5.4
10 1.9 2.0 6.5 4.8 2.4 3.5 6.4 5.6 3.6 4.6
11 1.6 5.9 5.5 4.1 4.6 3.6 5.6 4.6 5.8 6.4
12 2.9 4.2 6.6 2.3 2.7 2.4 3.4 6.4 5.2 6.1
+4Gz '
1 0 . 6 5.8 5.4 2.0 3.7
2 2.0 3.8 3.9 1.4 4.3 TABLE 10 .2
3 2.0 3.8 6.5 3.6 2.7
4 1.6 4.0 5.0 2.2 2.6 Serum LH levels obtained in 5
5 1.9 3.4 6.0 3.0 2.6 subjects at 5 +Gz acceleration
6 1.8 4.2 2.3 1.0 3.9 levels Values uncorrected for
7 2.1 3.2 8.2 2.5 3.2 plasma volume changes.
8 1.6 2.7 8.2 2.0 5.9 (Protocol : Section 4)
9 4.0 3.0 10.0 6.8 3.9 r
10 4.8 1.9 5.0 6.0 4.5 Normal Range : 3-12 I.U./L
11 5.3 5.3 6.6 6.2 3.7
12 2.6 3.6 7.2 5.4 6.2
186
+lGz
Sample
No
DG RE
buoj ecc 
BL IH
o u d j ecu
AD
1 1.1 1.05 1.85 1.1 2.0
2 1.0 1.15 2.45 1.8 2.5
3 0.55 1.55 2.05 2.0 2.2
4 0.5 1.7 2.0 1.9 2.4
5 0.5 1.65 2.0 2.0 1.8
6 0.5 1.6 2.1 2.0 2.9
7 0.45
No
sample 1.5
2.0 2.5
8 0.5 1.6 2.2 3.0 3.9
9 0.7 1.65 1.6 2.3 3.2
10 0.5 2.5 1.8 2.3 2.5
11 0.6 2.1 1.75 1.2 3.0
12 0.5 1.55 1.85 1.8 2.1
DG RE BL IH AD
1.0 1.15 1.95 0.9 2.0
0.5 1.6 1.8 4.6 2.4
1.0 1.05 1.55 5.8 2.5
0.55 1.05 1.65 6.9 2.7
1.05 1.15 1.30 8.4 2.6
1.0 1.15 1.35 7.0 1.5
1.1 0.95 1.50" 5.3 2.2
1.3 1.0 1.20 5.7 2.0
0.8 1.6 1.3 9.4 2.4
0.75 1.25 1.6 5.7 2.0
0.85 0.9 1.5 8.1 1.9
1.1 0.85 1.2 4.6 2.1
+5Gz
+3Gz
1 0.8 1.3 1.55 1.1 3.1 0.75 1.9 1.0 0.9 2.5
2 0.75 1.4 1.6 1.2 2.6 0.95 1.55 1.2 4.0 2.4
3 0.6 1.95 1.7 1.1 2.2 1.45 0.8 1.3 5.3 2.6
4 0.6 1.2 1.5 0.6 3.3 0.65 1.0 1.6 7.7 2.5
5 0.8 1.05 1.5 0.6 3.2 0.7 1.85 1.5 8.6 2.9
6 0.6 1.0 1.05 0.8 2.9 0.85 1.8 1.25 •9.1 2.0
7 0.7 0.55 1.7 0.6 2.3 1.05 1.5 1.25 4.4 3.1
8 0.5 0.7 1.4 0.9 2.9 1.1 1.5 1.05 1.8 2.7
9 0.45 0.9 1.65 1.3 2.9 1.2 1.3 1.7 1.6 3.6
10 0.5 0.95 1.9 1.4 2.1 0.9 1.85 1.65 2.5 2.3
11 0.6 1.1 2.0 0.9 1.2 1.15 1.25 1.0 1.9 3.5
12 0.7 1.2 1.9 0.9 3.5 0.7 1.5 0.6 2.5 2.6
+6Gz
+4Gz
1 0.6 1.3 1.45 0.8 1.9 TABLE 10.3
2 0.7 1.25 1.85 0.6 4.9
3 0.55 1.45 1.05 0.8 5.0 Serum FSH values (I.U./L)
4 0.55 1.45 1.05 0.6 5.2 obtained in 5 subjects at 5+Gz
5 0.8 1.55 1.1 0.6 6.5 acceleration levels. Values
6 0.5 1.25 1.05 0.6 6.2 uncorrected for plasma volume
7 0.7 1.1 1.05 0.6 4.1 changes. (Protocol : Section 4).
8 0.6 0.9 1.1 0.5 2.6
Normal FSH range : 0.5-5.0 I.U./L.9 1.0 1.3 1.2 0.8 1.2
10 0.8 1.2 1.25 0.8 1.6
11 0.8 1.45 0.85 0.8 1.7
12 0.7 1.25 1.45 0.9 2.7
187
Subject Subj ect
+lGz DG RE BL IH AD DG RE BL IH AD +5Gz
Sample
No
1 135 170 190 170 150 190 130 110 45 270
2 140 220 160 155 155 180 100 65 85 280
3 80 210 150 60 155 80 105 105 60 205
4 80 170 105 20 210 170 115 190 70 215
5 80 210 100 20 250 100 160 35 20 300
6 60 200 135 15 240 180 135 40 80 205
7 60
No
110 20 240 95 135 15 40 230
Sample
8 100 225 100 20 255 110 180 80 60 210
9 100 220 105 30 290 125 115 65 45 110
10 80 240 120 20 110 40 160 105 70 180
11 70 165 30 10 160 110 85 30 20 20
12 100 200 120 10 110 90 160 100 55 140
+3Gz +6Gz
1 180 230 260 10 250 130 95 120 65 190
2 120 160 70 20 95 ‘ 125 155 70 60 190
3 110 190 40 10 115 140 160 140 80 170
4 105 120' 55 15 140 135 180 95 175 205
5 110 120 65 10 300 95 160 145 125 205
6 100 100 40 20 265 100 205 140 110 210
7 95 105 30 10 330 135 260 125 160 204
8 80 105 60 20 200 105 260 85 70 145
9 70 90 60 20 70 90 140 90 55 120
10 110 100 25 20 70 90 135 80 20 105
11 90 120 20 10 70 40 200 55 110 60
12 100 125 40 10 90 60 115 90 95 20
+4Gz
1 190 130 50 10 90
2 110 80 45 20 90 TABLE 10. 4
3 100 100 40 20 120
4 125 125 10 30 130 Serum PRL levels obtained in 5
5 160 110 10 95 160 subjects at 5 +Gz acceleration
6 110 120 15 30 185 levels Values uncorrected for
7 100 105 20 30 100 plasma volume changes.
8 90 100 25 20 160 (Protocol : Section 4)
9 125 95 175 30 135
10 100 130 25 65 70 Normal PRL range : 60-360 ml.U./L
11 150 130 100 15 150
12 50 100 150 10 105
188
Subject Subj ect
+lGz DG RE BL IH AD DG RE BL IH AD +5Gz
Sample
No
1 0.4 0.8 0.8 1.2 1.1 0.6 0.4 0.1 0.7 2.55
2 0.5 0.7 1.5 1.4 1.3 0.6 0.5 0.5 0.8 1.65 ■
3 0.5 0.8 1.55 1.1 1.1 0.5 0.4 0.8 1.2 2.85
4 0.4 1.0 1.35 1.6 1.85 0.6 1.0 0.8 1.3 1.35
5 0.4 0.5 0.7 1.4 1.2 0.5 0.4 0.2 1.0 3.05
6 0.4 0.4 0.55 1.2 1.1 0.5 0.5 0.75 1.1 2.7
7 0.4 0.5 1.65 1.2 1.4 0.5 0.4 0.45 0.9 2.5
8 0.3 0.8 1.1 1.1 1.2 0.5 1.0 0.55 0.7 2.0
9 0.4 0.8 1.1 1.0 1.3 0.5 1.5 0.4 0.5 1.3
10 0.4 0.7 1.5 1.0 1.3 0.5 0.9 0.5 0.5 1.3
11 0.4 0.5 1.7 0.9 1.5 0.5 1.0 0.5 0.5 1.5
12 0.4 0.1 0.9 0.9 2.0 0.5 1.2 1.1 0.5 1.5
+3Gz +6Gz
1 0.4 0.6 0.9 0.8 1.4 0.4 0.5 0.45 0.7 1.35
2 0.5 0.6 1.3 0.8 1.9 0.7 0.5 0.4 1.2 2.1
3 0.5 0.8 1.1 1.1 1.5 0.6 0.4 0.4 1.1 1.7
4 0.5 1.1 0.9 1.2 1.2 0.4 0.9 0.3 0.9 1.9
5 0.5 1.2 0.5 0.9 0.45 0.4 1.1 1.2 0.4 2.2 *
6 0.4 0.9 0.2 0.9 0.45 0.3 0.8 1.4 0.3 2.0
7 0.5 0.7 0.1 0.8 0.3 0.4 0.8 1.1 0.3 1.6
8 0.5 0.7 0.1 0.7 0.3 0.4 0.7 1.2 0.4 1.7
9 0.5 0.7 0.2 0.5 0.4 _ 0.4 1.1 1.3 0.4 1.7
10 0.4 0.6 0.1 0.5 0.45 0.4 1.0 1.0 0.3 2.0
11 0.5 0.5 0.2 0.5 0.3 0.4 0.9 0.7 0.7 3.95
12 0.5 0.5 0.6 0.5 0.95 0.4 0.5 0.5 1.0 1.7
+4Gz
1 0.6 0.4 0.1 0.6 1.9
2 0.5 0.6 0.2 0.9 1.7 TABLE 10 .5
3 0.6 0.9 0.4 0.7 2.1
4 0.4 1.2 0.4 0.7 1.4 Serum TSH values (ml.U./L)
5 0.4 1.1 0.5 1.0 1.1 obtained in 5 subjects at 5+GGz
6 0.4 0.7 0.9 0.9 1.0 acceleration levels. Values
7 0.4 0.7 0.4 0.9 0.7 uncorrected for plasma volume
8 0.4 0.6 0.3 0.8 0.5 changes. (Protocol : Section 4)
9 0.5 0.5 0.2 0.7 0.5
10 0.4 0.6 0.1 0.6 0.4 Normal TSH range : 0-5 ml.U./L
11 0.6 0.7 0.1 0.6 0.6
12 0.5 0.5 0.1 0.5 1.1
189
OUUJ ttu L OUUJCUU
+lGz DG RE BL IH AD DG RE . BL IH AD +5Gz
Sample
No
1 1.0 0 0.1 0 0 0.1 0 0 0.4 0
2 28.4 0 0.1 0 0 4.9 0 0.1 1.76 0
3 27.2 0 0.1 0 0 6.6 0 0.2 11.6 0
4 25.0 0 0.1 0 0 5.7 0 0.3 12.5 0
5 28.1 0 0 0 0 5.8 0 0.6 12.7 0
6 24.2 2.9 0 0 0 5.5 0 0.6 10.9 0
7 20.1 N/S 0 0 0 8.6 3.7 0.8 9.0 3.1
8 12.85 12.8 0 0 0 9.5 8.4 0.8 13.0 7.4
9 15.8 4.5 0.2 0.1 0 17.4 11.1 0.4 19.2 12.8
10 1.59 1.05 0.8 6.4 0 11.1 6.2 0.3 28.0 20.6
11 0.2 0.1 0.1 16.3 0 3.9 0.8 0.3 1.3 7.0
12 0 0 0.1 5.0 0 0.2 0.2 0.4 0.1 0.8
+3Gz +6Gz j
1 0.4 0 0 0 0 0.6 0.5 0.1 0.5 0
2 27.5 0 0 0 0 13.3 0.3 0.2 4.3 0
3 20.25 0 0 0 0 17.2 0.1 0.1 4.4 0
4 26.5 0 0 0 0 13.8 0.1 0.1 3.8 0
5 27.6 0 0 0.2 0 11.0 0.1 0.1 1.75 0
6 29.8 o' 0 0.2 0 11.8 0.3 0.1 2.96 0
7 19.2 3.5 0 3.2 0.4 16.5 3.6 0.3 8.25 2.1
8 15.5 10.4 0 4.9 6.6 14.8 11.3 0.6 36.4 7.2
9 16.8 21.4 0 20.0 21.4 10.8 13.2 0.1 12.65 15.0
10 6.19 4.8 0 30.6 20.0 5.0 3.5 0.2 7.06 11.5
11 5.37 1.8 0 16.5 9.2 3.6 0.2 0.1 4.1 1.8
12 0.4 0 0 3.1 1.3 1.7 0.1 0.1 0.5 0
+4Gz
1 0 0 0 0 0.2
2 0.3 0 0 0 0.3 TABLE 10 . 6
3 0 0 0 0 0
4 0 0 0 0.4 0 Serum GH values (mIU/L) from 5
5 0 0 0 0.1 0 subjects exposed to 5 levels of
6 1.75 0 0 0.7 1.75 +Gz acceleration. Values uncorrectec
7 4.79 0 0.2 4.8 4.79 for plasma volume changes.
8 9.3 1.6 0 18.0 9.3
9 6.9 3.7 0 21.4 6.9 Normal range: usually <10IU/L.
10 8.5 11.4 0.1 37.0 8.5
11 6.6 2.34 0.2 7.8 6.6 Protocol: Section 4.
12 0.5 0 0 6.4 0.5
190
C,,*k 4
U U U J  C d .
O + m'UZ ~ ~ 4-u uuj (;l u
+1Gz
No
rZ DG RE BL IH AD DG RE BL IH AD
le
1 100 103 104 116 124 105 87 91 99 117
2 98 104 98 103 92 34 87 36 105 105
3 98 107 95 103 96 94 98 96 101 113
4 103 101 97 103 100 91 101 103 103 116
5 97 107 95 104 119 89 99 101 112 120
6 95 111 97 104 113 80 104 101 119 110
7 98
No
sample 98 105
121 88 98' 101 94 140
8 95 97 98 103 126 98 107 104 95 122
9 96 107 104 108 106 96 104 107 105 112
10 105 107 102 109 112 96 . 104 107 101 106
11 105 121 102 105 112 100 104 115 103 104
12 105 135 98. 112 101 99 104 113 107 107
+5Gz
-3Gz
1 88 94 100 101 98 110 99 108 101 126
2 97 82 89 97.5 98 100 95 102 95 116
3 98 85 100 li3 107 102 99 108 102 120
4 101 83 92 100 107 101 105 108 107 118
5 98 76 102 106 101 103 109 108 113 118
6 101 75 92 100 116 109 104 108 113 125
7 102 97 95 105 110 110 103 107 107 120
8 101 97 102 107 107 109 94 102 104 126
9 98 100 ' 103 108 108 106 101 108 97 123
10 97 104 102 108 102 106 96 108 100 117
11 95 92 102 97.5 106 105 88 104 100 117
12 107 98 •100 103 105 112 98 91 100 112
+6Gz
+4Gz
1 104 113 87 107 113
2 96 101 97 111 99
3 97 98 92 108 106
4 86 105 94 118 107
5 86 101 97 114 113
6 95 104 100 105 113
7 103 101 101 103 111
8 108 104 95 99 106
9 102 104 90 109 108
10 104 101 90 107 104
11 108 92 95 105 109
12 107 103 81 101 105
TABLE 10.7
Serum glucose values (mg%) obtained 
in 5 subjects at 5 levels of +Gz 
acceleration. Values uncorrected 
for plasma volume changes.
(lmg% = 0.055 mmol/L)
191
DG
W/15° 402.1 405.6 361.3 367.3 427.1
W /35° 373.1 364.1 403.3 425.4 339.2
W /45° 409.2 495.1 410.8 393.2 384.5-
W /80° 385.6 388.3 360.0 340.5 333.6
WO/150 480.4 483.2 617.9 641.2 446.6
WO/350 399.8 405.2 421.7 586.9 436.3
WO/450 326.3 327.8 465.7 616.1 449.7
WO/80° 457.6 430.0 420.5 392.1 434.2
STATIC 380.8 443.6 370.6 357.1 408.0
IH
W /15° 333.6 350.9 451.8 541.9 359.6
W /35° 412.8 482.7 555.8 613.1 426.2
W /45° 599.0 537.7.531.0 477.6 302.1 
W /80° -411.6 389.8 425.4 393.2 296.0
WO/150 482.7 520.7 638.7 690.9 737.3
WO/35° '425.4 535.1 547.8 636.2 508.7
WO/450 373.8 404.4 544.6 646.2 627.6
W0/800 697.9 677.7 648.1 552.6 490.3
STATIC 347.2 364.1 338.2 355.0 337.2
E l
W /15° 397.0 385.6 588.0 799.0 604.0
W /35° 420.5 456.7 624.6 642.4 434.6
W /45° 400.1 424.2 403.3 443.6 325.9
W /80° 526.3 463.0 432.5 378.6 463.4
WO/150 706.9-750.2 915.7 1094.5 676.4 
WO/350 430.4 387.9 689.0 825.0 681.0
WO/450 515.2 548.3 774.6 839.5 696.7
W0/80° 390.5 406.0 443.6 ,421.3 349.9
STATIC 387.1 403.6 389.4 358.9 442.7
6
AD
320.0 395.1 501.9 441.4 313.8 269.1
2 400.1 493.6 588.6 582.9 402.5 319.7
0 282.5 318.1 296.0 275.5 189.0 256.6
8 323.4 370.9 439.3 338.2 313.2 331.4
-9 400.9 428.3 697.-3 621.5 456.3 339.8
1 294.9 374.2 753.0 819.8 613.7 472.0
1 473.0 480.0 611.3 570.0 386.0 321.8
0 405.2 424.2 497.0 527.9 375.6 288.1
6 345.2 364.5 288.9 268.3 298.1 243.2
. 4
RE
216.2 207.9 209.0 188.5 174.4 233.2
.1 312.0 314.7 277.4 350.9 320.6 374.9
.8 201.4 207.4 189.2 184.2 260.4 250.3
.3 220.6 219.2 188.9 178.2 138.3 207.4
.3 197.1 211.0 456.3 593.8 469.3 343.2
.4 218.5 233.5 533.0 789.0 699.2 480.4
.9 244.5 240.1 316.9 287.5 226.2 167.0
.6 174.4 178.7 175.9 181.8 219.2 276.8
.6 229.5 262.4 208.3 198.2 215.3 317.2
TABLE 10.8
.9 Plasma cortisol levels in 5
.0 subjects exposed to +6Gz with (W)
.6 and without (WO) an anti-G suit at
.3 four seat back angles (15,35,45,80°) 
.0 and to a static (control straining)
.0 run at +lGz. Units = nmole/L.
Protocol: Section 5
.5
370
317
380
328
335
392
318
414
336
243
298
267
294
504
394
422
398
326
498
422
288
469
473
449
440
394
282
192
SAMPLE 1 2 3 1 2 3
DG
W /15° 3.3 4.4 3.3
AD
2.6 2.0 2.5
W /35° 2.8 2.5 2.8 0.9 1.1 1.0
W /45° 2.6 2.5 2.3 0.5 0.6 2.0
W /80° 1.6 2.7 1.8 0.5 0.4 1.0
W0/15O 1.5 13.0 1.9 0.8 6.1 1.2
WO/350 1.8 19.0 3.4 0.7 1.7 2.5
W0/45° 2.2 13.7 2.6 1.8 9.7 1.5
WO/8O0 1.8 2.6 2.4 0.6 0.0 0.9
STATIC 1.9 2.0 3.5 1.9 3.4 4.4
IH
W /15° 6.0 19.3 9.0
EE
6.5 8.6 0i8
W /35° 4.6 2.0 0.5 3.3 7.4 0.1
W /45° 5.8 1.7 1.2 2.3 2.3 3.6
W /80° 3.5 6.2 2.0 2.3 1.8 2.7
WO/150 3.7 7.4 17.4 0.1 0.0 4.0
WO/350 6.5 36.0 15.8 2.4 61.4 1.6
W0/45° 4.3 10.8 11.5 3.2 29.0 1.4
WO/8O0 11.3 2.7 1.6 2.0 12.5 8.8
STATIC 4.4 5.5 5.0 7.0 1.9 4.4
BL
W /15° 0.1 12.8 4.1
TABLE 10.9 
Plasma AVP levels (pg/ml) in five
W /35° 0.8 4.3 1.0 subjects exposed to +6Gz with (W) and
W /45° 2.5 1.9 2.3 without (WT0) an anti-G suit at four
W /80° 2.0 1.6 5.9 seat back angles (15,35,45,80°) and to
WO/15° 2.7 15.4 3.1 a static (control straining) run at +lGz
WO/35° 4.3 30.5 2.1
W0/45° 2.1 9.9 6.1 Protocol: Section 5.
WO/8O0 3.0 0.9 4.9
STATIC 4.3 3.9 1.3 (Normal range: 1-5 pg/ml)
193
DG AD
W /15° 295 244 0 94 116 19 259 1123 252 113 • 112 171
W /35° 70 398 143 84 272 195 123 456 201 37 69 137
W /45° 376 430 285 202 208 320 94 311 15 91 147 74
W /80° 55 116 113 264 225 273 208 326 67 78 71 94
WO/15° 209 413 183 228 160 238 304 352 103 159 138 164
WO/35° 363 482 404 222 418 292 219 567 437 308 418 410
WO/459 242 180 230 153 265 81 135 600 180 316 184 288
W0/80° 328 240 185 217 163 300 160 255 . 94 56 173 123
STATIC 78 131 155 163 297 146 31 49 30 20 26 19
IH ' RE
W /15° ' 143 372 320 188 329 306 262 53 67 29 213 228
W /35° 679 * 843 282 476 231 185 . 148 406 389 210 97 167
W /45° 594 933 147 484 295 182 •353 211 369 . 343 384 202
W /80° 250 291 265 298 211 362 166 254 311 305 84 125 -
W0/15° 466 757 265 336 266 474 - 278 734 202 278 171 221
WO/35° 418 794 224 215 309 462 235 911 208 347 260 162
WO/45° 359 2547 254 440 318 362 276 . 258 264 326 440 325
W0/80° 309 •531 318 417 498 606 137 230 269 387 404 425
STATIC 361 626 315 400 371 361 20 563 218 224 74 24
BL TABLE 10.10
W /15° 300 390 296 218 180 372 Plasma noradrenaline: levels in
W /35° 218 348 263 152 238 135 five subjects exposed to +6Gz with
W /45° 152 497 252 149 178 265 (W) and without (WT0) an anti-g
W /80° 597 573 332 402 793 520 suit at four seat back angled
WO/150 329 380 -551 106 188 172 (15,35,45 ,80°) and to a static
WO/35° 287 673 305 266 372 357 (control straining) run .at +lGz.
WO/45° 382 442 258 332 213 565 Units: pg ml.
WO/800 , 299 296 133 246 172 269 Protocol: Section 5.
STATIC 184 584 462 436 ' 158 133 Normal range: 100-600 pg/ml
(supine, n o r m otensive 
subjects)
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SAMPLE
DG
1 2 3 4 5 6 1
AD
2 3 4 5 6
W /15° 140 55 43 19 42 22 32 217 15 2 10 20
W /35° 22 107 65 19 14 4 19 150 23 13 13 62
W /45° 110 82 61 19 8 33 13 77 11 29 2 1
W /80° 25 8 32 58 80 51 20 115 8 21 28 18
WO/150 58 165 36 68 89 190 67 191 36 10 19 30
WO/35° 27 151 73 74 94 89 36 205 42 37 26 66
W0/45° 129 104 83 50 104 65 49 381 19 8 31 77
W0/80° 82 78 41 31 36 99 74 54 22 - 14 28 25
STATIC 30 63 30 72 94 8 9 10 10 4 5 8
IH
W /15° 38 282 43 43 3 49
RE
48 51 84 21 70 79
W /35° 163 443 41 231 81 32 48 67 48 10 5 43
W /45° 166 168 56 162 42 24 • 66 28 58 36 149 71
W /80° 55 102 34 62 47 45- 85 351 229 119 73 115
WO/150 138 1291 127 107 55 147 101 706 178 28 68 182
WO/350 154 633 116 163 87 229 32 678 93 85 22 26
WO/45° 145 238 46 67 93 93 32 197 33 50 53 19
W0/80° 35 102 11 17 146 56 44 85 57 147 26 13
STATIC 112 101 48 49 99 44 25 286 95 31 4 24
BL
W /15° 40 220 115 44 54 90
W /35° 55 60 34 21 51 21
W /45° 37 108 73 11 128 87
W /80° 99 48 91 45 72 67
W0/15° 47 351 6-3 26 59 97
WO/350 55 154 13 25 37 49
WO/450 45 225 18 41 42 57
W0/80° 48 69 26 75 65 56
STATIC 55 83 86 66 49 49
TABLE 10.11
Plasma adrenaline levels in- five 
subjects exposed to +6Gz with (W) 
and without (WO) an anti-G suit at 
four seat back angles (15,35,45,80°) 
and to a static (control straining) 
run at +lGz.
Units: pg/ml 
Protocol: Section 5.
Normal range: 0-65 pg/ml
(supine, normotensive 
subjects)
SAMrLHi l z 0 0 l z 3 4 0
DG
AGS/6G 328 383 371 340 307 218
AD
324 382 440 385 246 271
AGS/PPB/6G 349 433 450 449 343 311 304 352 516 513 330 335
AGS/PPB/PJ/6G 388 407 339 347 257 300 284 314 384 367 239 168
AGS/PPB/1G 333 310 307 285 251 373 330 354 323 306 238 201
HYPOXIA 399 377 360 318 272 287 317 318 295 279 226 209
IH ' * BL
AGS/6G 234 370 500 563 391 268 '485 412 613 597 436 339
AGS/PPB/6G 321 474 579 673 569 416 476 399 503 619 508 567
AGS/PPB/PJ/6G . 328 397 545 547 393 252 572 576 644 1094 668 484
AGS/PPB/1G ’ 315 336 305 290 415 282 377 379 291 286 344 441
HYPOXIA 311 342 327 351 348 362 ’ 604 599 •518 654 486 548
BC
AGS/6G 426 407 478 495 380 227
AGS/PPB/6G 249 392 402 462 292 208
AGS/PPB/PJ/6G 184 368 404 427 160 178
AGS/PPB/IG 483 594 504 476 331 203
HYPOXIA 336 308 285 272 193 276
TABLE 10.12
Plasma cortisol levels in five subjects exposed to +6Gz wearing an 
anti-G suit (AGS/6G); wearing an anti-G suit^pressure breathing (AGS/PPB/6G); 
and wearing an anti-G suit, pressure breathing aided by a pressure jerkin 
(AGS/PPB/PJ/6G). Subjects were also exposed to control runs at +lGz 
wearing an anti-G suit and pressure breathing (AGS/PPB/1G) and to hypoxic 
conditippis (HYPOXIA) at +lGz.
Protocol: Section 6.
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SAMPLE 1 2 3 1 2 3
DG
AGS/6G 2.5 2.5 3,7
AD
3.4 3.2 1.5
AGS/PPB/6G 3.0 4.0 3.1 5.0 4.2 3.3
AGS/PPB/PJ/6G 2.6 2.1 1.4 2.4 3.5 2.0
AGS/PPB/1G 3.4 1.5 1.6 3.4 2.5 4.4
HYPOXIA 5.5 2.8 3.4 5.9 4.0 4.3
IH
AGS/6G 4.6 3.8 3.8
BL
4.7 4.0 4.2
AGS/PPB/6G 3.4 6.7 4.6 4.2 5.2 5.6
AGS/PPB/PJ/6G 4.6 3.1 3.6 6.0 4.7 5.1
AGS/PPB/1G 4.2 4.1 4.0 3.8 5.0 6.0
HYPOXIA 3.9 4.0 2.0 4.7 3.5 4.3
BC
AGS/6G 3.4 5.6 4.0
AGS/PPB/6G 3.7 4.4 3.9
AGS/PPB/PJ/6G 5.0 4.4 3.7
AGS/PPB/1G 4.7 4.6 3.4
HYPOXIA 4.1 4.1 3.0
TABLE 10.13
-
Plasma AVP levels in five subjects exposed to +6Gz wearing an anti-G 
suit (AGS/6G); wearing an anti-G suit, pressure breathing (AGS/PPB/6G) 
and wearing an anti-G suit, pressure breathing aided by a pressure 
jerkin (AGS/PPB/PJ/6G). Subjects were also exposed to control runs 
at +lGz wearing an anti-G suit and pressure breathing (AGS/PPB/1G) 
and to hypoxic conditions (HYPOXIA) at +lGz.
Protocol: Section 6.
SAMPLE nX. 2 o /.T 5 6 1X o *3 /. CnJ 6
DG . AD
AGS/6G 429 855 740 242 102 428 321 390 180 363 164 347
AGS/PPB/6G 302 391 192 144 125 261 308 574 136 62 205 126
AGS/PBB/PJ/6G 486 745 283 422 215 477 258 370 125 219 185 258
AGS/PPB/1G 121 200 181 277 204 ' 260 116 463 118 66 205 86
HYPOXIA 678 330 446 516 506 582 62 114 182 144 401 72
IH BC
AGS/6G 163 756 .210 283 243 211 622 1101 404 364 200 722
AGS/PPB/6G 450 ,. 1304 174 266 126 . 182 302 776 220 236 166 270
AGS/PPB/PJ/6G 342 930 240 305 262 258 366 1119 302 379 94 508
AGS/PBB/1G 844 950 542 444 926 656 487 489 475 461 418 —
HYPOXIA 245 256 '453 213 158 206 530 456 278 199 153 586
BL
AGS/6G 185 303 212 254 209 46
AGS/PBB/6G 288 431 488 385 363 ‘ 456
AGS/PPB/PJ/6G 681 1156 470 922 438 874 \
AGS/PPB/1G 129 128 445 126 79 206 *
HYPOXIA 226 281 354 223 458 209
TABLE 10.14 '
Plasma noradrenaline levels in five subjects exposed to +6Gz wearing 
an anti-G suit (AGS/6G); wearing an anti-G suit, pressure breathing 
(AGS/PPB/6G); and wearing an anti-G suit, pressure breathing aided by a 
pressure jerkin (AGS/PPB/PJ/6G). Subjects were also exposed to control 
runs at • +lGz wearing an anti-G suit and pressure breathing (AGS/PPB/1G) 
and ,to-. hypoxic conditions (HYPOXIA) . at +lGz.
Protocol: Section 6.
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SAMPLE 1 2 3 4 5 6 1 2 3 4 5 6
DG
AGS/6G 23 120 33 26 10
AGS/PPB/6G 28 196 22 60 66
AGS/PPB/PJ/6G 102 290 25 38 37
AGS/PPB/1G 50 83 54 56 20
HYPOXIA 102 47 53 67 35
IH
AGS/6G 113 1167 95 174 76
AGS/PPB/6G 105 1513 92 112 19
AGS/PPB/PJ/6G 123 848 91 123 61
AGS/PPB/1G 245 286 172 79 215
HYPOXIA 41 60 181 48 90
BL
AGS/6G 5 17 2 1 1
AGS/PBB/6G 16 178 109 8 57
AGS/PPB/PJ/6G 186 402 27 278 104
AGS/PPB/1G 3 14 4 3 17
HYPOXIA 60 62 137 29 90
4
AD
90 62 32 102 88 39
38 39 195 2 6 25 18
32 36 143 24 26 6 17
14 20 80 31 7 51 ' 2
61 13 18 35 19 39 9
90
BC
43 166-' 45 30 9 17
96 43 275 25 20 98 24
107 126 494 7 18 5 48
97 51 81 36 87 46 -
79 9 5 9 2 2 12
1
33
226
86
73
‘t a b l e 10.15
Plasma adrenaline levels -in five subjects exposed to +6Gz wearing an 
anti-G suit (AGS/6G); wearing an anti-G suit, pressure breathing (AGS/PFB/6G) 
and wearing an anti-G suit, pressure breathing aided by a pressure jerkin 
(AGS/PPB/PJ/6G). Subjects were also exposed to control runs at >lGz 
wearing an anti-G suit and pressure breathing (AGS/PPB/1G) and to hypoxic, 
conditions (HYPOXIA) at +lGz.
Protocol: Section 6.
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SECTION 11 : APPENDIX 3 : GLOSSARY OF TERMS AND ABBREVIATIONS
r
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Some of the terms and abbreviations used in this thesis are peculiar 
to the study of acceleration physiology offendocrinology. Since the reader 
is only likely to be conversant with the language of one of these two 
disciplines, this glossary has been provided to assist his understanding of 
this thesis.
TERMS
Acceleration 
Anti-G suit
Black-out
Counterpressure
Cut-in
G-tolerance
Grey-out 
M-l manoeuvre 
M-l procedure
Positive pressure breathing 
Pressure jerkin 
Valsalva manoeuvre 
Velocity
: rate of change of velocity (see page 7)
: an air-inflated garment worn over the lower 
limbs and abdomen (see page 19)
: total loss of vision, but not loss of 
consciousness, due to cerebral hypotension 
induced by +Gz acceleration (see page 13)
: air supplied under pressure e.g. 5 mmHg G 
to a pressure jerkin surrounding the trunk 
(see page 22)
: the level of +Gz acceleration at which an anti-G 
suit or other garment is first inflated
: the level of +Gz acceleration.which may be
' tolerated by a subject. Classically measured 
using visual criteria e.g. grey-out
: loss of peripheral vision following a darkening 
of the visual field (see page 13)
: forced expiration against a partially closed 
glottis (see page 17)
: same as M-l manoeuvre
: breathing under positive pressure during 
exposure to acceleration (see page 22)
: air inflated device to produce counterpressure 
over the trunk of the wearer (see page 24)
: forced expiration against a closed glottis 
(see page 17)
! change in speed or direction of motion of a 
body (see page 7)
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ACM : "aerial combat manoeuvre" (see page 23)
ADH : antidiuretic hormone (synonymous with AVP)
AVP : arginine vasopressin (synonymous with ADH)
ANOVA : analysis of variance
CP : counterpressure (see page 22)
FSH : follicle stimulating hormone (see page 41)
GH : growth hormone (see page 38)
+Gx : transverse acceleration , ON
(see page 8)
+Gz : headwards acceleration
IAM : Institute of Aviation Medicine
LH : luteinising hormone (see page 41)
PPB : positive pressure breathing (see page 22)
PJ : pressure jerkin (see page 24)
PRL : prolactin (see page 40)
RIA : radioimmunoassay (see page 59)
Sa02 : arterial oxygen saturation (see page 113)
TSH : thyrotropin (see page 41)
PV : plasma volume (see page 69)
(sec page 43)
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